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Abstract 
 
Clinical trials play an important role in advancing therapeutic and 
preventive care with many current modalities resulting from prior 
research.   While prior research has described barriers to participation 
in therapeutic clinical trials, much less in known about barriers related 
to participation in trials aimed at prevention, prostate cancer 
prevention in particular.  Physicians have been shown to play a critical 
role in access to trials; however, less is known about the individual 
and structural factors that influence their participation in prostate 
cancer prevention trials.  This research provides rich ethnographic 
detail within the context of an ongoing trial.  Research participants 
included physician/investigators who were either directly (serving as a 
co-investigator) or peripherally (referring patients for participation) 
involved in prostate cancer prevention intervention clinical trial 
(PCPICT), as well as those who were considered for participation but 
declined.  Methods included open ended semi-structured interviews, 
participant-observation and a survey. Participants were recruited via 
direct inquiry, email and/or letter regarding participation.  The results 
of this study show that individual and structural factors intersect, 
ix 
 
influencing both the willingness and ability of physician/investigators 
to participate or refer patients for participation in a prostate cancer 
prevention intervention clinical trial.  Individual factors such as 
explanatory views on prevention, notions of risk and uncertainty, 
shared decision-making and duality of roles appear to have a greater 
influence on the willingness of physicians to participate while structural 
factors such as staffing, other resources and time are more influential 
in regards to the ability to participate.   This research served as a 
critical first step towards providing an in-depth understanding of the 
individual and structural factors that influence a physician’s 
participation in this type of trial.  It builds from prior work where a 
better understanding of barriers and identification of successful 
strategies to overcome them was a noted void.  The researcher 
identifies areas where additional research would be beneficial and 
provides applied recommendations for those considering the design of 
future cancer prevention intervention projects. 
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Chapter One: 
 
Introduction 
 While completing my doctoral studies I was uniquely situated, 
also working as a project manager for a multi-site, cancer prevention 
intervention trial in the biomedical arena.  During this time I often felt 
I was in a very liminal space, navigating the “rules” and languages of 
two very disparate worlds, wondering if they would ever intersect.  My 
role as project manager had increased my awareness of the challenges 
inherent in the design, implementation and daily work of conducting a 
prostate cancer prevention trial.  Simultaneously, my doctoral studies 
increased my skillset, providing a new perspective and toolkit with 
which to examine the world.  My aim with this dissertation research 
was to show how the two worlds could indeed merge, with each 
informing the other.    
This chapter will introduce the challenge of recruitment to cancer 
prevention clinical trials.  The rationale for conducting this study will 
be described and the study objectives explained.  The research 
questions and hypotheses will be introduced.  The significance of the 
study and benefits of an anthropological perspective will then be 
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discussed.  Finally the theoretical frame will be presented and an 
overview of the dissertation will be provided.    
Statement of the Problem 
 Clinical trials are widely recognized in the medical and research 
communities for their role in advancing both therapeutic and 
preventative care (Baquet et al. 2009; Orozco 2009; Yates 2003) with 
many current modalities resulting from prior research.  
Chemoprevention, or the use of drugs, vitamins, or other agents to 
reduce the risk of, or delay the development or recurrence of cancer 
(National Cancer Institute 2011) is suggested as one of several means 
to reduce cancer incidence (Ford 2003).   Enrolling an adequate 
number of patients, within a reasonable time period is particularly 
critical in chemoprevention trials (Sharp and Pentz 2004).  
Unfortunately, poor enrollment is common with less than twenty 
percent of subjects identified as eligible for cancer prevention trials 
actually recruited (Chlebowski et al. 2010; Kumar et al. 2011; Ruffin 
IV and Baron 2000).    
Barriers to participation in therapeutic clinical trials have been 
well described (Hall et al. 2010); however, it is suggested that unique 
barriers present an ongoing challenge in the recruitment of healthy 
individuals as well as cancer survivors (Ford et al. 2009; Frayne 2001; 
Ott 2006) and overall less is known about the influences of 
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participation in clinical trials aimed at prevention.  The identification of 
procedural, structural and infrastructural barriers is seen as critically 
important in order to evaluate the increasing number of new 
chemoprevention agents (Dilts and Sandler 2006).  Referring 
physicians play a major role in accessibility to trials (Ford 2003, 
Kumar et al. 2011, Miller et al. 1998) and genuine commitment and 
trust have been identified as two critical components to a successful 
primary care/investigator relationship (Frayne 2001); however, less 
is known about the individual and structural factors that 
influence a referring physician’s participation in cancer 
prevention trials compared to therapeutic trials.  
 Significant challenges in recruitment to cancer prevention 
intervention trials exist.  The need for studies of physicians’ attitudes 
and behaviors regarding clinical trial participation was identified by 
Swanson and Ward (1995) and though researchers responded with 
studies examining attitudes related to therapeutic clinical trial 
participation (Melisko et al. 2005), there remains a paucity of data 
specifically related to cancer prevention trials.   Considering the 
important role of the physician in recruitment to prevention trials 
(Miller et al. 1998) and the status of health care professionals as 
gatekeepers for clinical trial participation (Probstfield and Frye 2011), 
an exploration of the structural and individual factors influencing their 
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involvement (or lack thereof) in cancer prevention intervention clinical 
trials is warranted.   
Specifically related to cancer prevention clinical trials, Frayne et 
al. (2001) reported three areas of “physician-level” concerns including: 
1) the dual role played as advocate for patient and research; 2) the 
threat to maintenance of the primary care relationship; and 3) the 
general philosophy of the physician towards prevention.  Trial 
enrollment is likely the product of interactions between physicians’ 
beliefs and values, support from medical leadership (Somkin et al. 
2005), access and other factors which have yet to be reported or 
explored.  It is also likely that just as in the primary care setting, 
competing demands are a factor in recruitment to cancer prevention 
intervention clinical trials as well.  Nguyen et al. (2005) suggested that 
the identification of barriers that prevent physicians from discussing 
research participation with their patients is a potential way to improve 
enrollment. Tailoring approaches to a specific practice area (academic 
vs. nonacademic) (Meropol et al. 2007) and the use of health 
maintenance organizations or managed care groups have been 
suggested as a ways to optimize participation while utilizing 
infrastructure that is already in place (Ruffin IV and Baron 2000).   
Similar to the essential nature of physician involvement in the 
provision of preventive services, committed physician involvement has 
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been shown to be critical for successful recruitment to an ongoing 
prostate cancer chemoprevention trial (Kumar et al. 2011).  
Additionally, the researchers recommended a more in-depth 
exploration of infrastructural level challenges, which may vary across 
research sites, in order to find solutions to current challenges in 
recruitment to this type of trial.  Effective strategies to improve 
participation must consider the multiple competing demands 
(individual and structural factors) faced by physicians, as well as 
variants in practice area in order to succeed. 
Rationale and Significance  
 This research served as a critical first step towards providing an 
in-depth understanding of the individual and structural factors that 
influence physician’s participation in a prostate cancer prevention 
intervention clinical trial (PCPICT).  This timely work provides 
ethnographic detail within the context of an ongoing PCPICT. The 
results can be used to inform the design of future cancer prevention 
intervention trials which require multi-site participants reflective of our 
diverse population.    
Study Objective/Research Questions and Hypotheses 
I was interested in: a) exploring the factors that influence a 
physician’s participation in a PCPICT and b) identifying ways to 
improve collaboration between researchers and physicians, thus 
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improving the success of future projects.  This study was designed to 
explore and document the individual provider level factors (such as 
notions of risk and shared decision-making, explanatory views on 
prevention, and duality of roles) and the structural (organizational and 
infrastructural) considerations that influence a physician/investigator’s 
participation in a PCPICT.  Additionally, it included a consideration of 
how practice area (specialty centers, academic centers, Veteran’s (VA) 
medical centers, community offices) impacts the feasibility of 
participating in such a trial.   The guiding research questions for this 
study were:  
1) What individual factors influence a physician’s participation in 
a PCPICT?  
 
2) What structural factors influence a physician’s participation in 
a PCPICT?  
 
3) How do these factors vary depending on the practice site/area    
            (specialty centers, academic centers, Veteran’s (VA) medical   
            centers, community offices)? 
  
The primary hypothesis was that both individual and structural 
factors intersect and influence both the willingness and the ability of 
the physician/investigator to participate or refer patients for 
participation in a PCPICT.  Figure 1 shows the proposed model that 
undergirds the hypothesis tested in this study.  Additionally, it was 
hypothesized that these factors will vary based on practice site/area 
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and the interactions will both facilitate and deter participation in these 
types of trials.   
 
 
Figure 1. Proposed Model: Individual and structural factors influencing 
physician participation in cancer prevention, intervention clinical trials 
 Dark blue boxes represent individual factors believed to impact the 
physician’s participation in cancer prevention intervention clinical trials  
 Light blue boxes represent structural factors believed to impact the 
physician’s participation in cancer prevention intervention clinical trials 
 
Benefits of an Anthropological Perspective 
 The absence of anthropological contributions in this specific area 
suggested a void where further investigation to explore the role of 
physician/investigators as gatekeeper in a prostate cancer prevention 
intervention trial was warranted.  The holistic anthropological 
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perspective can provide a deeper understanding of the issues, linking 
disparate views that might not otherwise be seen as influential or 
interrelated.  Similarly, the proposed model attempts to capture these 
disparate factors of influence within this particular context.  Lambert 
(2002) suggested that an anthropological perspective may facilitate an 
examination of the boundaries of a problem and provide useful insights 
to health research, particularly when considering the social and 
cultural dimensions of health, ill health and medicine.   Additionally, 
since the knowledge and practice of “experts” is seen as locally 
variable, anthropologists in the healthcare setting can offer valuable 
insight to encompass the views, ideas and practices of not just lay 
participants but of professionals as well (Lambert 2002).   
Ethnography, the hallmark methodology used by 
anthropologists, engages with others and their practices to better 
understand their local worlds (Kleinman 2006).  Ethnographic research 
provides  a rich, textured description of a phenomenon, providing 
insight into the views and experiences of a specific group (Abadie 
2010).  These methods are useful to tease out the data and 
information that contributes to deep knowledge and better awareness 
within a certain context.  Anthropologists have previously used 
ethnography to explore community attitudes toward cancer and the 
impact of these attitudes on the implementation of messages from the 
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scientific community that were aimed at the adoption of lifestyle 
changes thought to reduce cancer risk.  The research revealed that  
community members’ beliefs regarding cancer prevention were quite 
different from those presented by the scientific community and that 
community resistance to health messages were purposeful acts in 
response to a loss of control in power and social class (Balshem 1991).  
 In other work, Gregg and Curry (1994) examined cultural 
models for breast and cervical cancer among low-income African-
American women and explored how these models may impact 
screening behavior.  Their findings suggested that cancer models held 
by the patients and physicians differed substantially in regards to 
etiology, methods of cancer screening and prevention, as well as 
treatments for cancer and the authors suggested that mutual 
understanding between physicians and their patients is needed to 
improve screening rates (Gregg and Curry 1994).   Though this work 
was completed some time ago it highlights the importance of mutual 
understanding between physicians and patients in regards to health 
care decision-making.  Similarly, this reciprocal understanding may be 
relevant and influential when considering participation in a PCPICT.  
 Specifically in regards to the crisis in clinical trials, Hales et al. 
(2001) noted that a better understanding of the problem is needed for 
resolution of the current challenges.  Similar to work by other 
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anthropologists, the use of a novel perspective to address a previously 
identified challenge was seen as beneficial in the design of this project.  
It was my hope that ethnography would add a new perspective not 
previously considered and provide a rich, textured description of the 
local context (Abadie 2010) surrounding a PCPICT, as well as insight 
into the views and experiences of the physician/investigators that are 
directly or are peripherally involved. 
 When considered as a vantage point to examine the current 
challenges of recruitment to clinical trials in general and cancer 
prevention intervention trials in particular, anthropology offered a 
valuable lens through which to better understand the complex and 
interrelated phenomena that influence this issue, particularly focusing 
on the critical role of physician/investigator.  By using observation, 
participation and interviews, ethnography is useful to expand a model 
and discover associations between domains or variables (Schensul et 
al. 1999).  Hemmings (2005) recognized the importance of the 
presence of medical anthropology within medicine, yet following an 
extensive review of the influence of anthropology on medicine 
spanning two decades, he concluded that unfortunately, medical 
anthropology continues to make little impact.  Further clarifying, he 
noted that while medical anthropology has indeed helped to identify 
and articulate the problems of medicine, it has failed to provide 
11 
 
realistic solutions (Hemmings 2005).  As such, with this research an 
anthropological perspective allowed for broad examination with an 
applied, solutions-oriented focus. 
Theoretical Frame 
Theory helps to explain, predict and interpret phenomena of 
interest and is important to understand potential links, confounding 
variables and the context in which a phenomenon does or does not 
occur (Bradley 2007).   Thus, theory provides a framework, guiding 
the questions asked and ultimately answered in a research study 
(Bradley 2007; Creswell and Plano Clark 2011).  The process for 
developing theory is diverse  and depends on several factors including 
the topic of study, its context and the experience of the researcher 
(Bradley 2007).  Schensul et al. (1999) stated that formative theory 
includes an issue or problem, in addition to some ideas about the 
components of the physical, social or institutional environment that 
may be associated with a problem.  It may originate from preexisting 
information about the research community or topic, a review of the 
related literature, the prior experience of the researcher, or the 
experience of a local community.  Thus, formative theory serves as a 
guide for the research and provides the opportunity to generate 
hypotheses from which observations can then be compared (Schensul 
et al. 1999).   A theoretically informed focus helps ethnographers to 
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concentrate their fieldwork and to organize the information into a 
logical framework.   
While designing this project, various theories and constructs 
were considered for their overall appropriateness in relation to the 
research goals.   This included consideration of theories traditionally 
used within the field of anthropology as well as those utilized by 
researchers in other fields such as such as Political Economy of Health, 
Critical Medical Anthropology, the Ethnomedical Model, Explanatory 
Models, the Cultural theory of Risk, Notions of Risk, Clinical interaction 
and decision-making, Cancer Fatalism, Duality of Roles and the Theory 
of Competing Demands.  Those theories and constructs that were 
determined to be most relevant to this project are expounded upon in 
Chapter Two, the Review of Literature within the context of the various 
research objectives.   The overall intent was to let theory guide the 
methods chosen to answer the research questions, in order to 
contribute to a more in-depth understanding and provide applicable 
recommendations.   
Physician involvement is thought to be essential for the provision 
of many services with the physician serving a critical link in the chain 
of events leading to the delivery of preventative services including 
cancer screening.  The theory of competing demands has been used to 
recognize the multiplicity of factors that compete with the provision of 
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preventative services and influence their delivery by physicians in the 
primary care setting (Jaen et al. 1994).  It is suggested that the 
primary components (physician, patient, and practice environment) 
are further influenced by factors such as attitudes, knowledge, 
expectations, practice organization and alternative demands.  As a 
result, the multiple demands of the medical encounter “compete” with 
those related to prevention during the limited time available.  The end 
result is that some but not all agenda issues may receive attention at 
the specific visit (Jaen et al. 1994) with preventative services often 
peripheral to other perceived priorities.    
Nutting et al. (2001) also used this model to examine factors 
influencing physician recommendation for screening mammography.  
Interestingly, their findings suggest that the characteristics of the 
physicians, patients and the office visit were equally important in 
impacting the frequency of recommendation for mammography.  
Additionally, the authors suggested that effective strategies to improve 
the delivery of preventative services must go beyond physician 
education and performance feedback to consider the multiple 
competing demands faced by physicians and patients in order to 
prioritize services (Nutting et al. 2001).  Prior to data collection, it was 
proposed that there is likely similar competition in the urologist’s  
office, when a patient receives the results of a prostate biopsy that 
14 
 
ultimately influences the likelihood that the recommendation is made 
to participate in a cancer prevention, intervention clinical trial. 
In other related research, a case study by Joseph and Dohan 
(2009) was initiated with the expectation that multiple, competing 
demands vied for physicians attention and resources specifically as it 
relates to clinical trials recruitment.  The authors proposed that some 
of these demands would encourage the recruitment of diverse patients 
while others would distract clinical investigators from these goals.  
Their findings suggested that enrollment in therapeutic cancer clinical 
trials was shaped by both biomedical and social factors (Joseph and 
Dohan 2009).  Though focused more specifically on an examination of 
diversity in recruitment to treatment trials, there are certainly 
important findings that could be applied to a study examining 
individual and structural factors influencing a physician’s involvement 
in prostate cancer prevention, intervention clinical trial.    
Biomedicine, broadly speaking, is a sociocultural system, with its 
own unique values, premises, and problems (Hahn and Kleinman 
1983).  As a part of the biomedical system, the realm of clinical trials 
is also a sociocultural system; and the specific arena of cancer 
prevention, intervention clinical trials yet another.   The concept of 
competing demands was a logical and comprehensive starting point for 
this project; however, on its own the adequacy to examine all of the 
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potential sociocultural factors of influence at both the individual and 
structural levels was questionable.  I also felt that it was likely that no 
single theoretical frame was adequate in isolation to fully explore the 
research questions.  For this reason, an adaptation of the theory of 
competing demands that included a theoretically-grounded exploration 
of individual provider level factors (such as notions of risk and shared 
decision-making, explanatory views on prevention, and duality of 
roles) as well as structural level factors (such as practice area and 
organizational/infrastructural considerations); informed by the 
constant comparison of the similarities and differences of concepts that 
emerged in the field as suggested by Glaser and Strauss (1967), was 
proposed for this project.  As previously noted, the theories and 
constructs that were thought to be influential and determined to be 
the most relevant are expounded upon in Chapter Two, the Review of 
Literature within the context of the various research objectives.  Within 
this comprehensive frame, I was able to draw upon both micro and 
macro level factors to provide a more holistic understanding of the 
multitude of variables influencing the physician’s participation in a 
PCPICT.   
Organization of the Dissertation 
 This research examines the intersection of competing demands, 
the individual and structural factors that influence both the willingness 
16 
 
and ability of physician/investigators to participate or refer patients for 
participation in a PCPICT.   It extends the theory of competing 
demands into the anthropological literature and examines its relevance 
to a prostate cancer prevention intervention clinical trial.  With the 
results, I was able to identify key findings useful for funding agencies 
and those designing prevention trials in the future.  I also discuss 
opportunities and directions for future research.   
The dissertation is divided into five chapters.   Chapter Two 
provides a review of relevant literature.   Chapter Three provides a 
brief overview of the setting of the current study in the context of the 
currently evolving health care arena in addition to the methods for 
data collection and analysis and a discussion of ethical considerations.  
Chapter Four contains the results of the dissertation reported 
according to the study objectives and research questions noted 
previously.  Chapter Five is the discussion of the findings and is 
similarly organized by the study objectives and research questions.  It 
also includes a discussion of the contributions to theory, applied 
anthropology and biomedicine (with application to future trials 
discussed); a consideration of limitations, reflections on familiarity in 
the research setting, a presentation of opportunities and discussion of 
dissemination and future directions, in addition to a conclusion.  
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Chapter Two: 
 
Literature Review  
 
Introduction 
Prevention trials with a specific disease focus, such as cancer, 
may aim to prevent disease initially (primary prevention) or to prevent 
recurrence (secondary prevention) (National Institutes of Health 2011) 
and have been suggested as a  sound medical strategy, particularly 
when resources are limited (Sharp and Pentz 2004).   A growing body 
of research supports the reduction of cancer incidence through primary 
prevention (via lifestyle factors), early detection, and interventions 
with chemoprevention and vaccines (Ford 2003).   Advances in the 
understanding of cancer biology and pathogenesis have identified 
molecular pathways that may serve as indicators for cancer risk, 
thereby providing the opportunity for prevention and early detection 
trials to play an important role in reducing the burden of this disease 
(Cox and McGarry 2003; Yates 2003).  Well-designed cancer 
prevention studies are needed to validate molecular endpoints and 
their role in cancer prevention (Hall et al. 2010).   
 Adequate recruitment is essential for the completion of a clinical 
trial, whether preventative or therapeutic in nature (Lovato et al. 
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1997; Probstfield and Frye 2011).  Poor accrual limits not only the 
advancement of science but the generalizability of cancer research 
(Ka'ano'i et al. 2004) and the societal benefit resulting from clinical 
trials is currently jeopardized due to declines in timely patient 
recruitment in all patient groups (Murthy et al. 2004; Probstfield and 
Frye 2011).  Different from therapeutic trials, where treatment is for a 
disease or other adverse conditions already present, cancer prevention 
trials generally seek to enroll healthy, disease-free, asymptomatic 
individuals who may be at an increased risk for cancer due to a 
personal or family history of cancer or a pre-malignant condition (Hall 
et al. 2010; Hudmon et al. 1999).  Additionally, the benefits from a 
prevention trial may be less readily evident than those of a therapeutic 
trial due to the desired outcome of disease prevention (Hudmon 
1996).  When the population is considered to be healthy, there is also 
an increased challenge and ethical responsibility to keep the 
participants healthy (Sharp and Pentz 2004).  Despite the potential 
benefit of a reduction in disease burden, this expansion of medical 
research is not without its challenges (Lovato et al. 1997).  Unique 
barriers are thought to present ongoing challenges to the recruitment 
of healthy individuals (Frayne 2001; Hall et al. 2010; Hudmon 1996; 
Korde et al. 2009; Lovato et al. 1997; Meropol et al. 2007; Ott 2006; 
Sample 2002; Tangrea 1997) and complex interactions between 
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participants, physicians, study designs and characteristics of the U.S. 
healthcare system are all suggested as barriers to participation in 
cancer prevention and control trials (Comis et al. 2000; Hudmon 1996; 
Ruffin IV and Baron 2000; Sample 2002; Tangrea 1997).   
Influence of Practice Area 
Since most cancer prevention trials are aimed at the general 
population, primary care physicians (PCPs) are considered by some to 
be the best source of referral for participation in these trials.    
However, Crosson et al. (2001) reported that PCPs prefer to defer 
cancer treatment to an oncologist and therefore may not discuss 
clinical trials opportunities with their patients, even if they are related 
to cancer prevention.  Hall et al. (2010) found that oncologists were 
interested in referring patients to prevention trials, but did not have 
access to eligible (i.e., healthy) patients.  These findings suggest that 
at least some of the variance in referral and participation rates may be 
attributed to the area of practice (generalist or specialist).   
Meropol et al. (2007) noted that tailoring approaches to a specific 
practice area (academic vs. nonacademic) may help to optimize 
participation.  It is also noted that logistical barriers must be 
addressed and infrastructural support improved in order to increase 
participation and enrollment (Ford 2008; Ka'ano'i et al. 2004). These 
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notions required further exploration especially as they may relate to 
participation in a PCPICT.   
Prevention trials also present access issues at the individual as 
well as institutional level, further contributing to the challenge of 
recruiting at risk populations (Korde et al. 2009).   Clinical research 
opportunities are frequently associated with academic centers as 
opposed to community and other medical institutions and the 
opportunity to participate may not be a reality for all.   Research done 
primarily in university or teaching centers may result in unintended 
subject bias due to the population seeking care there (Carbone et al. 
2005) and increased availability within the community setting has 
been encouraged (Baquet et al. 2009).  It is suggested that differential 
access to research opportunities due to structural or other barriers 
may disparately impact certain populations (Azevedo and Payne 2006; 
Murthy et al. 2004).  Since the standard of care in many medical 
treatment regimens is the direct result of clinical research, this has 
implications for many conditions, including across the spectrum of 
cancer care from screening and prevention through diagnosis and 
treatment to survivorship.   
  Sharp and Pentz (2004) noted that a study must be 
representative of the population that the intervention would be applied 
to if proven efficacious.  Thus, equitable access to trials is  
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important in order to reduce sample selection bias.  This is a clear 
challenge when most recruitment occurs at academic medical centers 
and not within the community.  Meropol et al. (2007) recommended 
increased accessibility within the community setting as one solution.  
This would likely be beneficial for a PCPICT as well, since potential 
healthy subjects are less likely to receive care at a specialty center.  
By improving accessibility within the community (via collaborations 
with physicians in private practice) such projects would be available to 
a greater number of individuals including those that are not receiving 
their care at academic or specialty centers.  Hales et al. (2001) also 
reported that it may be less disruptive to enroll patients at their usual 
site of healthcare delivery then to refer them elsewhere.  The literature 
from these sections informed the elaboration of the first study 
objective:   
Consider how practice area (specialty centers, academic centers, 
Veteran’s (VA) medical centers, community offices) impacts the 
feasibility of participating in a PCPICT. 
Structural Considerations 
 Organizational support and other health care system related 
factors are noted as predictors of enrollment as well as barriers to 
participation in treatment trials, with infrastructural support (including 
support staff) noted as critical (Roberts 2002; Ruffin IV and Baron 
2000; Somkin et al. 2005).  The development of systems that ease the 
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participation of the healthcare provider are suggested as opportunities 
to improve enrollment (Ford 2008).  Infrastructure, realignment of 
incentives and compensation, and improved patient and physician 
navigation systems have all been suggested by surgeons as ways to 
improve their engagement in clinical trials (Al Refaie 2011).  Though 
this research was with treatment trials, these factors likely affect 
enrollment for a PCPICT and were worthy of further examination. 
 Little research has been done to explore barriers in nonacademic 
environments (Nguyen et al. 2005); however, these settings have the 
potential to recruit a larger and more representative sample (Somkin 
et al. 2005) and the exploration of the structural dimensions that may 
impact the provision of trials in such settings has been identified as a 
research need (Baquet et al. 2008).  Increased access to clinical trials 
via collaborations between non-academic, community settings and 
academic centers is suggested as a way to improve physician and 
health provider awareness about available trials and presumably a way 
to impact participation (Baquet et al. 2008; Colon-Otero et al. 2008).  
Ford et al. (2003) suggested that research results will come faster if 
clinicians and researchers can collaborate and promote studies.   
Frayne et al. (2001) suggested that recruitment to prevention trials 
may require a combined effort between oncology researchers, 
oncologists and primary care providers, and while the number of 
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cancer-prevention trials has increased, very little research has been 
done to explore how investigators and primary care physicians may 
coordinate efforts to recruit as well as retain subjects.  Additionally, 
Ruffin IV and Baron (2000) recommended further research to not only 
better understand barriers unique to prevention trials but to identify 
successful strategies to overcome them.   The literature in these 
sections informed the elaboration of the second study objective:  
Explore and document structural (organizational and infrastructural) 
considerations that influence participation in a PCPICT (with a 
comparison of factors across types of sites). 
Individual Considerations 
Notions of risk/shared decision-making. 
  Risk is characterized by various disciplines in diverse ways, with 
anthropologists traditionally viewing it as a cultural phenomenon 
(Althaus 2005).  Anthropologists Douglas and Wildavsky (1982) 
consider risk perception to be beliefs, attitudes, judgments and 
feelings as well as the socio-cultural disposition that people adapt 
towards both hazards and their benefits.  The significance for this 
project is that in the context of health-related risks, views about 
expertise, scientific integrity, professional reliability and integrity and 
the credibility of health-related messages are likely to be influenced by 
the context in which judgments are made (Tansey 1999).  While risk 
may have varied meanings to different groups, all risk must be 
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understood within the larger social, cultural and economic context that 
it occurs (Douglas and Wildavsky 1982). 
Hunt et al. (2006) reported that risk and “risk status” are 
complex notions that have multiple meanings and are understood 
differently by clinicians and patients.  Their research highlighted the 
important (and often neglected) differences between epidemiological 
(the statistical associations within a population), clinical (the 
probability of the occurrence of a particular disease or outcome for an 
individual) and lay (signifying current or future illness) notions of risk 
and how these important differences may be ignored or treated as 
equivalent when they in fact are not (Hunt et al. 2006).  Clinicians 
often discuss risk in clinically meaningful terms while patients must 
translate risk into terms that are personally meaningful and applicable 
to their unique circumstance.  The authors explore how notions of risk 
impact patient’s decisions about prenatal genetic testing and suggest 
that failure to acknowledge the varied and often contrasting meanings 
of risk may impact communication and the ability of patients to make 
autonomous and informed choices about their care (Hunt et al. 2006).   
Though not directly related, this research has the potential to 
inform when applied to a different context- the role of physicians in 
cancer prevention, intervention clinical trials.  A consideration of the 
various meanings of risk and how they may be used by clinicians and 
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patients is important when examining the individual factors influencing 
a physician’s recommendation related to participation in a PCPICT.   As 
observed by Hunt et al. (2006), risk may have multiple meanings 
which influence the evaluation of what is at stake as well as treatment 
options, and this may be an individual factor of influence when a 
patient has an abnormal yet non-cancerous biopsy result, ultimately 
influencing the likelihood that participation in a PCPICT is offered by 
the physician.  Additionally, Hunt et al. (2005) found that when 
clinicians and patients have disparate starting points related to a 
perceived problem this greatly influences the options considered in 
regards to prevention or control and a shared decision making 
approach is recommended to arrive at the ideal decision for each 
individual situation.  Since physicians are often recognized as a trusted 
source of health information (Crosson et al. 2001) and their input is 
frequently a key consideration in patient healthcare decision making 
(Roberts 2002), a better understanding of notions of risk and risk 
status and how this impacts physician recommendations and decision 
making for their patients was thought to be potentially relevant in 
regards to the decision to participate or refer to a PCPICT and further 
exploration was warranted.  Attention to the varied meanings of risk 
may help both physicians and patients make truly informed decisions 
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about managing individual risk, specifically as it pertains to prostate 
cancer prevention and the opportunity to participate in a PCPICT.   
Explanatory views on prevention. 
 Prior research has explored physician’s attitudes to the delivery 
of preventative interventions with a wide range of variance in 
importance seen, depending on the screening measure noted (cancer 
screening vs. blood pressure control) (Cornuz et al. 2000).  This may 
have direct implications for interventions aimed at cancer prevention 
as well.   Tangrea (1997) noted that physicians often play a critical 
role in deciding if a patient should enter into a trial and since they play 
an important role in the delivery of preventative services, it is possible 
that the gatekeeper role extends beyond preventative interventions to 
providing information about PCPICTs as well.   
Interestingly, Hall et al. (2010) reported that the majority of 
oncologists (79.4%) were “not at all” or “a little” interested in offering 
cancer prevention trials to their patients, noting that medical training 
was focused on treatment of active disease and reducing its further 
burden, making it challenging to incorporate prevention trials into their 
practice.  Chavez et al. (1995) noted the importance of including 
physicians in the analysis of the social and cultural construction of 
biomedical disease concepts since along with patients; they are 
considered actors in the ethnomedical belief system warranting an 
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analysis of their beliefs.  The culture of biomedicine also determines 
how physicians make decisions within a certain context.  For the 
purpose of this project and context, a consideration of the physician’s 
social and cultural construction of the concept of disease (cancer) 
prevention was thought to be important and further investigation of 
these concepts within the specific context of a PCPICT was included.  
Duality of roles.  
 It is suggested that the varied and separate roles of 
physician/clinician and investigator may contribute to conflict related 
to the ultimate goals and populations targeted (Frayne 2001; Hales et 
al. 2001; Orozco 2009) and may be particularly salient in regards to 
cancer prevention intervention trials.  Ka'ano'i et al. (2004) identified 
interference with the doctor/patient relationship, as well as conflict 
between the roles of clinician and research advocate as physician-
related barriers to participation in cancer prevention clinical trials.  The 
literature in these sections informed the elaboration of the third study 
objective: 
Explore and document individual provider level factors (such as 
notions of risk and shared decision-making, explanatory views 
on prevention, and duality of roles) that influence participation in 
a cancer prevention intervention clinical trial. 
The anthropological voice has been present in discussions and 
research in the area of cancer as well as that of clinical trials.  The 
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literature reviewed for the initial stages of this project identified gaps 
in the research to date, particularly in regards to PCPICTs.  These 
gaps, in addition to the lived experience that will be further detailed in 
the next chapter provided the impetus and direction for this research, 
to examine if prior findings resonated beyond those groups previously 
studied.  Specifically, the limited anthropological contributions in this 
area provided the groundwork for an exploration of the role of 
physicians as gatekeeper and how various individual and structural 
factors intersect creating unique challenges for those investigators 
conducting PCPICTs.   
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Chapter Three: 
Methods 
Setting the Stage 
 There are several factors believed to be important to set the 
stage for this research project.  While pursuing my doctorate, I also 
served as a co-investigator and project manager working at a National 
Cancer Institute (NCI) Comprehensive Cancer Center in Tampa, FL.  
Observations and challenges noted throughout the daily participation 
in this work were in large part, the impetus for the design of this 
dissertation research.  More specifically, after appropriate channels for 
institutional approval were navigated,  this project was considered a 
supplement or ancillary project to a currently ongoing prostate cancer 
chemoprevention clinical trial, Phase II, Randomized, Double-blind, 
Multi-centered Study of Polyphenon E in Men with High-grade Prostatic 
Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar 
Proliferation (ASAP) (IRB 105730).  As such, resources, including 
access to the faculty and research sites participating in the parent 
study were available and helped to successfully facilitate the 
completion of this project.  Funding for the time and travel to complete 
the data collection also allowed for completion without the need to 
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secure additional financial support.   My experience conducting 
research in a familiar setting will be more fully discussed in Chapter 
Five.  
 The sample chosen for this study was physician/investigators 
who had been either directly (serving as a co-investigator) or 
peripherally (referring patients for participation) involved in the 
previously mentioned prostate cancer chemoprevention clinical trial, as 
well as those who have been considered for participation but declined.  
By considering the views of those that had been directly or 
peripherally involved (participants) as well as those that had not (non-
participants), a better and more comprehensive understanding of the 
factors influencing the actors within their local context was sought.  
The research took place at current sites (n=8) of the prostate cancer 
chemoprevention clinical trial in the states of Florida, Illinois, 
Louisiana, and Minnesota.  Participants in this PCPICT were thought to 
present a unique and important vantage point from which to obtain 
timely and relevant information about their current study participation 
and access was considered to be strength in the design of this 
research.  
In order to reach a broader audience of physicians and elicit the 
opinions and experience of participants as well as non-participants in 
the PCPICT, I also sought to conduct research with urologists working 
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in private practice in the greater Tampa Bay area.  The potential key 
personnel (n=21) from these sites had either inquired about 
participating in the trial or been asked to participate or refer subjects 
for participation but had not.  The reasons for this were not well 
understood or documented, stimulating the interest in obtaining the 
views from this subset in addition to that of those who were currently 
participating in the clinical trial. Documentation of the lived experience 
via the methodologies that will be described more fully in the later part 
of this chapter helped me to explore in-depth the factors that influence 
the physician’s participation (or lack thereof) in the PCPICT, as well as 
factors that may influence possible future participation.   It is the 
sincere hope that the findings from this exploratory research will 
directly contribute not only to the successful completion of the ongoing 
PCPICT but will also inform the design, development and 
implementation of future chemoprevention trials and with its applied 
focus help to address the bigger challenge of recruitment to clinical 
trials.    
Also relevant to the results and discussion that will follow is the 
mention of an historical event and ongoing controversy, mention of 
both which was noted during data collection:  1) the passing of the 
Patient Protection and Affordable Care Act (PPACA) in March 2010 
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(Harrington 2010) and  2) the lack of uniformity in prostate cancer 
screening guidelines in the United States (Gomella et al 2011). 
PPACA. 
The Patient Protection and Affordable Care Act (PPACA) is 
considered the most significant social legislation passed in the United 
States since Medicare and Medicaid were enacted in 1965 (Harrington 
2010) with the goals of expanding coverage, controlling health care 
costs, and improving  the health care delivery system (Kaiser 2012).  
Changes related to expanded health insurance coverage will become 
effective in 2014 so the full effects have not been seen at the time of 
this writing.   The market reform changes went into effect beginning in 
2010, the possible impacts of which are already being noted by 
participants in this project.     
Prostate cancer screening. 
Prostate cancer has been said to present a public health dilemma 
with screening guidelines varying not only between countries but also 
within various medical organizations within countries such as the 
United States and a recent literature review by Gomella et al. (2011) 
suggested that there is indeed no standard of care for prostate cancer 
screening.  As such, the lack of agreement in guidelines for prostate 
cancer screening is an issue that remains contested among 
practitioners in the field.  This was noted during data collection and 
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clearly has implications for future prostate cancer chemoprevention 
studies since screening leads to the identification of those who may be 
eligible for participation in such a trial. 
As previously noted, with this research the investigator was 
interested in: a) exploring the factors that influenced a physician’s 
participation in a PCPICT and b) identifying ways to improve 
collaboration between researchers and physicians, to improve the 
success of future projects.  The research questions guiding this study 
were:  
1) What individual factors influence a physician’s participation in 
a PCPICT?  
 
2) What structural factors influence a physician’s participation in 
a PCPICT? 
 
3) How do these factors vary depending on the practice site/area    
             (specialty centers, academic center, VA medical centers,    
             community offices)?   
 
The primary hypothesis was that both individual factors such as 
notions of risk and shared decision-making, explanatory views on 
prevention, and duality of roles and structural factors such as 
institutional support and requirements, resources, time and patient 
pool intersect and influence both the willingness and the ability of the 
physician/investigator to participate or refer patients for participation 
in a PCPICT.  Additionally, these factors were predicted to vary based 
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on practice site/area with the interactions both facilitating and 
deterring participation in these types of trials.    
Based on the prior experience of the investigator and the 
resources at hand, this project was designed with a mixed-methods 
approach and was thought to have a good chance of success.   By 
building on the relationships that were already established with 
physician/investigators that were participating in the ongoing PCPICT, 
the project was predicted to have legitimacy in the eyes of the key 
informants, helping to facilitate their acceptance and willingness to 
participate.   Since I was conducting research in a familiar setting, the 
lack of consensus regarding possible objectivity and potential for role 
confusion associated with familiarity in the research setting is noted 
and this will be discussed in more detail as it specifically relates to this 
project, in Chapter Five.  Entrée into the private practice arena was 
anticipated to be slightly more challenging; however, referral from a 
respected group member was predicted to increase acceptance and 
willingness to participate so that the data collection could be expanded 
to include the voices of as many private practice/community urologist 
offices as possible.     
Research Design 
Exploratory methods are particularly useful to examine domains 
which may be important to the research question, yet not much is 
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known.  They are also useful to explore a phenomenon in greater 
depth, and to measure its prevalence.  An exploratory design can also 
be useful to generalize the findings of a few individuals (Creswell and 
Plano Clark 2011).  Mixed methods research is ideal to combine the 
exploration of qualitative methods and generalization of quantitative 
methods.  This merger of modes of inquiry can provide more evidence 
and a more complete understanding than either method by itself with 
the strengths of one method often offsetting the weaknesses of the 
other (Creswell and Plano Clark 2011).  Additionally, inductive inquiry 
allows for the emergence of processes and explanations that occur 
within the complex reality of life (Bradley 2007).  Since this may not 
necessarily be the way a researcher would expect or predict them, 
inductive approaches are useful to examine provider perspectives that 
have received little or no previous attention (Hay and Craddock Lee 
2009), such as the examination of provider perspectives related to 
participation in a PCPICT.   In order to meet the objectives, this 
formative, exploratory study employed a mixed methods research 
design using qualitative, ethnographic (open ended semi-structured 
interviews and participant observation) and quantitative (survey) 
methods to examine the individual and structural factors that influence 
physician/investigators within the context of participation in a PCPICT.    
 Glaser and Strauss (1967) suggested that theory building is a 
36 
 
process of constant comparison of the similarities and differences 
between the concepts that emerge in the field.  This approach 
assumes that theory is “grounded” in data, not specified at the onset 
of research and in its purest form there are no preconceived ideas of 
importance (Brod et al. 2009).  Though it was virtually impossible to 
approach this project without any preconceived ideas of importance, 
based on the experiences that led me to choose this topic as well as 
the comprehensive review of the literature that was conducted, a 
grounded theory approach was useful to consider.  This methodology 
has been suggested as a useful strategy to study the chronic illness 
experience (Charmaz 1990) and has also been utilized by 
anthropologists to study home birth (Cheyney 2008).  Likewise it was 
an important methodology utilized with this research as well.   
While challenges to recruitment in clinical trials have been well 
documented, the specific role of physicians in prevention intervention 
clinical trials was yet to be examined using ethnographic methods prior 
to this project and such methods can be especially useful to explore 
the cultural and social patterns and meaning within a particular 
context.  Most notably, the hallmark iterative technique  the constant 
comparison of emerging concepts  was very important as fieldwork 
was conducted at the various sites for this project.  The use of this 
technique allowed for the analysis or emerging themes and categories 
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while in the field, at times shaping the subsequent data that was 
collected and leading me in directions that were not anticipated, a 
benefit of this technique also noted by Charmaz (1990).  This 
methodology was also useful when determining the point of saturation, 
when no new themes emerged from data collection (Guest et al. 
2006).   
Additionally, this approach allowed for an in-depth exploration of 
individual experiences and meanings related to cancer prevention and 
participation in cancer prevention intervention clinical trials while also 
paying attention to the larger and unavoidable structural factors that 
impact the practice of medicine, particularly as they relate to 
participation in a PCPICT.   A better understanding of the specific 
“how’s” and “why’s” would not have been easily obtained through 
other methodologies and was necessary to glean a better 
understanding of all of the factors influencing this challenge and to 
inform future research efforts.  Crabtree et al. (1998) utilized similar 
methodology (observation) to study the medical office as a whole 
system and explore competing demands within the primary care 
setting and noted physician and practice level constructs influencing 
the delivery of preventive services in this context.  Similarly, Jaen et 
al. (2001) utilized mixed methods (observation, interviews and audits 
of medical records) to examine compliance with smoking cessation 
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practice guidelines in primary care practices.  Their results 
documented that a smoking cessation agenda was frequently 
overridden by competing demands seen as a higher priority during the 
time limited visit (Jaen et al. 2001).  Guided by formative theory, this 
novel project utilized anthropological methods to gain a greater 
awareness within a very specific context and explore the ways that the 
actors (physician investigators) are influenced by multiple competing 
demands both at the individual and structural level.  I also attempted 
to seek solutions to overcome the current challenges faced in this very 
specific context: recruitment to PCPICTs.   
Sampling 
Structured purposive sampling techniques were employed to 
recruit physician/investigators who have been participants and non-
participants in the ongoing prostate cancer chemoprevention clinical 
trial.  During the design of the study, a pool of thirty potentially 
eligible participants was identified from the parent project, from 
various practice areas, as Table 1 describes.   
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Table 1.  Subject Pool 
 
Practice Area # of Key informants 
A-specialty (cancer) center 2 
B-specialty (cancer) center 1 
C-specialty (cancer) center 2 
D-VA medical center 1 
E-VA medical center 1 
F- VA medical center 1 
G-Academic/teaching hospital 1 
H-Academic/teaching hospital 1 
I- Private practice (community) 20 
 
Eligibility Criteria 
In order to participate, the following eligibility criteria were 
required: (1) Physician/investigators were involved or considered for 
participation in the prostate cancer chemoprevention clinical trial; (2) 
English speaking (as this is was the common language spoken by 
researcher and all participants); (3) Willing and able to provide 
informed consent; (4) Willing and able to participate in the open ended 
semi-structured interview and/or complete the survey.   Any potential 
participant not meeting eligibility criteria one through four was 
excluded from participating.  
Subject Recruitment 
Participants were recruited via direct inquiry, using the 
recruitment letter /script found in Appendix A or B, depending upon 
their participation status in the ongoing clinical trial.  Current 
participants (physicians/investigators) in the PCPICT were contacted 
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regarding participation directly via email or letter from me.  Physicians 
that had inquired about participating in the trial or been asked to 
participate or refer subjects but declined (non-participants) and were 
not part of a local urological association were also contacted via letter 
from me.  Physicians that had inquired about participating in the trial 
or been asked to participate or refer subjects but declined (non-
participants) and were part of a local urological association were 
contacted first via email from the respected group member/key 
informant and then via letter from me.   Prior to scheduling any 
interviews, all potential participants were contacted by me to confirm 
interest, eligibility and willingness to participate and the details of the 
meeting were arranged at that time.  A written confirmation was 
provided as well as a reminder phone call or email the day prior to the 
scheduled meeting time.      
Methods and Data Collection  
Open ended semi-structured interviews. 
Open ended semi-structured interviews are conducted to explore 
the multiple angles surrounding an issue and to discover the shared 
understandings of the participants (DiCicco-Bloom and Crabtree 2006) 
with a goal of achieving thematic saturation of key content areas.  As 
power calculations and quantitative sample size estimations do not 
apply in qualitative research, Guest et al. (2006) noted that 
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nonprobabilistic, purposive sampling instead relies on saturation to 
determine when enough data is obtained.   Krueger and Casey (2009) 
suggested this is the point where you have heard a range of ideas and 
are no longer obtaining new information.  When using a mixed 
methods approach, Creswell and Clark (2011) suggested the use of a 
small purposeful sample in the first phase and a larger pool of different 
participants in the second phase of research to help minimize bias. 
In terms of specific sample size necessary to reach thematic 
saturation, there is a great deal of variation reported in the literature.  
Romney et al. (1986) reported that small samples, with as few as four 
individuals, can sufficiently provide complete and accurate information 
within a particular cultural context, if the participants possess a degree 
of expertise and competence about the domain of inquiry.   A review 
by Guest et al. (2006) showed that though numerous disciplines utilize 
the term and encourage saturation of themes, few actually provided 
guidelines for sample sizes using nonprobabilistic sampling.  The point 
at which the research findings have meaningful themes and useful 
interpretations yet no new information or themes are observed usually 
occurs within twelve interviews, but may occur with as few as six  and 
it is also suggested that saturation will be reached sooner,  the more 
similar participants are in their experience with the research domain 
(Guest et al. 2006).  According to Bernard (2011), sample size may 
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vary between ten and twenty knowledgeable sources, with the goal to 
uncover and understand the core categories in a cultural domain.   
Creswell and Clark (2011) suggested that the sample size should 
relate to the research question as well as the approach used and can 
vary widely between one and thirty. 
For this project, open ended semi-structured interviews were 
aimed at eliciting individual and structural factors influencing the 
willingness and ability of physician/investigators to participate in a 
prostate cancer prevention intervention trial.  They were also used to 
identify factors that may be unique to the various practice areas.  The 
interview guide consisted of seventeen questions, developed by me 
and in collaboration with the dissertation committee and other 
researchers familiar with clinical trials, after an extensive review of the 
literature and with specific consideration of the objectives of this 
project in mind.  Key informants were asked to describe challenges as 
well as share any suggestions to improve future collaborations.  Based 
on strong existing relationships with the majority of participants at 
least a 50% acceptance rate was anticipated prior to the initiation of 
the data collection.  The length of the interviews ranged from thirty to 
ninety minutes, based on the scope of information and responses 
shared by each interviewee.  
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Participant observation.  
Participant observation or learning via exposure (Schensul et al. 
1999) was also carried out at the various research sites, where 
possible as approved by the local IRB.  This collection of data focused 
primarily on the interactions between the physician researcher and 
research team in order to better understand the internal working 
mechanisms of each facility and the process of research at the 
healthcare site.  Observation occurred primarily in the backstage 
(Ellingson 2005) of the clinic environment where staff function “behind 
the scenes” and did not include any observations of provider-patient 
interactions.  An observational checklist was designed to specifically 
note structural factors (such as use of a clinical trial alert system), 
noted previously in the literature as well as those observed by me to 
have an influence on participation in clinical trials, both therapeutic 
and prevention focused.  The goal for this methodology was that it be 
utilized at a minimum of five sites (the non-VA medical center sites 
currently involved in the prostate cancer chemoprevention project), 
during routine site visits.   
Survey. 
The survey was developed by me in collaboration with the 
dissertation committee and other researchers familiar with clinical 
trials, after a review of the literature and with specific consideration of 
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the objectives of this project in mind.  The survey was used to  capture 
demographic information such as years in practice, practice location, 
prior clinical trial involvement, as well as elicit feedback related to 
areas shown by other researchers to be factors in recruitment to 
therapeutic and cancer prevention intervention trials such as impact on 
primary role and time and financial constraints.   By comparing current 
responses across sites and to prior findings it was possible to 
determine if similar factors are salient with those participating or 
considered for participation in a PCPICT.  
The participant survey was administered to the same key 
informants (n=12) who were invited and agreed to participate in the 
open ended semi-structured interviews.  It was also offered to 
urologists (n=19) working in private practice within the state of 
Florida, primarily the greater Tampa Bay area that had inquired or 
been invited to participate in the prostate cancer chemoprevention 
clinical trial.  Unfortunately direct access to the majority of these 
individuals as originally planned was not possible due to an 
unanticipated change in the functioning of local business group 
(urologists working in private practice in the Tampa Bay area).  Access 
that was previously offered (invitation to visit a local urology group 
meeting) was no longer possible.  As a result, these potential 
participants were first asked to complete the survey via email request 
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(including the survey link) from a respected group member/key 
informant and/or via an invitation letter (including survey and return 
stamped envelope) from me.  A modification of the Dillman Total 
Design Survey Method (Hoddinott and Bass 1986) was employed to 
maximize response and follow-up postcards (including the survey link) 
were sent one week after the initial mail-out.  This group was also 
offered the opportunity to participate in the open ended semi-
structured interview as well if desired.  Based on the established 
relationship with parent study participants and a strong relationship 
with a key informant and “insider” with access to this group of non-
participating physicians, at least a 50% acceptance rate was 
anticipated.  Table 2 reflects the planned methodology at each site. 
Table 2.  Planned Methodology by Site 
Practice Area/Research Sites # of Key 
informants 
Methodology 
A- specialty (cancer) center 2 1, 2, 3 
B- specialty (cancer) center 1 1, 2, 3 
C- specialty (cancer) center 2 1, 2, 3 
D- VA medical center 1 1, 3 
E- VA medical center 1 1, 3 
F- VA medical center 1 1, 3 
G- Academic/teaching hospital 1 1, 2, 3 
H- Academic/teaching hospital 1 1, 2, 3 
I-  Private practice (community) 20 3, 1* 
1-Open ended semi-structured interviews 2-Participant observation 3-Survey 
*If agreeable 
 
 
 
46 
 
Data collection tools. 
The Interview guide can be found in Appendix C, followed by the 
content matrix in Appendix D.  The content matrix further delineates 
how the various questions helped to address the study objectives.   
After IRB approval and prior to the initial interview the guide was pre-
tested with one researcher and two physicians familiar with clinical 
trials.  Following the pre-test some questions were further divided into 
sub questions to ease future analysis.  The overall content did not 
change and since no substantive revisions were needed, additional IRB 
approval was not required prior to the initial interview.  The participant 
survey, consisting of nineteen questions, can be found in Appendix E 
and F.  The observational checklist used during all participant-
observation sessions can be found in Appendix G.   
Data Quality and Management 
To assure data quality: (1) I conducted all interviews; (2) 
interviews were audio-recorded (with permission) using an Olympus 
WS-700M digital voice recorder to ensure that no material was missed 
during analysis; (3) audio files were downloaded to a secure, personal 
laptop computer immediately following all interviews; (4) transcription 
occurred as quickly as possible (usually within twenty four hours) 
following the interview; (5) analysis was concurrent with data 
collection; and (6) all thematic analysis was conducted by me.  
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Detailed field notes were transcribed after each observation period and 
used to compare observations across sites including items such as the 
use of clinical trial alert systems, availability of dedicated research 
staff, and communication between staff related to potential eligibility 
to participate in a study, that were not collected by other means.   
Survey data was entered directly into Qualtrics build 38768 
(Qualtrics 2011) by the participants or captured on paper and 
transferred verbatim into Qualtrics by me.   All data was stored on a 
secure, password protected, single access computer, to which only I 
have access.  
Data Analysis Plan 
Qualitative.  
Open ended semi-structured interviews were audio-recorded and 
then transcribed verbatim by me with complete transcriptions 
completed in two to three hours, depending on the length of the 
interview. Each transcript was then reviewed for accuracy, organized 
by question and compiled into the research database.  Information 
collected from the interviews was then analyzed for themes and 
patterns via analysis of recurring words and phrases to specifically 
address the study objectives and research questions.   The constant 
comparative method was used to compare the views and experiences 
of respondents from across the various sites to help explain important 
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differences (Barbour 2001).  Information from the observations was 
incorporated were relevant and appropriate throughout the discussion.  
Quantitative. 
As is standard in qualitative research, the demographic 
information collected via survey was summarized, using descriptive 
statistics to better describe the population as a whole (Kidd and 
Parshall 2000).  This data is not linked in any way to the results of the 
semi-structured interviews or individual survey responses.  The results 
from the interviews, observation and surveys was analyzed 
independently and integrated for the purposes of interpretation in 
order to address the objectives.   
Human Subjects 
This research adhered to professional guidelines and codes of 
ethics for the protection of human subjects.  The purpose of the 
research was explained to all participants who were provided the 
opportunity to ask questions and voluntarily participate in the research 
prior to data collection.  To ensure the confidentiality of all key 
informants, pseudonyms were assigned to all participants and research 
sites in the following format:  
interview number-site type-participation status (01-S_P) 
Site types were designated as specialty centers (S), academic centers 
(A), VA hospitals (V) or private practice/community (P).  Participation 
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status was further delineated as participant (P) or non-participant (N).  
Prior to any subject recruitment, the study was approved for 
adherence to Human Subjects Protection by the University of South 
Florida Institutional Review Board (Pro #7442).  A waiver of consent 
was received and though the informed consent document was 
reviewed prior to all interviews, a signature was not required.  For 
those that completed the survey only, consent was implied with the 
provision of their responses.  This project was also reviewed for 
scientific merit and approved by the Scientific Review Committee at 
the Moffitt Cancer Center, in Tampa, Florida prior to receiving IRB 
approval.    
Summary 
 This chapter set the stage and described the impetus for this 
research.  It then described the qualitative and quantitative methods 
utilized in this study to explore the factors influencing a physician’s 
participation (or lack thereof) in a PCPICT.  The methods included open 
ended semi-structured participant observation and survey 
administration.  This study adhered to professional guidelines and 
ethical standards to assure the protection of human subjects.  Results 
will be presented in Chapter Four and Chapter Five will include a 
discussion of these results.  
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Chapter Four: 
Results 
Introduction 
The purpose of this analysis was to conduct a constant 
comparison of the similarities and differences between the concepts 
that emerged in the field during data collection (Glaser and Strauss 
1967) and the literature presented in Chapters One and Two.  The 
methods, study objectives, and research questions were guided by a 
consideration of the various theoretical frames and constructs noted in 
Chapters One and Two, in conjunction with the use of a grounded 
theory approach as discussed in Chapter Three.  As previously noted, 
grounded theory methodology was also useful while collecting the data 
and at times led the discussion between researcher and participant in 
directions not anticipated, a benefit of this iterative technique, also 
observed by Charmaz (1990).  This vantage point was considered 
advantageous in order to effectively examine the factors influencing 
physicians in their important role as gatekeeper to access to PCPICTs.  
An exploration of the disjuncture that exists between the desire to 
participate or refer participants and the reality of the cultural and 
social factors influencing participation in each local context was 
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constantly considered as data emerged.  This allowed for an in-depth 
exploration of individual experiences and meanings related to cancer 
prevention and participation in cancer prevention intervention clinical 
trials within the context of the larger and unavoidable structural 
factors impacting the practice of medicine, particularly as they relate 
to participation in a PCPICT.   The analysis was conducted with the goal 
of answering the research questions:  
1) What individual factors influence a physician’s participation in 
a PCPICT?  
 
2) What structural factors influence a physician’s participation in 
a PCPICT? 
 
3) How do these factors vary depending on the practice site/area    
    (specialty centers, academic centers, Veteran’s (VA) medical  
    centers, community offices)? 
 
Responses are organized by these questions and as they relate to the 
study objectives noted previously.   Due to limitations that were 
unforeseen at the time of study design (lack of access to a local 
urology group meeting, as described in Chapter Three), there was an  
unanticipated change in the total sample size for some of the methods.  
Additionally, the distribution of participants from various settings was 
altered from the original research proposal.  These modifications 
allowed the objectives, main research questions, and hypotheses to be 
addressed though possibly in a more limited manner.  The final 
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analysis reflects the actual data collected from various methodologies, 
as illustrated in Table 3.  
Table 3. Actual Methodology by Site 
Practice Area Trial 
Participant 
# of Key 
informants 
Methodology 
A- specialty 
(cancer) center 
Y 1 1, 2, 3 
B- specialty 
(cancer) center 
Y 1 1, 2, 3 
C- specialty 
(cancer) center 
Y 1 1, 2, 3 
D- specialty 
(cancer) center 
Y 1 1, 2, 3 
E- specialty 
(cancer) center 
N 1 1,3 
F- VA medical 
center 
Y 1 1, 3 
G- VA medical 
center 
Y 1 1, 3 
H- VA medical 
center 
N 1 1, 3 
I- Academic center Y 1 1, 2, 3 
J- Academic center Y 1 1, 2, 3 
K- Academic and 
Private practice  
N 1  1, 3 
L- Private practice 
(community) 
Y 1  1, 3 
M- Private practice 
(community) 
N 1 3 
N- Private practice 
(community) 
N 1 3 
O- Private practice 
(community) 
N 1  3 
P- Private practice 
(community) 
N 1  3 
1-      Open ended semi-structured interviews 2-Participant observation 3-Survey 
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The results presented are divided into four sections.  Section I 
describes the key informants.  Section II reports on the qualitative, 
ethnographic findings obtained from the open ended semi-structured 
interviews.   Section III reports on qualitative, ethnographic data 
obtained from the participant observation.   Section IV reports on the 
quantitative data obtained from the completed surveys.   A final 
summary concludes the chapter.  
Section I- Key Informants 
 Qualitative. 
The key informants for the open ended semi-structured 
interviews were physician/investigators who had been either directly 
(serving as a co-investigator) or peripherally (referring or asked to 
refer patients for participation) involved in the Phase II, Randomized, 
Double-blind, Multi-centered Study of Polyphenon E in Men with High-
grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small 
Acinar Proliferation (ASAP) (IRB 105730) trial. All interviews took place 
at a mutually agreeable location at a time that was not in conflict with 
the interviewee’s work responsibilities.  In total twelve interviews were 
completed and the informants could be further stratified and described 
as nine participants and three non-participants in the larger/parent 
clinical trial.  Demographic data was not collected for this portion of 
the project; however, based on survey responses, all participants were 
54 
 
male, ranging in age from 30 to >70.  Informants were initially asked 
describe the organization that they work for, and this is elaborated in 
the following responses: 
I work at an academic cancer center NCI designated we’re a 
tertiary care referral center for patients with genitourinary 
malignancies (01-S_P) 
A federal hospital. Large volume. Many social disadvantaged 
individuals. Significant proportion of minority patients (04-V_P) 
We are not considered in the community (to be) a tertiary 
medical center, or quaternary medical center.  (The) perception 
here (is) it doesn’t draw that patient population (for cancer 
prevention research); we have to go out and get it.  Some of the 
things that are unique here is we have to go out and get 
patients.  If we were absolutely focused on clinical research, we 
would go out and do that and we don’t really have the resources 
to do that (07-P_N) 
The hospital that I work at is closely affiliated with the academic 
institution but they are not the same entity.  It absolutely feels 
more like an academic center than a community hospital       
(10-A_P)  
This is two parts organization. My own practice, it’s a private 
practice but it’s not exactly like a regular community based 
practice.  We see more complicated cases, do more complicated 
surgeries and see a lot of referrals from other urologists. 
Basically it’s like an academic practice without being in 
academia.  We are part of bigger group, which has many 
urologists. Everybody has his own office but we work as a group 
we share some common business office and some ancillary 
services (11-P_P) 
Using the criteria originally defined by me, practice sites can be 
categorized as follows: Specialty (n=5), Academic (n=2), Veterans 
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Affairs (n=3), Private practice (n=1), and both academic and private 
practice (n=1).  By considering the views of those from the range of 
various practice sites that have been directly or peripherally involved 
in the trial (participants) as well as those that have not (non-
participants), a better and more comprehensive understanding of the 
factors influencing the actors within their local context was possible.   
 Quantitative. 
The key informants completing the survey included the twelve 
noted above that participated in an interview as well as four that did 
not (n=16).  This group of four additional participants can be further 
described as physicians who had been invited to participate or refer 
patients for participation in the aforementioned PCPICT but had 
declined.  Survey administration took place following the semi-
structured interview for most respondents (n=8).  Two surveys were 
completed by participants separately from the in person interview and 
later mailed to me.  Four respondents (2 participants; 2 non-
participants) completed the survey using the on-line format and two 
non-participants completed the survey and mailed it to me.  As such, 
all responses were entered directly into Qualtrics by the key 
informants (n=4) or captured on paper and transferred verbatim into 
Qualtrics by me (n=12).   In order to be able to make comparisons 
across groups, respondents were sub-divided into two groups, 
56 
 
participants in the PCPICT (n=10) and non-participants (n=6).  As is 
standard in qualitative research, the demographic information 
collected via this methodology is summarized, using descriptive 
statistics to better describe the population as a whole (Kidd and 
Parshall 2000).   
Participants. 
These respondents (n=10) report a range of 6 to 32 (mean 15) 
years in practice.  Medical specialty was reported as follows: urology 
(n=5), medical oncology (n=2), urologic oncology (n=2) and cancer 
prevention/epidemiology (1).  Participants were also asked to report 
the country in which their primary medical training occurred with 
results as follows: United States (n=5), Turkey (n=1), Canada (n=1), 
Ireland (n=1), India and Great Britain (n=1) and Egypt and the United 
States (n=1).  In terms of demographic information, all participants 
completing a survey were male, ranging in age from 30 to 70 years or  
older and specific of each category are found in Table 4 below.   
Table 4.  Participant Age (n=10) 
 
Age range # responses % 
20-29 0 0 
30-39 1 10 
40-49 3 30 
50-59 2 20 
60-69 3 30 
70 years or older 1 10 
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Ethnicity was self-reported as Not Hispanic or Latino (n=9), with 1 
incomplete survey.  In response to the question “How would you 
describe your race” participants were encouraged to select all 
categories that applied and answered as shown in Table 5.  
Table 5. Participant Race (n=10) 
Race # responses % 
American Indian or Alaskan Native 0 0 
Asian 1 10 
Black or African American 1 10 
Native Hawaiian or Other Pacific Islander 0 0 
White 7 70 
Other, Egyptian, Middle Eastern  1 10 
 
Non-participants. 
Those non-participants (n=6) who completed the survey report a 
range of 2 to 28 (mean 13) years in practice.  Medical specialty was 
reported as follows: urology (n=3) and radiation oncology (n=1) and it 
is noted that not all respondents answered all the survey questions. 
Non-participants were also asked to report the country in which their 
primary medical training occurred with results as follows: United 
States (n=3) and Egypt (n=1), again with missing data noted.  In 
terms of demographic information, all non-participants that the survey 
was sent to were male; however, not all respondents answered this 
question.  Those completing a survey report an age range of 30 to 49 
years, though incomplete data also was reported for this question. 
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Ethnicity was self-reported as Not Hispanic or Latino (n=3) and 
Hispanic or Latino (1) with incomplete responses to this question as 
well. In response to the question “How would you describe your race” 
participants were encouraged to select all categories that applied with 
three reporting their race as White while one reported as Black or 
African American. There were three non-responders for this question 
as well.  
The surveys were designed to capture demographic information 
such as years in practice, medical specialty, and prior clinical trial 
involvement so as to better describe who is participating in the 
ongoing clinical trial.  This is a first step at describing this specific 
population, since data on physician participation in prostate cancer 
prevention trials has not been previously reported in the literature.    
The surveys were also intended to elicit feedback related to areas 
shown by other researchers to be factors impacting recruitment to 
both therapeutic and cancer prevention intervention trials, such as 
impact on primary role as well as time and financial constraints.  The 
survey data is not linked in any way to the results of the 
semi‐structured interviews or individual survey responses. 
Section II- Qualitative Findings  
Verbatim transcripts of the open ended semi-structured 
interviews were analyzed by research objective and question, using 
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constant comparison and key words to identify themes and other 
findings. The first group of responses reported here relate to research 
question one (What individual factors influence a physician’s 
participation in a PCPICT?) and an exploration of the individual 
provider level factors -explanatory views on prevention, notions of risk 
and uncertainty, shared decision-making, and duality of roles- that 
influence participation in a cancer prevention intervention clinical trial).  
Individual provider level factors. 
Participants were asked what factors were influential to them 
personally when they made the decision to participate (or not) in a 
cancer prevention intervention clinical trial.  Academic recognition and 
the ability to publish articles was noted by participants from a specialty 
center as well as academic/teaching hospital but not by those in 
private practice as noted with the following responses:  
I think like anything, being in an academic institution- 
publication, participation in the study itself (01-S_P)    
One gets the objective impressions of contributing to progress as 
well as getting academically recognized beyond personal 
satisfaction.  I think also the data, the theoretical underpinning 
for the prevention trials or endeavors, ought to present in such a 
way that they raise interest and enthusiasm because that also 
facilitates selling the trial to the patients. Authorships and design 
(also) entice (04-V_P)  
This suggests that motivations for participation could vary between the 
various practice sites.  Interaction with those within the community 
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was also noted by one participant.  Responses suggested a 
combination of the desire to work together yet also a warning of the 
potential for competition as the following response elaborates:  
I think also having them (trials) readily available for your 
colleagues in the community (is important). To reach out to you, 
for participation and putting patients on trials is definitely 
something which is key because oftentimes they will call and 
they will ask is there a trial you can potentially do for that.  
There are certain other cancer centers in our community actively 
who have clinical trials in GU and other areas and really doing as 
good a job as we are opening trials. I think it’s important for us 
to be able to at the very least have comparable type studies and 
sorta keep up with the Jones’ (01-S_P) 
 
One participant from a VA hospital simply noted the cost/benefit ratio 
as influential with the following response:  
The likely benefit of the trial versus how much effort is at stake 
(02-V_NP) 
 
Institutional support was noted by one participant in a specialty 
center:  
Institutional support. (laugh) It goes back to that. That should 
be top on the list because our mission reads: contribute to the 
prevention and cure of cancer.  So, it’s half of our mission. If you 
look at it from that perspective, half the resources should be 
allocated to that.  Or a significant amount of resources should be 
allocated (03-S_P) 
 
Personal interest/belief in prevention was noted by several physicians, 
at all types of institutions, as the following responses demonstrate:  
I think from my perspective those are studies that should be 
done (03-S_P) 
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If it’s something that I’m interested in.  If I don’t have any 
interest you obviously can see that there’s no sense in agreeing 
to something (08-A_P) 
I can see where all this is going and how it makes sense.  I 
understand what it’s for and so that’s the biggest thing for me to 
understand the trial where they are going with it, what it means.  
Secondly to make sure it has an endpoint that is of interest to 
me and that I well that it’s of interest to me that’s the main 
thing. It would be lovely if we could cure cancer and I wouldn’t 
have a job.  I know that’s not going to happen but if we could do 
something that ultimately lead to less people having it then you 
know, that’s something I’m interested in too (10-A_P) 
The possibility of prevention was noted as well as altruism and support 
for the cause was noted in the following responses:  
Oh, that’s easy. Because prevention of a disease is always more 
attractive option than trying to treat the disease. At a minimum 
it might allow disease that’s a very, very early stage perhaps 
earlier than the traditionally defined clinical stage and I think 
that it will help certainly potential patients avoiding trouble or at 
least minimizing trouble down the road. I think, yes there is no 
question, prevention is better than therapy (04-V_P) 
 
Well as a provider, honestly if it basically helps the fight against 
cancer in any way I think I would be a go anytime.  Contributing 
to the fight against cancer is the most important (05-V_P) 
We try to do trials that meet the greater need (12-S_P) 
Additionally concerns for the patient were noted as evidenced by the 
following responses:  
I think when it deals with prevention if the patients really not 
motivated and their concern is quite low I don’t really feel 
strongly that I would push for some sort of prevention trial but 
when patients are really quite motivated and specifically ask 
what can I potentially do to minimize my risk I think those are 
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suitable patient especially if they are compliant if they live fairly 
close to the institution.  I think degree of commitment and 
interest is really ultimately the strongest predictor of how 
successful they will be compliant with participation (01-S_P) 
Well, that’s like several things 1. Is it something I think the 
patients need? Is there a definite human need there for some 
help (06-S_P) 
Must be patient friendly (07-P_N) 
Scientific merit and feasibility were also noted as important as 
evidenced by the following comments: 
And then #two would be, is it a good scientific question (06-S_P) 
 
There must be a rational for prevention (07-P_N)  
and #three is it feasible?  (06-S_P) 
The ability to enroll patients #1 (08-A_P) 
Also noted as factors likely to influence participation at the individual 
level were the ability to stay current and provide patients access to 
new care as the following respondent explains:   
I look for the trials to one, kinda keep me current plus. I mean 
current with medicine, but a little aware of what might be next. 
Not to get way far ahead of where I’m supposed to be making so 
many assumptions that I’m actually 5 years ahead of the rest of 
the world. We like trials where they bring in new medications not 
new that they are phase 1, we’re not too much on the phase 
ones we’re pretty much the new phase 2 things (12-S_P) 
 
The most frequently noted response categories related to individual 
factors influencing participation in a PCPICT follow below in Table 6.  
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Table 6. Individual Factors of Importance (n=12) 
Comment Site Type (Frequency)  
Scientific Merit  S (1) A (2) V(2) P (2) 
Personal Interest in 
Prevention 
S (1) A (3) V(2) 
Publication/Academic 
recognition 
S (2) A (1) V (1)  
Patient friendly A (1) P(2) 
Patient Need/Altruism S (2) V (1)  
Community engagement S (1) A(1)  
Feasibility S (1) A(1)  
Institutional Support S (1)  
Cost/ Benefit V (1)  
Who is running study P (1) 
Keep current S (1) 
Adequate funding S (1) 
S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice 
Explanatory views on prevention.  
To solicit views on prevention, participants were asked about 
their general philosophy towards preventive medicine.  Based on their 
responses there was wide variation in their interpretation of the 
question.  Some participants spoke of preventive medicine in general 
as the following quotes reflect:  
I think that as we embark in medicine today I think the 
emphasis is sort of moving away from treatment to prevention. 
We know that it’s more cost effective. We know from a society 
standpoint, if we can prevent something you’re much better. 
From a patient standpoint, obviously if you can prevent and not 
have to deal with actual malignancy, prevention is the ultimate 
goal. It’s what we strive for everyday.  So I think that prevention 
is the future of medicine (01-S_P) 
 
I think that’s the wave of the future..we talk about hypertension, 
diabetes, many of the cancers and now there is a better 
understanding for when one could intervene very early (03-S_P) 
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I think it should be the main focus of medicine.  Better to 
prevent than have to treat (06-S_P)  
The government wants to put a lot of money into it so there are 
opportunities for grants and research regarding it.  I don’t see 
how you can be against preventative medicine (10-A_P)  
Other spoke more specifically about cancer prevention as seen with 
the next responses: 
I think there’s lots to do with preventive medicine for cancer. 
Unfortunately, most of the time we see and treat cancer when 
someone’s already got cancer (05-V_P)   
Prevention is very important you know whether it is cancer or it 
is stones or whether it is infection you know that’s that will cut 
the health (care) cost, it will improve the patient well fare.  
When you wait for patient to be treated, there is nothing without 
a price whether it is a surgery or medications. Even you put the 
patient on medication, medicine has side effects too (11-P_P) 
Some spoke more broadly about prevention while others noted specific 
types of interventions that they thought would be most beneficial as 
seen with the following responses: 
My general philosophy is that for most chronic diseases like 
cancer, heart disease, cardiovascular disease, diabetes, the most 
important thing is physical activity and I know my personal 
philosophy is that we need to do more studies using 
intervention, using physical activity as intervention. And the 
second most important thing is diet.  The studies investigating a 
healthy diet rich in vegetables, low in sugar, fat and salt, those 
kinds of things, that’s prevention.  To me the most important 
ones are (those) that look at exercise and diet especially in 
young people, because once those habits get established and if 
you’re approaching 50 year old 60 year old people with 
prevention studies, it may be too late. They have already their 
BMIs already 35 or 40 and you know it’s not easy to get 50 60 
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70 year old people to get motivated to lose weight and start 
physical activity when all their lives they’ve been couch potatoes 
and not eating healthy, not doing enough physical activity. So 
my own personal belief (is) that those kinds of studies are very 
important (09-S_N) 
In general, I think that there’s a lot of screening and prevention 
that we do or call preventive medicine, when a lot of screening 
potentially may not show benefit for example: prostate cancer.  
There’s numerable studies that show benefit of prostate cancer 
screening but there’s probably equal as many or more that show 
there’s no benefit towards prostate cancer screening. And so 
why do I still offer prostate cancer screening to my patients? I 
think that if you can prevent a disease than you should, but how 
many lives or how many tests do you have to do to perform that 
before you know at least when it comes to screening (08-A_P) 
There’s a lot to do with preventing cancer with dietary habits, 
with having good food habits. So many things, day to day 
activities-exercise, good sleep at night. Things like that that 
which might sound ridiculous but they do in the long term diet I 
think plays a lot of role in cancer. So does exercise. So I guess 
that’s important (05-V_P) 
One participant suggested that prevention may work better in some 
situations than others:  
It’s often a good idea. I don’t have a great philosophy.  I think in 
certain situations it works really well other times it doesn’t it just 
depends on all the details of what you are trying to prevent   
(02-V_NP) 
Another participant challenged the definition of preventive medicine as 
well as wellness, posing the question of “when does prevention start” 
and suggested that prevention may need to be better defined, as seen 
in the following quote:  
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That’s a difficult question to answer. In the first place how do we 
define preventive medicine? It means that you know that 
something can go wrong. The issue is the definition of wellness. 
I think in oncology the most important thing is to change the 
image of cancer (for) the population (to) understand it’s a 
chronic disease which probably is a result of a chronic process of 
abnormalities which eventually lead to a malignancy or 
malignancies and therefore just like prevention of other 
diseases, nutritional changes, environmental changes, lifestyle 
changes, the same should be applied to preventing oncologic 
diseases and therefore the definition of when to start ought to be 
better defined.   And the other issue is where does cancer 
prevention start? Could you start to detect molecular fingerprints 
of a micro subclinical cancer and prevent that from becoming a 
real problem?  Is that prevention? Or is prevention trying to 
demonstrate that you prevent even the early oncogenic steps?  
It’s a matter of target of definitions.  So it’s not so simple to 
design these studies (04-V_P) 
 
Overall participants can be described as supportive of preventive 
medicine and a summary of the range of responses can be found in 
Table 7.  
There was generally similarity in responses across all groups 
with themes such as cost effectiveness, preference of prevention to 
treatment and recognition of the value of prevention based on 
expanding medical knowledge noted.  Several participants mentioned 
prevention as the “future” of medicine.  Interestingly, some that were 
surgeons felt that their role in prevention was limited though could 
certainly see the value of prevention as the following response 
elaborates: 
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You know I constantly counsel my patients towards smoking 
cessation for example.  (Those) that don’t have physicians want 
to treat their blood pressure and cholesterol and all that so I set 
them up and tell them they need to do that at their age, if it’s 
appropriate for that. But what do I do with my practice to 
prevent things? I guess I really don’t.  So if asking what my 
philosophy is, I guess it is that I support it. It’s hard for a 
urologist to practice it but I do try and talk to them about 
smoking cessation and get them hooked up with appropriate 
primary care (07-P_N) 
 
Table 7. Explanatory views on prevention (n=12) 
Comment Site Type 
(Frequency)  
Supportive of it S (3) A (2) V(2) P (2) 
Prevention better than treatment S (2) A (1) V(1) P (1) 
Doesn’t work well for all cases, depends what 
trying to treat 
V(1)  
Future of medicine S (2)  
Challenging to define when prevention starts V(1)  
Challenging to design prevention studies V(1)  
Should be main focus of medicine S (1)  
Hard to practice in my arena P (1) 
Need more prevention studies because they are 
important 
S (1)  
I don’t see how you could be against preventive 
medicine 
A (1)  
Government has put a lot of money into it A (1)  
  
S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice 
Following their initial response, participants were asked if what 
they stated was based on what they had learned in their training or 
was more influenced by their professional practice or even personal 
experience.  The responses varied with most noting influence from one 
area or more as seen with the following responses:  
I think I am more attuned to prevention then my training got me 
thinking about. I’ve evolved into more prevention (07-P_N) 
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It’s evolved since then. But, that question may be a little bit 
unfair because I went to med school in foreign county X.  Let’s 
just say that, preventive health may not have been a priority 
there (08-A_P) 
It’s pretty much what I’ve learned in my training. And it’s pretty 
much what life teaches you in a bit of time. You’ve seen people 
die and born in front of you and grow up into men and women in 
front of you and people who were adults when you were children 
you see them pass away by the time you are in this age that I 
am so it kind of gives you a broader perspective of life. Plus 
what I’ve learned in medicine as well.  So both personal and 
professional influence the broader perspective (05-V_P) 
Interestingly, there was varied commentary as to the past and current 
preventive training specifically with reference to American medical 
schools as the following statement:  
Well, in the days that I trained we weren’t really taught about 
the importance of prevention, diet, exercise and all of that.  
More recently, they are becoming more into focus and in medical 
schools and in the scientific community. Fifteen years ago, 
people were very skeptical about diet and exercise so the 
accumulating data is clearly showing that these are very 
important for the past couple of decades. You know there’s more 
and more realization that you’ve got to make real changes (to 
prevent) disease, chronic disease.  These are the things we have 
to change (09-S_N) 
We don’t do a lot of preventive training (with our) surgical 
training. Med school yeah, in terms of primary care they talked 
about preventive strategies, not necessarily preventive 
medications or chemoprevention, things of that sort. Healthier 
living and eating and not smoking and not drinking and things of 
those sort. You know being fit, exercising. Those things are 
stressed and prevention from that point. Healthy lifestyles to 
prevent you from getting cancers and other disease but that’s 
about it (10-A_P) 
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A summary of the responses related to the influence of professional 
practice and personal experience on views about prevention follows in 
Table 8.  
Table 8. Influence of personal and professional experience on views on 
prevention (n=12) 
Comment Site Type (Frequency)  
Personal S (3) A (2) V(3) P (2) 
Professional S (3) A (2) V(3) P (2) 
Changed over time S (1) A (3) V(2) P (1) 
S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice 
Following this, participants were asked to consider how they 
thought their philosophy towards preventive medicine may influence 
their willingness to participate in a PCPICT.   Responses varied in 
specifics; however, there was some homogeneity with all participants 
noting at least some positive influence, regardless of their practice site 
as the following responses demonstrate: 
More and more, I am finding that prevention is probably one of 
the most important components in healthcare and to move it up 
in the agenda to be not the all encompassing but very, very 
important (03-S_P)   
I think it influences it in the positive for sure because I think it’s 
a good thing to be able to prevent disease processes from 
occurring in the first place (10-A_P)   
Well I’m absolutely for it, yeah.  Being in the trenches, seeing 
what disease is at the other end, what is worth preventing    
(04-V_P) 
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Notions of risk. 
Notions of risk came up in various responses, and were 
expressed as a means to determine who may be a good candidate to 
participate in a prevention intervention trial in general as suggested by 
one participant: 
Probably the ideal patient is somebody who has a risk factor for 
a major disease and I think that’s the incentive for getting them 
involved in the first place (06-S_P) 
 
As well as a consideration by clinicians as to when follow-up care may 
be provided, as the following response suggests:  
The high risk feature on a path report might influence how 
aggressive we are together in terms of repeat biopsy. I might 
biopsy them at 6 months but most of the guys don’t get biopsied 
until a year after diagnosis. I’m not convinced that high grade 
PIN (prostatic intraepithelial neoplasia) is perfect just like PSA 
(prostate specific antigen) is not perfect. So I use PSA, the 
presence or absence of PIN.  I use you know patient individual 
factors to say ok, when are we going to do another biopsy and I 
prepare them prior to initial biopsy that we may end up doing 
some more biopsies as time goes by (07-P_N) 
 
As well as who may be offered or encouraged to participate in a 
prostate cancer prevention intervention trial as explained by another 
participant: 
Depending on which condition it is, premalignant condition, if it’s 
something which has a significantly increased risk of cancer 
development I definitely think that they’re at a significant higher 
risk of cancer developing then I’m a little more strongly positive 
influenced or motivated to try to encourage patients to 
participate in a trial.  I think that if it’s something which I think 
the risk is potentially increased but only slightly increased I think 
that I’m very clear to the patients in terms of what the likelihood 
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is of developing a condition and then sort of leaving it up to the 
patient based on how they feel whether they want to participate.   
I think I discuss it with them really keeping that specific relative 
risk really at the as an essential component of the discussion 
(01-S_P)   
 
The interpretation of risk within the medical community and how it 
may influence participation in a prostate cancer prevention 
intervention trial was also discussed as the following responses 
elaborate:  
You know the other thing that’s detrimentally affecting 
particularly prostate cancer I think is the ambiguity in the 
medical community about the significance of prostate cancer and 
the significance of prostate cancer treatment and if we can’t get 
our sh** together at the end of the day, patients think nothing 
why do I even have to prevent it? So, I think that we have to 
start from there but if the consumer thinks that prostate cancer 
is a non-entity then in reality why are we doing the study? That I 
think is probably the biggest nut for the consumer to swallow. 
They don’t realize the significance of prostate cancer.  I as a 
surgeon feeling more and more pressure to discuss active 
surveillance with patients and so the consumer hearing that also 
feels perhaps more and more that they may have a cancer of 
little significance and that being said, do I need to do anything 
about it? (08-A_P) 
I personally think one of the keys is the urologists, and how do 
they want to deal with the reporting of prostate biopsy showing 
PIN. One of them over there will refer because he just doesn’t 
say it’s benign we’ll see you in six months and recheck your PSA 
and exam.  He  will actually spend an extra minute and say it’s 
benign but there’s changes that I think you better go talk to 
them they have an interesting, and I do believe he uses the 
word interesting trial based on green tea.  But he’s got three 
partners not a one of whom has ever sent anything over        
(12-S_P) 
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A summary of the various ways in risk was considered by the 
respondents can be found in Table 9.   
Table 9. Risk (n=12) 
Comment Site Type (Frequency)  
Influences who is offered/encouraged to 
participate in a trial 
S (4) A (2)  
Helps determine who is a good candidate to 
participate in PCPICT 
S (3) A (1)  
Perceived risk determines clinical care S (1) A (1) P (2) 
Physician’s perception of cancer risk  S (3) A (1)  
Overall risk level (safety) of trial impacts 
participation 
S (1) V(1)  
Patients perceived risk and how it influences 
trial participation 
P (1) 
S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice 
Uncertainty. 
Participants were asked to reflect upon times that they had 
decided to offer participation in a clinical trial and to consider how the 
possibility of uncertainty in the plan of care may have played a role in 
their decision to offer the trial.  For those working at a specialty 
center, the possibility of uncertainty did not seem to play a role in the 
decision to offer the trial.  One participant described the 
comprehensive approach taken when considering a patient for a trial 
and another noted that an unknown end is indeed the nature of 
research:   
So you know depending on the patient, on their overall medical 
condition, their general well-being, I discuss it very clearly with 
them that we don’t truly know what the results are going to be 
of a study and potentially they may develop complications from 
the chemopreventive agent or the additional procedures that 
they need to undergo.  I think it’s important not to sort of 
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minimize those and make it very clear that at the end of the day 
we don’t know what the results are going to be and it’s 
important to discuss with them the study design and what 
additional tests are going to need to be done and what the 
commitment is going to be from their end of things (01-S_P)  
 
No. this is not a factor (03-S_P) 
No, I think when you do research you don’t know what’s going to 
be the end (06-S_P) 
Similarly, respondents from two academic institutions noted that 
familiarity with a study protocol helps to eliminate uncertainty as a 
factor of influence when offering a trial and one recognized that too 
much uncertainty could be a factor impacting participation as seen 
with the responses that follow: 
No. I would say that I am if the studies that I enroll patients in, I 
for the most part know the study inside and out (so that 
uncertainty is minimized) (08-A_P) 
 
I feel like I understand the protocol well enough in the beginning 
that I know what the plan is going to be so I don’t feel like 
there’s that much uncertainty. If there was that much 
uncertainty in the plan I probably wouldn’t participate (10-A-P) 
Those from the VA medical centers had not experienced uncertainty in 
the plan of care though similarly to the prior comment, one participant 
did note that if present it could influence the likelihood of offering 
participation: 
If there’s uncertainty then I think it’s less likely (that I would 
offer it). If it’s not a large uncertainty then it doesn’t matter. 
Only if it’s a big difference (02-V_NP) 
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If one has a large or sufficient patient population which might fit 
recruitment to studies, not offering the population access or 
studies shortchanges science (04-V_P) 
Finally, those participants working in private practice noted that 
uncertainty in the plan of care was not a factor of influence when 
considering whether to offer trial participation to a patient.  Instead 
they noted the absence of harm and similarity to usual treatment plan 
as more important as evidenced by the following statements:  
No, I don’t think so. I think as long as the intervention isn’t 
gonna cause harm, I don’t think that that’s an issue (07-P_N) 
It (participation) did not change my treatment plan. This is what 
I usually do. If I get a protocol that does not make sense to me I 
don’t participate but this particular study, it did not change the 
treatment plan.  If a study design was completely different than 
my usual care it would impact my decision to participate       
(11-P_P) 
Participants were then asked how has the possibility of 
uncertainty in the outcome associated with participation in the trial, 
played a role in their decision to offer the trial.  There was little 
variation both between and within groups.  Those participants working 
at a specialty center suggested that uncertainty in the outcome was 
not influential and even suggested the imperfection of medical 
knowledge, importance of rationale for a study and the suggestion that 
uncertainty is the nature of science as demonstrated in the following 
responses: 
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No, on the contrary because  one of (the) things with prostate 
cancer is that most of the knowledge we have is imperfect and 
sometimes it can be erroneous and we are assuming that that 
knowledge is the real truth, which it is not (03-S_P) 
 
You don’t want to do something just blindly, guessing or hoping 
this will do something, you need to have a rational for it        
(06-S_P) 
 
It doesn’t really affect my participation because I think by 
definition that we know that there is uncertainty when you do 
research, otherwise why would you do the research if you were 
certain of the outcome? I believe only through clinical trials 
we’re going to find the truth so there is going to be uncertainty. 
That is a given. It’s the nature of science (09-S_N) 
There was some heterogeneity in the response from those practicing 
at an academic center with one noting that uncertainty would influence 
the way a patient was counseled as well as noting his “patient first” 
perspective as the following responses demonstrate:  
If there was uncertainty it would make it harder for me to 
counsel patients in an unbiased way.   You have to dissect them, 
have to be interested enough in the trial and the outcomes to 
know. And, I guess I put my patients first always so I you know 
if the patients aren’t going to benefit, I won’t even look at those 
trials (08-A_P) 
 
Another disregarded uncertainty as influential and similar to other 
respondents suggested that it was inherent to the nature of research:   
(That’s) why it’s called a trial, we don’t know what is going to 
happen at all.  No, that hasn’t influenced it at all. I would think 
that for prevention it would be less of an issue because we’re 
trying to prevent the disease process.  If it works great; if it 
doesn’t we’re right back in same boat that you were in before.  
As long as doesn’t make it worse but we’re monitoring it to make 
sure it doesn’t make it worse (10-A_P) 
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Those at the VA sites also did not report uncertainty as a factor 
associated with participation in the trial and similarly to other 
respondents noted the importance of safety as evidenced by the 
following comment:   
If there are no significant safety risks, no.  Prevention is looking 
towards avoiding something which might be defined only once it 
comes up, while therapy you already have the target, it’s well 
defined. (When)  preventing cancer, I think that the metrics are 
a little bit less well defined because ideally you should not 
prevent what we now define as established cancer (04-V_P)  
 
Another respondent discussed honesty and communication with the 
patient as important means to deal with the possibility of uncertainty 
as noted in the following response: 
I think if you are honest with your patient, with your potential 
recruit, upfront and tell them this is a possibility.  You might get 
some side effect or if it’s a double blinded trial you may get a 
placebo or exact medicine we don’t know.  So (this way) the 
patient knows they might or might not benefit or might get side 
effect or they might have to stop the medication, things like 
that. I think as long as you are up front from the very beginning 
I don’t think I see a problem with that. Patients understand   
(05-V_P) 
One participant in private practice made similar comments to others 
regarding harm or risk with the following remark:  
If it doesn’t help it’s not going to hurt, you know. I have no 
problem with doing that (11-P_P) 
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Various perspectives regarding uncertainty were noted during the 
interviews.  A summary of the range of responses related to 
uncertainty follows in Table 10.  
Table 10. Responses related to uncertainty (n=12) 
Comment Site Type (Frequency)  
Not a factor S (1) P (1) V(3) 
Participation less likely if there is uncertainty V(1)  
Not an issue with cancer prevention studies V(1)  
Not an issue because understands study 
“inside and out” 
A (1)  
Uncertainty lessened because know what plan 
of care/course of treatment will be when on 
study 
A (1)  
No uncertainty if not significant safety risks V(1)  
Communication with the patient reduces 
uncertainty 
A (1)  
When you do research you don’t know what is 
going to be at the end 
S (1)  
There is uncertainty in research, it’s the nature 
of science 
S (1) 
Rational for prevention reduces uncertainty  S (1) 
Uncertainty would make it hard to counsel in 
an unbiased way 
A (1)  
“That’s why it’s called a trial. We don’t know 
what is going to happen.” 
A (1)  
S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice 
Shared decision-making. 
In an attempt to solicit perspectives regarding shared decision-
making, participants were asked two separate lines of questions.  One 
sought to address possible issues relevant to sharing decision-making 
with another provider, as may be necessary if a patient participated in 
a trial at a location away from their usual care.  The other question 
dealt with how participation in a cancer prevention trial impacts the 
physician-patient relationship.  First, participants were asked to 
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describe their thoughts about sending their patients to another facility 
to participate in a cancer prevention intervention trial.  Participants 
were next asked about alternatives to referring their patients 
elsewhere such as having outside study staff come to their office or 
work place.  Another alternative presented was the provision of 
support to train their own staff so that patients could participate in a 
cancer prevention trial but did not have to leave their usual office.  
Many considerations were noted by participants, with factors 
influencing all possible scenarios noted.  A summary can be found in 
Table 11. 
Table 11. Considerations when trial not available at site of usual care 
 (n=12) 
Comment Site Type (Frequency)  
Would consider referring out /would not be a 
problem  
S (1) A (1) V (2) P (1) 
If it was of significant benefit to my patient S (2) A (1) P (1) 
If the trial could take precedence over 
standard treatment 
S (1)  
If patient willing V (1)  
If supports future research V (1)  
The protocol must be logical P (1) 
S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice 
Themes that emerged were the importance of patient benefit, 
financial concerns, the detailed work of running a clinical trial, 
ownership and time. In particular, those that were agreeable or 
supportive of referring patients for participation at another site 
similarly identified themes such as the possibility of a positive 
experience or benefit for their patients and were agreeable to make 
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the referral due to and lack of availability at their own institution as 
the following responses demonstrate:  
Yes, I would. I wouldn’t say no just for the sake because we 
don’t have something available here in our facility as long as the 
patient is happy doing that.  If patient is willing and it helps, 
helps research for the future I would say yes, definitely yes   
(05-V_P) 
Yeah.  I wouldn’t mind that (08-A_P) 
Absolutely. If I have a patient who is eligible for a prevention 
trial somewhere else and if I don’t have something for that 
population I would send them.  Wherever there is a good study 
for the patient, we send them (09-S_N) 
Yes, because it’s something you don’t offer here and they 
potentially could benefit from participating at another place   
(10-A_P) 
I would be if I felt that the agent or the trial being considered 
was potentially quite appealing from a biological standpoint and I 
thought there may be a significant benefit to my patient        
(01-S_P) 
The possibility of “losing” patients or having them “stolen” was noted 
by several participants.  Variance occurred across the types of sites 
where participants worked, with those working at academic centers 
and in private practice more concerned than those working at specialty 
centers, as the following responses suggest:   
No, in the sense that you are sending your patients somewhere 
else and they may not come back. So, why should they? It’s 
almost like saying that if you’re not cutting edge enough to have 
their research trial at your institution so why should I come back 
to you? (10-A_P) 
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One of the major reasons that people do not like to participate in 
the project done in centralized area is that they lose control of 
the patient (11-P_P) 
Well, we don’t worry about people stealing our patients. I think 
that’s probably the big thing. So we wouldn’t mind sending them 
(06-S_P) 
Comments by another participant suggest that the tenure of 
experience may also influence the likelihood that this is a concern:  
You ask a guy like me, I’m not just beginning out in this 
business. I’m not as threatened by sending off as some might 
be.  So no, I wouldn’t have trouble with that.  If you talk to 
someone who’s trying to build a practice they might be less 
inclined to do that (12-S_P) 
 
Concerns related to the coordination of all the details involved in 
referring patients outside the site of usual care was expressed in 
several different ways, in the following responses:  
I’m always more in favor of keeping patients within my 
institution. All of us have a fear that when patients leave here, 
(are) sent out, they can be lost in the paperwork and the shuffle.  
Therefore, if there is an opportunity to have some coordinators 
come here and patients being managed on a trial and kept here 
that would definitely be more suitable or ideal (01-S_P) 
It would find that to be overtly cumbersome.  That’s nothing I 
would encourage (08-A_P) 
I think that would be ok. The only problem I guess is just 
logistics. Who and when are they coming to visit the patient? 
You have facility fees involved, things of that sort that would 
have to be worked out on a higher level. Those things are 
important because if they’re occupying a clinical room then that 
means another patient is not there so potentially losing money. 
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It always comes back to money.  I would much rather have it 
done here (10-A_P) 
A summary of concerns that were noted when a trial was not available 
locally and referral to another site was possible are found in Table 12.  
Table 12. Concerns related to referral to another site (n=12) 
Comment Site Type (Frequency)  
Logistics are challenging A (1) V (1)  
Losing patients to other providers A (1) P (1) 
Lack of transportation to other locations S (1) A (1)  
“Overtly cumbersome” nothing I would 
encourage 
A (1)  
Someone is going to be losing money A (1)  
I would much rather have it done here A (1)  
Volume of patients P (1) 
Complexity of the trial P (1) 
Adequacy of current staffing levels to support 
volume of work 
S (1)  
Patients “lost in shuffle” when “sent out” S (1)  
No concerns at all about this V (1)  
S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice 
The possibility of training current staff in order to keep the 
project at their own site was appealing, yet limitations were noted in 
the following responses:  
It would be in theory. I know that some of the major constraints 
we have today is the number of research staff that we have and 
(the) ability for them to participate in all of our active trials.  I 
think if we ever (are) to do that we would need to increase our 
research staff. If we did that then yes, that would definitely be 
suitable (01-S_P) 
 
So from the research point of view you are better off sending 
your own people because they dot their I’s and cross their T’s.  
All the things that these people don’t care about. If you are not 
sitting next to me by the time the patient left half of the things I 
didn’t do because  I am doing my own stuff (and forgot)       
(11-P_P) 
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Depends on what the trial is.  I mean if it’s really complicated 
that’s one thing. If it’s not that complicated then I think we can 
handle that. A lot depends on if it involves a whole lot of 
technology, it just depends on the details (12-S_P) 
 
With the following statement, one participant was quick to clarify that 
the concern was not related to training, but rather the lack of time:  
The training is not a problem, the time to do it that’s the issue  
(02-V_NP) 
 
Participants noted that these options were not mutually exclusive and 
may actually be complementary and/or interrelated as suggested by 
the following responses: 
I think the three are not exclusive. They are complementary             
(03-S_P) 
 
I think that they are interrelated, they are not exclusive. That 
they’ll occur even within the same site and there will be different 
reasons for why patients can or can’t be referred- distance, 
neighborhood, whatever (08-A_P) 
 
Interestingly, one noted that prevention trials may not be appropriate 
for the patient population served at their facility, with the following 
response:   
If you’re talking about prevention trials they don’t come up very 
often in our discussions because the people I am seeing already 
are sick, they already have cancer (09-S_N) 
 
 Physician-patient relationship. 
The second line of questioning was designed to elicit feedback as 
to just how participation in a cancer prevention trial impacts the 
physician-patient relationship.  Those participants who practice at 
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specialty centers  all noted it as a positive experience with some 
indicating that it fostered trust, the sense of a common goal and 
allowed for the provision of involvement at a different and more 
holistic dimension, and allowed for a continuum of care as the 
following responses demonstrate: 
I think it positively impacts it because patients are realizing you 
are trying to strive for minimizing their risk of cancer 
development that you are offering them treatments that they 
would potentially not be getting anywhere else so I think it 
fosters a degree of trust and of a common goal trying to be 
achieved (01-S_P) 
 
I think it makes it better because it’s more holistic. (You) get 
involved with that particular person at a different dimension, a 
different perspective which is a perspective that many things 
many conditions can be prevented and we just scratching the 
surface of that.  And that would make the relationship more solid 
because one is starting to know the patient very early. You know 
them for longer periods of time. There’s more continuation of 
care (03-S_P) 
It was a positive, that’s about all I can say (06-S_P) 
Any clinical trial I don’t think there is any negative effect on 
physician- patient relationship.  You know most of my patients 
are participating in clinical trials they understand how important 
they are and some of them are very very happy that they are 
participating because they feel that not only are they potentially 
helping themselves but may be helping other people too through 
their participation (09-S_N) 
Those at an academic institution also note a positive experience that 
allowed for a more comprehensive level of care as described in the 
following responses:  
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I speak of this only because of what I have heard from patients 
is that they are actually very happy to come to the university 
setting to hear about nutritional changes. Patients time and time 
again have made the comment that these are things that are not 
talked about with them at other institutions or whether it be in 
the community or what have you. Or they actually seek that 
they want that knowledge and I think that the fact that we do 
participate in these trials helps the patient physician relationship 
and it also lets the patient know on a different level that we are 
concerned about their overall health (08-A_P) 
 
I think it’s a positive thing because you can tell the patient that 
you are participating in that type of a trial that kinda lets them 
know that you’re not just the surgeon that can’t wait to cut on 
you.  It lets them know that you are interested in overall patient 
care and so this is something I can offer you besides just waiting 
for your next biopsy to come up. An opportunity to for me to 
intervene again, so there’s something I am interested in doing 
that might help you not need that intervention.  So I think it’s a 
positive thing for the patients. I think they appreciate that     
(10-A_P) 
Response from those participating from the VA medical centers was 
the most varied, yet also overall considered participation to have a 
positive and rewarding influence on the relationship as well as benefits 
to the patient in respect to contributions to the greater good as 
evidenced by the following responses:  
Oh it’s wonderful because the patients are interested.  Nobody 
wants to get sick. They would like as much as possible to 
participate. Once your patient is in trials even when participation 
is completed, I still see them in my research clinic and you know 
it’s actually (a) very good rewarding relation.  Some get 
recycled; they enter new trials, similar disease spectrums. Oh 
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it’s very rewarding. Wonderful relationship with this patient. It’s 
fun.  Absolutely (04-V_P) 
I think patients by and large appreciate that as a physician you 
are trying to do something for the betterment of humanity.  I 
think the patients feel good about it as well themselves because 
they feel that they are doing something which is helpful for the 
future generations.   As a physician patient relationship I think it 
makes you feel good, that’s my personal feeling. You get to 
know them. They come every so often so you get to see them 
(and) often you develop a relationship with the patients. Both 
the physician and the patient know that it’s something which 
goes beyond the day to day activity, something for the 
betterment of humanity.  (It’s) definitely a positive experience, 
different than the normal (05-V_P) 
The participant working in private practice reports no change in 
physician-provider relationship and suggests that overall patient 
satisfaction is dependent on multiple factors as seen in the statement 
which follows:  
Nothing changes.  They depend upon the outcome you know; if 
the patients have good outcome and good experience they are 
happy. If they didn’t have a good experience they come back 
and express their dissatisfaction.  Does (the) patient leave me 
because I sent him to the study? No. Is (the) patient mad at me 
because I sent him to the study? No. Some of them they feel 
that it is good, that it is better because they have more frequent 
check-up, more frequent lab work. Some of them see this as a 
risk and (some) as a reward you know? (11-P_P) 
A summary of the impact of participation in a PCPICT on the physician-
patient relationship can be found in Table 13.  
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Table 13. Impact of participation in PCPICT on physician-patient relationship 
(n=9) 
Comment Site Type (Frequency)  
Positive Impact S (2) A (2) V (2)  
Doesn’t change/impact it S (1) P (1) 
Makes it better, more holistic S (1)  
S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice 
Duality of roles. 
Prior research suggests a possible conflict when a provider plays 
the dual role of advocate for the patient and for the research.  To 
address this, participants were asked how their ethical responsibilities 
as a physician change when a patient participates in a cancer 
prevention intervention trial.   Many noted that ethical responsibilities 
did not change as seen in the following responses:  
I don’t think they ever change. I mean I think that the patient 
comes first. I don’t think they ever change (08-A_P) 
 
I don’t think they change at all.  I have the same responsibilities. 
Whether they are in a trial or not you still are working under the 
same ethical premise I would think (02-V_NP) 
One informant commented more specifically in relation to the ongoing 
trial and introduced the concept of risk.  Additionally, he suggested 
that the goals of chemoprevention and therapeutic trials may be 
different as elaborated in the response below: 
Good question. I think that they ultimately remain the same.  
One of the premises of being a physician is do no harm. So I 
think that you need to be very clear that when you discussing a 
chemopreventative trial that the goal remains the same as do no 
harm and potentially prevent cancer, but that there are risks.  
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Those risks are what you need to discuss, what those relative 
risks are in terms of percentages of the various complications 
you may have with them.  So, I think your role as a physician 
doesn’t change but (patients) need to understand clearly you’re 
ultimately not knowing what the results are going to be for that 
specific intervention, which is a little bit different from when you 
treat a condition, when someone has a physical malignancy that 
you are treating. So, obviously you are earlier in the spectrum of 
disease but the goal is the same-minimizing the progression of a 
condition (01-S_P) 
 
Several informants did reference the scientific merit of a study and 
how that may be a factor in minimizing any potential conflict related to 
duality of roles as seen in the following responses:  
I think it’s part of the ethics of the practice of medicine.  As long 
as the science is sound and makes sense (03-S_P) 
 
Well, one has to be objective about the study design.  If the 
study is well designed with appropriate controls; reasonable 
ethical eligibility criteria, does not push the envelope, does not 
promise hyperbolic outcomes I don’t see ethical issues, no    
(04-V_P) 
One participant did not report ethical conflict; however, did make 
reference to the fact that a research participant may be treated 
differently than a non-research as seen in the statement which 
follows:  
I am doubly careful about the patient because he has voluntarily 
agreed to do something which may have deleterious effects on 
him. So, I am doubly careful with my research patients to ensure 
that no harm comes to them and that’s true for any patient 
which we would deal with but more so with our cancer research 
patients. One does tend to be a bit extra careful with the details 
and everything else (05-V_P) 
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There was overall no variance in response across types of sites with 
informants from several referring to the Hippocratic Oath and 
physician’s responsibility to first do no harm.  Interestingly, one 
physician working in private practice suggested a potential difference 
between pharmaceutical and prevention trials with the following 
remark:  
I think that exists a certain extent in pharmaceutical trials where 
there’s dollars coming in.  I suppose that the same could hold 
true for a prevention trial depending upon what the budget 
might or might not allow (07-P_N) 
A summary of the responses related to changing ethical responsibilities 
is found in Table 14.  
Table 14. Ethical responsibilities (n=9) 
Comment Site Type (Frequency)  
Ultimately remain the same, premise of being 
a physician is to “do no harm” 
S (1)  
They don’t change at all. I have the same 
responsibilities 
V (1)  
No ethical concerns as long as the science is 
sound and makes sense 
S (1)  
No ethical concerns as long as the study 
design is good 
V (1)  
“Doubly careful” with research patients to be 
sure no harm comes to them 
V (1)  
No change P (1) 
“They don’t ever change. The patient always 
comes first”  
A (1)  
They don’t change S (1)  
“I’m not sure they really do. You still have to 
be the doctor and do your best.” 
S (1)  
S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice 
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Next, participants were asked to discuss any experiences related 
to role conflict when they played the role of advocate for the patient 
and for research simultaneously.  Two responded yes and provided the 
following explanations:  
I have, yeah.  Some trials where I’m a PI  and I’m discussing the 
study and I make it very clear to the patient what my role is in 
the study, I am really forthright about it. I tell them since I am 
the one that designed the study that obviously I may be a little 
biased that I think this study may be beneficial to you, but I 
make it very clear to them what the pros and cons are going to 
be and I make it very very clear to them that the end of the day 
whatever decision they make does not change ultimately how I 
treat them and they will ultimately  get the best quality care 
they can but obviously (it) may vary depending on whether they 
participate or not (01-S_P) 
I would say yes, you know when these LFTs (liver function tests) 
are elevated, how elevated? Is it elevated enough to take them 
off the study? Is the drug doing some harm? So yeah, every 
time there is something (like that) you have to consider (that) 
there’s conflict.  It’s a balance, ok is he really being harmed or is 
he not being harmed?  Is he being harmed enough to come off 
the study or not? Those kinds of things, I just make the decision 
that’s best for the patient. Always do what you think is best for 
the patient (10-A_P) 
Others reported that they had not experienced conflicting roles 
commenting how factors such as financial interest and IRB oversight 
may be influential as noted in the following responses:  
No, I think they come together and it comes with an 
understanding that the research is part of care and is an 
enhancer to the care (03-S_P) 
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I feel that my role is primarily being (an) advocate for the 
patient. So if I don’t see any conflict of interest or ethical 
problems participating in the research.  I’m (honoring) my 
responsibility of being an advocate for my patient. I would do it 
if I were the patient myself so I don’t see any conflict there   
(09-S_N) 
 
No, if I don’t have any financial interest or financial benefit and 
(it) is a study I am convinced to do, I don’t think it changes 
anything. Also (if) the study passes the IRB, you know that (it is 
ethical) (11-P_P) 
 
While others noted that though they had not personally experienced 
role conflict, they could imagine how it was possible as the following 
responses illustrate:  
I could see how that would happen, I haven’t really had any 
personal conflicts but I could definitely see how that could be an 
issue (02-V_NP) 
 
Well, I think that there can be, I wouldn’t say coercion but 
motivation of interest on both sides, if one is willing to accept 
monetary advantages.  Some people have to bring in their 
dollars for research resources and percentage of time and so 
forth that might be squeing a little bit the balance but for me 
personally that has not been an issue (04-V_P)  
 
I have not personally, but I can see how that could happen. I’ll 
give an example: there’s a big group here in town who has a 
whole wing on their building that is dedicated to clinical research 
for profit so while it has not influenced me, I can see how that 
how that potentially could influence people (07-P_N)  
 
A summary of the responses related to duality of roles and possibility 
of role conflict is found in Table 15.  
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Table 15. Duality of roles/role conflict (n=12) 
Comment Site Type (Frequency)  
 
Yes 
 
When PI (Principal Investigator) that helped 
to design 
S (1) 
When labs abnormal A (1)  
 
No 
 
Have not experienced S (2) A (1) V(3) P (1) 
As long as I don’t have financial interest or 
benefit 
S (1) P (1) 
Not if the study passes IRB P (1) 
 
Can understand how it could be an issue 
 
S (1) V(2) P (1) 
S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice 
Changing relationships. 
Participants were also asked to describe changes that occur 
when a patient converts to research participant.  On multiple 
occasions, the informants stated that the actual care of the patient did 
not change.  However, specific changes were noted with the 
coordination of care, workload and documentation requirements, as 
the following responses demonstrate:   
I think that when someone becomes a research participant there 
are more people involved in their active care so there is an 
additional component of coordination that needs to be involved 
(01-S_P) 
 
There is a heck of a lot more paperwork. That’s I mean that’s 
really the main thing but you know typically we’re doing the 
same things for similar reasons (02-V_NP)  
 
Well, once the patient becomes a research participant we have 
to follow everything that is written in the protocol to the minute 
detail because if we don’t do everything exactly as it’s written 
you get a lot of protocol deviations…That’s the only thing that 
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changes once a patient becomes a study subject.   As far as 
patient’s care it never changes (09-S_N) 
 
Additional comments hinted at necessary changes in the level of 
patient commitment or ownership of their care when participating in a 
trial, as the following responses suggest:  
Their treatments or the way they are being cared for is more 
rigorous and requires more of a commitment from them as well 
(01-S_P) 
 
Well I think it makes the patient take more ownership of the 
care and the other thing about prevention trials is that the 
ownership of the individuals care starts earlier down the 
continuum of care (03-S_P) 
The importance of the relationship between the patient/research 
participant and the research team, as well as hints of possible changes 
in this relationship was suggested by the following responses:  
You have to be willing to understand that the research subject is 
a special patient. For technical reasons there are certain 
(protocol) parameters that have to get fulfilled. One cannot cut 
corners and by the same token if the research team does not 
pay attention to the details and accommodate a patient, one 
ends up with noncompliance, drop outs, etc. So, the research 
patient has to be accommodated and (the team must) pay 
attention very very close because otherwise one loses him.  One 
has to be flexible (04-V_P) 
 
I’m trying to look for a change but the only thing I see 
sometimes is that the patient physician (bond) may become 
stronger (08-A_P) 
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Variance in response could not be associated with a specific site type 
as similar themes were noted by participants from specialty, academic, 
VA and private practice sites.  
Participants were also asked to describe any changes that 
occurred when the research participant completed the study and 
converted back to patient again, at the time of study completion. 
Responses by all participants varied, with not all reporting changes.  
Themes that were noted ranged from possible changes in terms of 
trust to a reduction in paperwork and documentation requirements as 
evidenced by the following remarks:    
Sometimes patients, if they’ve had side effects (they) may be a 
little bit skeptical about what you are offering them next.  I think 
you need to discuss with them why their complication happened 
or ultimately outline for them what our treatment goals are 
going to be going forward.  But there may be some challenges in 
terms of the trust (01-S_P)  
 
Of course, once they if they are off study then you don’t have to 
worry about the deviations anymore. You just do your usual 
standard, good clinical practice (09-S_N) 
 
We track them less because we don’t have to see them so often  
(10-A_P) 
 
The most commonly noted change in the physician-patient relationship 
was a strong and lasting bond or attachment between the two as 
reflected in the following responses:  
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You get the impression that they have a stronger bond (08-A_P) 
 
One gets attached to patient and patient gets attached to PI… I 
think it becomes almost like (a) family apparatus or relation, 
which it’s actually very rewarding. Very rewarding (04-V_P) 
We do develop a good rapport once being a study subject and it 
carries on after they are off the study (05-V_P) 
A summary of responses can be found in Table 16. 
Table 16. Changing relationships (n=9) 
Comment Site Type (Frequency)  
People (patients) are more involved in their 
care 
S (1)  
Additional coordination is required S (1)  
Trust may be challenged depending on what 
happens during the study 
S (1)  
Hope the patient becomes a better health 
consumer 
S (1)  
  
Patient-physician bond strengthened A (1)  
Keep them happy so they stay on the study A (1)  
PI-Patient attached like a family apparatus V (1)  
Nothing. We do the same things for similar 
reasons 
V (1) 
We develop a good rapport V (1) 
Patient is special and has to be accommodated 
or you will lose him 
V (1)  
S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice 
Preferred time of involvement. 
Participants were then asked at which point in the research 
process they prefer to become involved, (i.e., conception/design, 
implementation, etc.).  Those working at specialty centers all preferred 
to be involved early at the conceptual and grant writing stages as 
opposed to becoming involved later and gave very concrete and 
specific reasons for this as the following responses elaborate:  
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Early on. I think if possible at the conceptual level because I 
think it gives (me) the ability to give some input from a clinical 
standpoint in terms of what may be important to look at, what 
may be hindrances to the study itself (01-S_P) 
 
As early as possible.  Prevention is (a) very complex issue which 
requires a lot of multi disciplinary approach from the research 
(team), from the basic research, from the translation from the 
clinicians.  And in order to develop a trial all have to be involved 
from the very beginning and not only to understand the trial 
better to be sure that it makes sense and to be sure that 
downstream when has been designed and more importantly 
implemented there is a very clear understanding of what the 
objectives are from the get go (03-S_P) 
The earlier the better because if I’m going to be participating in 
a study I would like to be involved in the planning stages. You 
know, even writing the grant. Having more people involved early 
on you can identify pitfalls and potential problems or even 
assess feasibility better if you have people involved (then)    
(09-S_N) 
The responses from those working at an academic center were more 
split with one experienced participating at all levels yet expressing 
benefits of participating early as well, especially with trials involving 
multiple sites as seen with the following response:  
I have participated in all levels. The ones that I find the most 
valuable are the ones with design (of the study)… I think that it’s 
valuable that if you are thinking of involving 10 institutions that 
they all participate at design level or at least get input at design 
level (08-A_P) 
 
This response was similar to those noted by physicians working at 
specialty centers.   Another physician working at an academic center 
mentioned preferred involvement at the activation and recruitment 
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stage; however, noted that earlier involvement may be beneficial, as 
seen with the response below:   
I like…where I was brought in (to the project), kinda I guess 
towards the end...  because there’s less to do besides just enroll 
the patients.  But, I don’t think I would mind at all being 
consulted earlier on regarding the clinical aspects that could 
potentially play a role later on.  My perception is just that the 
physician probably was not as helpful as (he) could have been 
(with this study) because (he was) so busy (10-A_P) 
Those working at VA medical centers expressed the most variance in 
their responses with one noting that it would depend on the trial yet 
was unable to elaborate and provide more specific details for his 
response.  Another theme observed though not expressly stated, 
seemed to be associated with tenure and prior experience as a 
researcher as the following participant elaborates:  
Well, I believe that after decades in the field, probably some 
individuals like myself might be able to contribute some 
impressions and some valuable details in the planning phase of 
such projects. Not  based on just lab experience (but from) 
being in the trenches, seeing what disease is at the other end--
what is worth preventing and what perhaps is not worth 
preventing (04-V_P) 
 
One physician from private practice preferred to be involved with study 
activation and initiation and not in the planning stages as seen with 
the following response:  
I like to join a study at the beginning. I don’t necessarily want to 
be involved in study design (07-P_N)  
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The physician who has had tenure in both academia and private 
practice noted that several factors influenced when he would prefer to 
become involved: 
It depends upon the study itself and the investigators and my 
degree of how much I know him how much I don’t.  I have a big 
academic background so I don’t mind looking at a study (early 
on to provide input) (11-P_P) 
 
Different from responses to the prior questions, there was greater 
heterogeneity between but not within the types of sites. A summary of 
responses follows in Table 17.  
Table 17. Preferred time of involvement (n=12) 
Comment Site Type (Frequency)  
Design/conception S (4) A (1) V(1)  
When initiating new sites, training and 
recruiting 
S (1) A (1) P (1) 
It depends on the trial V(1)  
“I’m a clinician.  I want to be involved in the 
clinical part of it.” 
V(1)  
Analysis S (1)  
All depends on who the investigator is P (1) 
S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice 
Future participation. 
I will remind the reader that participants were previously asked 
which factors were important to them when considering whether or not 
to participate in a cancer prevention intervention clinical trial.  In the 
final question to address research question one, participants were 
asked what would help to increase the likelihood of participation in 
cancer prevention clinical trials in the future.  This question was 
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designed to focus on factors at the individual, provider level not at the 
broader institutional or structural level. However, the responses 
addressed factors at both levels as well as some specifically related to 
their patients.  I will focus on the individual factors here (though it is 
sometimes difficult to separate the two) and address the larger more 
structural issues in a different question.  
Those participating from specialty centers especially discussed  
larger structural factors and also offered some solutions but none 
noted specific individual or personal level factors that may influence 
their participation in future trials.  This could be a result of the fact 
that due to their high level of specialization (surgical and medical 
oncology) it is challenging to imagine a role for prevention with their 
particular patient populations.  Responses from those at academic 
centers ranged from individual factors such as personal motivation or 
interest and patient factors to academic recognition as seen with the 
responses that follow:   
I thought for a while there that if I… personally became more 
motivated towards nutritional treatment for disease that that 
might also drive my patients to do so too, but I didn’t 
necessarily see that panning off in that they would be 
participating in clinical trials. They may be taking matters into 
their own hands but why they’re not choosing (to participate), I 
don’t know why.  Maybe because they don’t feel that the end 
product for them is tangible, that’s their lack of desire to 
participate.  If there is something tangible they knew that they 
could say hey…I can hang my hat on this. But there’s no science 
there to support anyone making those statements so you can’t 
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make a leap of faith in order to try to get them to buy in       
(08-A_P) 
 
I enjoy participating in the trials.   I’m in academia so I enjoy 
being on the papers… So, certainly having publications…I mean 
the only reason to be involved besides your own personal 
interest if in academia is the fact that you can get your name on 
some papers and if you’re interested can be involved in some of 
these cutting edge evolving things. That’s what it is for me, just 
kinda the personal interest. I like research (10-A_P) 
 
Larger, structural factors such as funding were also noted as influential 
by seen with the following response:  
I think one of the most important factors is if I join as a co-
investigator in a trial will there be enough funds for us to do the 
trial? … And if the clinical trial is providing you that money then 
you know, I would be more inclined to participate and 
institutionally also they will not obviously support a study that’s 
underfunded.  That’s one of the things they look at: does the 
study have funding? Adequate funding. So that’s number one 
and also …the second thing that would be important to me is, is 
it something that I am interested in personally? You know if I’m 
interested personally in that clinical trial design or the 
intervention then I am more likely to participate in it… If I am 
not interested in the trial or don’t think it’s a good idea then 
obviously I am not likely to participate (09-S_N) 
 
Responses from two participants not working in private practice 
provided potential insight into factors that may be influential to a 
physician who was, noting finances and perceived benefit of 
participation in the statements below:   
I don’t know how you would incentivize a guy in private practice 
to participate in trials like this. It would almost have to be 
completely financial somehow.  There are some big groups in the 
country who do participate in trials like that. They present it at 
meetings and they talk about how financially lucrative they can 
be. And a lot of those are pharma trials.  Chemoprevention like 
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this I just don’t know how you would incentivize them because 
you have to have extra visits, you know for research and you 
have the IRB stuff to go through. I don’t know how you would 
incentivize them (10-A_P) 
 
I think most of it would come down to what urologist’s 
perception of the benefit (whether or not he/she would be 
involved) (12-S_P) 
 
In sharp contrast to factors suggested as influential to physicians 
working in private practice, those from the VA centers responded 
differently with both academic and scientific recognition as well as  
more altruistic factors suggested as likely to influence their future 
participation as seen with the following responses:   
You know getting proper credit for contributing patients I think is 
important. It’s not money; it’s academic and scientific credit  
(04-V_P) 
If the study appeals to my mind, that the study is going to be 
something good for the betterment for the future, in my little 
field.  If I can kind of help things along or kind of change things 
fighting cancer that would be one of the factors.  It really gets 
down to nuts and bolts, the crux, what is the study trying to 
achieve? Are we helping the future?  Are we helping the cause, 
fighting against cancer?  That is the bottom line.  This would be 
the primary thing. Everything else is secondary (05-V_P) 
One participant working in private practice noted some similar factors 
to those working in other areas with the following response:  
I have to be interested in the type of cancer that we are trying 
to prevent so that’s number one.  It has to be an organ system 
that I work with closely.  Then the prevention itself has to have 
some rationale, something that seems reasonable and the last 
thing it has to be very simple.  The other thing, I suppose it has 
to be somewhat appealing to patients (07-P_N) 
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Personal and professional interest in the topic of study, patient related 
factors and funding were all noted as important by participants.  The 
range of responses regarding personal factors influencing future 
participation in a prevention clinical trial can be found in Table 18.  
Table 18. Personal factors/future participation (n=12) 
Comment Site Type (Frequency)  
I must be personally interested in the trial S (1) A (1)  
Time V(1)  
“What is the study trying to achieve, will it 
help for the future?”  
V(1)  
More federal funding for prevention S (1)  
Must be patient friendly P (1) 
Must be a type  of cancer that I am interested 
in preventing 
P (1) 
Must be an organ system that I work with P (1) 
“Fewer steps for the patient makes it more 
appealing to me” 
P (1) 
Will there be enough funding for me to do the 
trial?  
S (1)  
Publications A (1)  
Must be a trial that patients are interested in 
participating in  
S (1)  
Academic/scientific credit V (1)  
If it appeals to my mind and is for the 
betterment of the future 
 
V (1) 
Urologist’s perceived benefit S (1) 
There must be a tangible measure that the 
participants can see 
A (1)  
S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice 
Structural level factors. 
The next participant responses are related to research question 
two (What structural factors influence a physician’s participation in a 
PCPICT?) and explore and document structural -organizational and 
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infrastructural- considerations that influence participation in a PCPICT, 
with a comparison of factors across types of sites.    
Influence of sponsor. 
Participants were asked to consider how organizational 
infrastructure may facilitate and constrain participation depending on 
the sponsor and to consider how some sponsors are preferred over 
others. There was great variance in the responses both within types of 
centers and when making comparisons across them.  Disjuncture 
between organizational mandate and allocation of resources was noted 
by an informant from a specialty center: 
From the organizational level our mandate is to do research.  
There is a difference between what is expected and the 
resources provided and the expectation that we would have to 
provide the resources and the organization somehow is the 
coordinator of those resources without allocation of resource. I 
understand the organization needs to be fiscally conscious and to 
be sure that we carry the business but if the organization doesn’t 
allocate the resources that we would need on top of what our 
responsibility is to fund some of that research, they are not 
proportional (03-S_P) 
 
The response from another key informant was suggestive of 
infrastructure related factors that may be influential when considering 
those physicians working in private practice, that are not  
participating: 
If I have to use my infrastructure, I don’t have anyone in the 
office so I have to go through the hospital or I have to hire 
someone. Hiring someone for a small project is not a good idea.  
You have to have the infrastructure, that’s why I think the 
103 
 
community guys shy away from research, there’s too much 
paperwork to do. Even through the paperwork, your examination 
is different, your documentation is different, your labs that you 
will draw is different (11-P_P) 
 
Funding was reported as influential, serving as both an institutional 
barrier and facilitator to participating in research by several 
participants as the following responses elaborate:  
A non-funded trial gets minimal effort from the clinical trials 
support staff (08-A_P). 
The institution wants money coming in the door.  So I think 
we’re getting away from research for the sake of research for 
sure but looking more at research that can pay because if it 
doesn’t pay it just can’t happen long term. There is just not 
enough money going around to pick-up the slack (10-A_P) 
The pharma trials, they basically give more money to do it, so 
sometimes it is easier to find those resources that you need to 
get the job done (02-V_NP) 
At the specialty centers there was a clearly stated preference for 
federally funded trials or those that had gone through some type of 
peer review as opposed to pharmaceutical trials as the following 
responses demonstrate: 
So my experience has been typically trials that are organized at 
the federal level are typically pretty rigorous and well designed… 
when studies are done at (the) federal level a lot of the 
administrative type responsibilities are not necessarily present.  
It is easy just to put the patient on and then everything else is 
taken care of…the flow is a little bit smoother and the effort is a 
little bit less.  We like to participate with some of the big 
oncology groups SWOG (South West Oncology Group) for 
example is one. I definitely think any studies that are being 
conducted directly through the NCI we actively try to participate 
in as well in urology, the SUO (Society of Urological Oncology), 
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has developed a consortium group …. and they have developed a 
couple of trials and I think those are trials we actively try to see 
if we can participate because we know that being open to lot of 
major cancer centers,  accrual should be good…(the) likelihood 
of achieving accrual goals is definitely there (01-S_P) 
 
Well our mandate of trials that are preferable are the 
investigator initiated trials which go through a(n)  outside peer 
review, which is basically federal or it could be at the state level.  
Then you have the pharmaceutical sponsored trials and they are 
at different levels. Definitely, there’s discouragement of doing 
post marketing trials. But there’s a hierarchy of preference that’s 
the expectation and I think pretty much everybody knows about 
the expectation (03-S_P) 
 
We always give precedence to studies that are NIH funded 
studies and investigator initiated studies and then if there is 
room then industry sponsored studies are supported. So NIH 
funded, grant funded studies, always take precedence and then 
followed by investigator initiated studies which may or may not 
be grant funded and then following them you have a drug 
company studies.  Of course you know when the funding is 
getting tougher to get you may have more pharmaceutical 
studies but it doesn’t change the rules that we use to activate 
studies (09-S_N)  
These types of trials were noted by other sites as well but for different 
reasons noted in the responses that follow, such ease of 
accommodation:  
Federally funded studies are easier to get accommodated then 
commercial studies based on fiscal and intellectual property, 
legal (type) aspects.  Some organizational related federal funds 
might be rather accommodated than others like VA cooperatives 
have priority over NIH/NCI studies and certainly over 
pharmaceuticals. VA cooperatives take precedence but without 
the infrastructure to necessarily support them (04-V_P) 
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Additionally, funding limitations at the federal level and the specific 
impact on clinicians interested in doing research locally were noted:  
They say that they (the institution) want us to get federal grants 
because those are more prestigious, even sometimes they don’t 
quite pay as much by the time you get all the directs, indirects 
and those kind of things.  At the same time, to get federal grants 
many times you have to have at least 40% dedicated research 
time and that makes a lot of clinicians not eligible.  So, if we say 
we can’t get these big grants from the government because we 
don’t have research time, rather than give us more research 
time then I think the shift is just to say, well try to get these 
other grants the pharma grants, and such that don’t have that 
requirement (10-A_P) 
A respondent also suggested that sometimes the prioritization of 
research projects shifts as seen in this response:  
Well, for one thing it’s very hard to get federal funding now. At 
least in terms of RO1 type grants for investigator initiated 
(studies). The cooperative group trials are not such a problem. 
Our infrastructure has influenced that a little bit, we participate 
in SWOG and to do that we have to put in a certain number of 
patients in studies every year.  Just recently our director gave 
notice to everybody that we are not putting enough patients on 
SWOG and to quit putting patients on the drug company 
sponsored studies unless there was really some unusual patient 
oriented circumstances.  It does change over time because if we 
are doing really great on SWOG (as) in just a few years past 
then it was ok to go out and get the other sponsors (06-S_P) 
The range of responses related to the influence of sponsor can be 
found in Table 19. 
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Table 19. Influence of sponsor (n=12) 
Comment Site Type 
(Frequency)  
There is a hierarchy of preference S (1)  
Investigator initiated then pharma trials S (1)  
Post-marketing trials discouraged S (1)  
We have a directive and it changes over time S (1)  
Currently cooperative group trials preferred 
over pharmaceutical trials 
S (1)  
NIH funded, investigator initiated then 
pharmaceutical 
A (1) 
Funded preferred over non-funded A (1)  
Institution just wants money coming in the door 
but federal are more prestigious 
A (1)  
Federally funded are easier to get 
accommodated based on fiscal and intellectual 
property issues 
V (1)  
There is no preference V (1)  
I don’t see a difference V (1)  
Not a good hierarchy, each department does its 
own thing 
P (1) 
Pharmaceutical can be easier because I don’t 
have infrastructure 
P (1) 
S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice 
Additional infrastructural barriers such as limited staffing and time 
were also noted by participants across several sites, as evidenced by 
the following responses: 
We are assigned nurse coordinators and it appears that the 
nurse coordinators are always playing catch-up because they are 
so busy.  And the institutional perception is that there are too 
many and they have to be rationed. So we have many studies 
that we want to get going and there is a push back institutionally 
because they say there are only so many nurse coordinators that 
you can use and you can allocate and you have to pay for it   
(03-S_P)  
 
Faculty, they are all incredibly stretched thin.  I think their 
limitation is similar to our limitation in terms of time (07-P_N)  
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One participant elaborated on the barrier of time in the following 
response:  
It’s got to be a trial that a doctor is willing to remember.  And 
then not only willing to remember but willing to spend some of 
their pressured time to bring up in the conversation with the 
patient. If it’s something where the doctor says I don’t mind you 
having that trial but he’s thinking to himself I don’t care about 
that then he’ll never offer it to anybody.   Will be aware but 
barely remember. Will be aware of it and he would remember it 
on multiple choice questionnaire that it’s there but not probably 
not remember to spontaneously bring it up when he’s in front of 
it.  And so you have to know the personalities of the doctors and 
what they are interested in doing (12-S_P) 
 
This insight may be particularly relevant to those in a community or 
private practice setting and should be considered in the design of 
future prevention trials.  
Financial loss. 
 
Next, participants were asked about concerns related to financial 
loss if a patient moved care to participate in a prevention intervention 
trial as well as for suggestions to mediate if it was a concern.  There 
was much heterogeneity in the responses both within and across 
groups as reflected in some of the responses from those working at a 
specialty center: 
(Financial loss is) not really (a concern).  I guess in theory there 
is but not really. I think ultimately that in prevention trials we 
really want to try to offer patients what we truly think 
biologically makes a lot of sense and as long as you continue 
following your patient I think that wherever a trial would be the 
most suited for someone is ultimately the best place for them to 
go (01-S_P) 
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Well it depends how you look at it…from the very bottom but 
irrational business level, yes because you are losing one patient 
but if you set up a system with the view of abundance  in which 
you have scarce resources and the thinking is you need to 
rationalize more and keep the resources to yourself …I  think if 
you have a good trial, subjects will come in…with the 
complexities of the trial you can get it going (and) trials that you 
thought would not accrue at all you start (and get) 20-30% 
which is more than the zero percent. And I think if you have a 
well designed trial, well coordinated if you look from that 
perspective you could be adding, more enlarging than restrictive. 
So if looking at that bigger view then not just business model, if 
you have a bigger network it ultimately becomes advantageous 
then because it becomes available to more people    (03-S_P) 
No, not at all.  For others, I don’t know of any way other than 
financial inducement (06-S_P)  
As well the responses from those working at an academic center: 
I’m an employee of the university I don’t feel a big loss if 
patients move. I look at it, and this is my opinion to the same 
extent if I think someone would be better served to have a 
treatment somewhere else, I’ll refer them there and so that 
being said, that’s probably bigger money loss then perhaps 
revenue generated through office visit for a clinical trial (08-A_P) 
Yes.  There’s no way I would send my prostatectomy patients to 
another facility.  No way. The only thing I can think of is if it was 
a disease process that was not very easy to take care of or if it 
was something that like a lot of the community doctors didn’t 
want to deal with then that would be a good excuse for them to 
send the patient away and have someone else deal with it but 
prostate cancer for example is so pervasive. That’s potentially a 
big money maker. Not only for surgical reasons but you have the 
biopsy involved, you have the follow-up clinical visits to follow 
the PSAs. You know, all kinds of things so if you lose a prostate 
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patient you have potentially lost a lot a of money over time even 
(10-A_P) 
Those working at a VA hospital had the most homogeneity within all 
groups, as well as the least concern regarding financial loss as 
evidenced by the following statements: 
Usually not. I mean I could see how there could be.  At a VA 
there’s not, at all (02-V_NP) 
No. We have so much volume that they don’t care about that 
(04-V_P) 
One participant hinted at the variance between clinical and business 
perspective, both of which cannot be ignored when planning future 
chemoprevention trials as the following quote demonstrates: 
(This) might be a little difficult question for me to answer 
because I don’t know the financials.  At my level, I’m a plumber 
you know? What I do is a bit of urology or go to the operating 
room or go to clinic do my procedures and don’t think too much 
about the finance part of it. I guess no institution would like to 
lose a patient because more patients, more procedures, means 
more money. That’s as simple as that. From their point of view, 
it’s a different ball game altogether. From my side it’s entirely 
clinical and that’s finances. So we need to kind of merge the 
two, find a median path (05-V_P) 
A participant from private practice provided insight into several issues 
including loss of control of the patient and financial concerns with the 
following response:  
It’s not, as long as they are coming back. If you look at bigger 
studies you know, you are not going not get the community 
involved within the design. But if you want to finish it early and 
get the cases, it’s your job to send it to them. You can do this 
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without them losing their control of the patient.  The community 
physician does not like to give up the case because this is how 
they make their money (11-P_P) 
 
These could be possible reasons for the lack of referrals from 
community physicians for the current trial.  These reflections should be 
considered for future projects as well.  A summary of the range of 
responses can be found in Table 20.  
Table 20. Financial loss (n=9) 
Comment Site Type (Frequency)  
I guess in theory there is but not really S (1)  
No S (1)  
It depends how you look at it S (1)  
At my level no but I don’t think too much 
about the finance part of it 
V (1)  
We have so much volume they don’t care 
about that 
V (1)  
Usually not V (1)  
I’m an employee of the university, I don’t 
feel a big loss if the patients move 
A (1)  
Yes A (1)  
Not a concern as long as they are coming 
back 
P (1)  
S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice 
Future participation-institutional perspective. 
The physician participants were next asked to consider factors 
from an institutional perspective that would increase the likelihood of 
participation in cancer prevention clinical trials in the future.  
Responses were varied and though this question was designed to elicit 
factors from an institutional perspective, both individual and structural 
factors emerged as evidenced by the following responses:   
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(Having) dedicated staff. I think that’s the critical point, need to 
have dedicated staff (and) that institution feels is important to 
do prevention trials and allocate them. Institutionally (03-S_P) 
Talking about developing cancer trials, we need more faculty in 
cancer prevention and control (06-S_P) 
Being willing to set up and open dedicated clinical research units.  
Which means clinic space, clerical staff, study nurses, and 
research staff support with the regulatory process.  Currently, 
everybody does it by himself or herself, the investigators. It 
stifles progress. There are lots of patients who are interested in 
trials but (there are) insufficient resources to help investigators 
bring trials to patients and accommodate patients in trials     
(04-V_P) 
I’m not in that division (but) I think that the only thing that 
prevents them from doing more studies is the lack of funding. If 
they had more funding I think they would be doing more       
(09-S_N) 
A summary of themes that developed included increased 
infrastructural support ranging from staff (both clinical research 
coordinators and faculty) to dedicated clinic space, as well as the 
necessity of funding and can be found in Table 21. 
Also mentioned were the current economic climate and its 
impact on healthcare as well as the interconnectedness of clinical 
activity and research as evidenced by the following response from one 
participant:  
I think that the financial climate…in the US overall right now is 
…with the recession, plays a role because right now people aren’t 
going to the doctor much because they don’t have as much 
income.  People are fighting for funded patients to come in.  The 
clinical activity is what pays for research really… it keeps the 
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doors open and the research dollars don’t keep the doors open 
it’s the clinical dollars that do and so we’re encouraged to do 
more clinical activity and the thing that suffers of course is the 
things that don’t make money.  Research typically doesn’t make 
the type of money, clinical does. So, that is not encouraged as 
much I don’t think as it could be. What is encouraged, I think 
sometimes are doing clinical trials that pay like some of the 
industry sponsored things. That’s more encouraged because 
that’s going to put some money in the bank so to speak. I don’t 
feel like there’s always a genuine interest in the research itself. I 
think it’s in the dollars that research can bring in. I think that 
clinical research is more of a priority because we do more clinical 
work here and then even a higher priority is doing clinical trials 
that pay (10-A_P) 
 
Table 21. Institutional factors/future participation (n=12) 
Comment Site Type (Frequency)  
Increased advertising S (1) V(1)  
Dedicated staff S (1) V(1)  
Dedicated research units with dedicated 
research staff 
V(1)  
Increasing patient awareness about trials   V (1)  
Financial incentives for the patients V (1)  
Less paperwork V (1)  
Need more cancer prevention faculty S (1)  
There has to be funding to pay for it A (1)  
Less ambiguity regarding significance of the 
disease and it’s treatment in the medical 
community 
A (1)  
It’s ultimately going to depend on the 
urologist’s perception of the benefit.” 
S (1)  
The institution has to feel it’s important to do 
prevention trials 
S (1)  
S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice 
The importance of incentives and advertising were also noted by 
participants as the following responses demonstrate:   
For (the) institution it would be an incentive to work harder and 
recruit more subjects (05-V_P)  
I think making sure they are publicized more (01-S_P) 
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The final responses related to research question three (How do 
these factors vary depending on the practice site/area (specialty 
centers, academic centers, Veteran’s (VA) medical centers, community 
offices?) and consider how practice area may impact the feasibility of 
participating in a prostate cancer prevention intervention trial.   
Influence of the organization.   
Participants were asked to discuss how the organizational 
infrastructure both facilitates and constrains participation in 
research/clinical trials.  
Facilitation. 
Responses related to the facilitation of research included a 
consideration of the types of patients seen at each site and the 
appropriateness for them to participate in prevention clinical trials as 
the following responses demonstrate: 
We see a fair portion of patients with unique clinical type 
dilemmas or genitourinary malignancies or premalignancies, 
which allow for participation in clinical trials and often times 
patients are seeking trials when they come to us (01-S_P) 
There’s a big referral base to the University for treatment, so it 
gives an opportunity to accrue patients to clinical trials (08-A_P) 
To the importance of integration of the research within usual clinical 
practices was also seen as important as evidenced by the following 
responses: 
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The research is actively integrated within our surgical practices 
(01-S_P) 
 
The other thing that we have that works really well from an 
infrastructure stand point is that we do actually discuss 
prevention (08-A_P) 
 
These trials we’re doing you know are for disease processes that 
I’m going to be dealing with anyway so it makes sense. We can 
just work it in to the natural flow (10-A_P) 
 
Also reported was the importance of having an environment that 
fosters research.  The presence of support was expressed in various 
ways and includes staffing, regulatory affairs assistance and 
administrative backing, as the following responses suggest:  
We have research staff that are present in our clinics (which) 
makes it that much easier to obtain consents and to conduct 
even questionnaires or surveys with patients.  I think similarly 
we have an active list of our clinical trials and protocols that 
we’re that patients may be suitable for in the clinic, and 
therefore, anytime we see patients we attempt to see if they 
would be candidates for one of these trials.  So, I think the 
whole environment is fostered to consider participation in studies 
when possible (01-S_P) 
The organization has mechanisms including a clinical trial office 
which facilitates putting studies through to get the required 
regulatory requirements...we have a research nurse who also 
assists not only in carrying the trial through but putting it 
together and thirdly our mandate and one of our missions is to 
do research (03-S_P) 
An IRB that helps us... research is encouraged by the dean; 
there are dean’s grants that are awarded yearly to facilitate and 
to encourage research. There’s   an office of research affairs that  
basically  makes sure that every research project that’s going 
here is functioning as it ought to and is compliant with you know 
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any standards that are put forth either nationally or locally by 
the IRB or the office of educational affairs to make sure they’re 
compliant (10-A_P) 
The importance of building and maintaining positive relationships with 
physicians within the community was also noted, as reflected in the 
following comments:  
I think we do try and maintain a good rapport with referring 
physicians in the community in order to keep them aware of 
what’s going on (08-A_P) 
We also have “friendly physicians” who are not afraid of losing 
patients. We can keep the care within our system and the 
patients do not have to travel far (to participate in clinical trials) 
(12-S_P) 
One participant noted that though infrastructure existed, this 
only allowed but did not help with the work of the study as seen with 
the following response:  
There’s nothing really to facilitate in any way. There’s 
infrastructure: IRB, research office doesn’t actually help you do 
the study, it just allows you to do it (02-V_NP) 
 
Another participant noted a lack of institutional support with the 
following response: 
No particular efforts on behalf of institution to facilitate 
research…. the institution is not very facilitating (04-V_P) 
Constraint. 
More specific responses related to the how the organizational 
infrastructure constrains participation in research will now be 
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presented.  The most frequently emerging theme, noted across all site 
types was time or lack thereof as noted in the following responses:  
I think part of it is clinical volumes being such, sometimes it 
becomes difficult to take the time to discuss all of the various 
studies that you have available to patients.  And sometimes with 
the volumes you don’t think about it or consider putting people 
on trial.  So I think that it’s a little bit of two way street in the 
sense that being actively busy gives you opportunities to see 
more patients who may be suitable.  Similarly (it) makes it 
difficult sometimes to actively try to recruit as many patients as 
possible for these studies (01-S_P) 
Resources would be me actually having the time to focus on 
patient recruitment, patient identification and managing that 
piece of patient through a study.  So when I say we lack 
resources we lack that type of resource. It’s not that I’m not 
interested but I’m pulled in too many directions. We’re a real 
small department and just don’t have that critical mass to do all 
things we need to do and still do a really quality job in clinical 
research in my book (07-P_N) 
Time definitely.  Time dedicated to the encounter...sometimes 
not having adequate support staff, clinical trial coordinators who 
are readily available. If you are scrapped for time and you know 
you potentially could accrue somebody, but yet you go to get 
somebody and they are not in the office because they are off site 
with someone else it’s like ok, we’ll make it a phone call then.  I 
think that we all know that your best attempt at getting 
somebody is after the physician has talked to them and when 
they are there in the office and quite often if you can’t accrue on 
site, it’s going to be hard to accrue them over the phone or in 
any other way without it sounding as though it’s coercive      
(08-A_P) 
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Additional themes that emerged were documentation  
requirements, limited resources and financial related issues. As the 
quotes will demonstrate, there is often overlap in these factors: 
There is this huge amount of paperwork. Essentially you have to 
have someone whose job it is to do the paperwork. It makes it 
logistically and monetarily harder to do it (02-V_NP) 
 
High volume of nonresearch patients strains all resources—time, 
space, laboratory, radiological and pharmacy resources... 
(Research), it’s a side kick to the general operation of the 
hospital. It’s not a research institution.  It’s accommodated on 
an individual base based also on available monetary resources 
(04-V_P) 
We need more support.... More clinical trials personnel....more 
coordinators and regulatory (staff).  It constrains because we 
don’t have enough staff. Lack of adequate personnel, it can slow 
things down.   You need clinical trial support to help with 
screening, consenting, regulatory and also obviously once the 
patients are on study making sure everything is done right.  In 
other words, the more clinical trials support you have the more 
patients you are likely to put (09-S_N) 
I think it’s just that everybody is so busy clinically that it makes 
it difficult sometimes to participate in research to the extent that 
you could.  We can’t make ourselves less busy, because need to 
be busy to pay the bills (10-A_P) 
We have some infrastructure that could facilitate (research) if 
people wanted to do it.  The problem, the difference between me 
doing this (and others in private practice) is that I send my 
cases (to you).  I don’t need any financial support.  This way I 
can participate as I want but don’t have to put investment into it 
(11-P_P) 
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Then and now. 
Participants were also asked about participation in research at 
other institutions they had worked and to describe similarities and 
difference to their current place of employment.  Not all had 
participated in research at other institutions. Those currently working 
at specialty centers noted some similarities in the responses below: 
I think on the whole scheme of things the framework is 
essentially the same.  We have research coordinators, we have 
research statisticians that we work with… clinical questions may 
vary but at the end of the day when you put them together it is 
close to similar.   (That) made it that much easier (when I came 
here) (01-S_P) 
 
(I am) coming Europe and North America because I came from 
Europe…I don’t see it as a whole lot of difference. Basically the 
bottom line is the same (05-V_P) 
 
And differences were noted across most site types.  Most commonly 
noted was variance in support staff and other resources as the 
following quotes suggest:  
I will say that I think at the current institution there is less 
support staff.  So I think PIs have to take a more proactive role 
and be involved with more of the day to days of how a study is 
conducted and the way it’s being registered and the way patients 
are followed and following specific end points or study (01-S_P) 
 
At the previous VA I worked for (had) internal administrative 
constraints, a lower staffing to patient ratio, much more limited 
diagnostic services, availability, significantly inferior parking 
facilities for patients (04-V_P) 
 
Well, at the NCI, it’s the government’s branch of medicine so 
resources were essentially unlimited while you were there 
because everything done there is done on protocol. So it’s 
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already approved so to speak ...it’s all intramural. It’s almost like 
having a credit card for research (10-A_P) 
 
Changing with the times. 
Those working in specialty centers also noted changes over time, 
most notably changes in funding as well as regulatory requirements as 
described in the following response:  
As time goes by there is less and less and less money.  (When I 
started) resources were almost limitless and you could do any 
research you wanted because there was a lot of money. Now 
money is very tight.  (Previously) one could do research on 
almost anything and now it is more tough and one has to 
prioritize. The point is that there are less and less resources 
available (03-S_P) 
Things have gotten more complicated for everybody now with 
HIPPA, IRB and all the regulations (06-S_P) 
Appropriateness. 
Participants were also asked if the trials that were available to 
them were appropriate for the population that they serve and to 
elaborate as to how this was or was not so.  Emergent themes and 
factors considered were the appropriateness of available patients for 
trials, risk, resource demands, reception by potential participants and 
the ability to “work” the study in to the usual care routine as noted 
with the following responses: 
We definitely should do a better job in looking at more 
innovative trials.  About 10-20% of my patients are seen 
possibly for screening, they are somewhat more appropriate in a 
sense that they already are at the higher at the level where the 
risk of having prostate cancer is higher, and they are in the 
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system. There are biomarkers that one can use now to then 
define whether there is cancer or not (03-S_P) 
 
Yes, so far.  They are relatively low risk and did not require 
extraordinary resources for execution.  Regarding prostate 
cancer prevention (we’ve had a) relatively good reception among 
potential candidates (04-V_P) 
 
Yeah, I think so; it allows me to participate in research that has 
a translational bent and also be able to work it into my regular 
routine of seeing patients (10-A_P) 
Disruptions and integration. 
In the final question to address this objective and research 
question, participants were asked about their experience enrolling a 
patient into a clinical trial and encouraged to discuss any disruptions 
related to enrolling them at their current site of healthcare delivery as 
well as referring them elsewhere. In regards to enrollment at the 
current site of healthcare delivery, it is not generally seen as disruptive 
mainly due to the structure and resources already in place and 
integration with current or usual care.  Enrollment in research was also 
seen as a way to provide a more comprehensive level of care.  These 
results were reported across all site types, as seen with the responses 
below:  
I think if you integrate it into your discussion when you see a 
patient and similarly as long as the logistics of the trial are such 
that you have research coordinators that are readily available (it 
is not disruptive).  I really don’t think it hinders or impacts the 
flow of a clinic or how it’s integrated into your practice.  In fact I 
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think it makes it that much more comprehensive and appealing 
to patients (01-S_P) 
Not that disruptive if you have a good coordinator (02-V_NP) 
The way we do it here, it’s not very disruptive. They come to the 
clinic and they have a problem already and we’re seeing them 
and the physician can say by the way we have this study (you 
may want to consider) (06-S_P) 
I don’t think it disrupted my care with them at all because these 
particular trials didn’t affect what I did at all (10-A_P) 
One participant clearly noted that it could be disruptive yet this was 
lessened with flexibility and dedicated staff as elaborated with the 
following comment: 
Trying to fit (research patients) between other patients, in order 
to accommodate them or research candidate patients is often 
cumbersome.  And (it) requires significant flexibility not just on 
my behalf but on other ancillary staff: study nurses, 
coordinators, secretary check-in check-out people, research 
pharmacy, labs, etc. We cannot have a research clinic every day. 
It’s not a research institution.  The research patient has to be 
treated personally with special attention. (He) cannot be left to 
generic clinics and non dedicated staff.  It backfires.  (04-V_P) 
 
Another participant expanded on the previously mentioned notion of 
time, as well provided a possible model to consider for future trials 
with this response:  
I don’t know about the word disruptive but it takes more time.  
The current study is not disruptive for us because the person 
comes in who already has the time set aside for the 
conversation.  Basically what happens is the urologist does the 
biopsies (and) when he gets the biopsy back and it shows that 
it’s PIN he’s going to do one of two things: he’s going to say 
that’s benign we’ll see you in 6 months just to follow up…or he’s 
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going to say well, it’s benign but you know it’s kinda worrisome 
we’ll send you over to the cancer center… they have some trials. 
But if one doctor was doing all that and they had three minutes 
to talk to you, their talk would be well it was benign see you in 6 
months versus a long(er) conversation about green tea.  You 
know which way they are going to have to go.  Otherwise if they 
(spend) 45 minutes (instead of three) then however many 
people they were going to have to see in those 45 minutes, they 
are backed up (12-S_P) 
 
In regards to referring patients to other sites for participation, there 
was vast heterogeneity in responses with positive and negative 
scenarios noted by respondents from all site types:  
It involves much more effort... there’s more opportunities for 
things to go awry... any time you add variables that could go 
wrong, it can go wrong (01-S_P) 
 
There are different types of constraints because they have to 
package the patient information including PHI and test results 
and so forth in such a way that it can be it becomes portable and 
sometimes there are hybrid situations.  One has to be creative. 
One has to be willing to be flexible and work with all systems, 
but that’s the price for clinical research (04-V_P) 
 
There’s a couple of variables there, it would depend on the 
facility where I am sending them to. How much confidence I 
have in that facility and I guess if I had to do that the best way I 
would do it is to speak to the person whom I am referring him to 
that facility so that he or she knows that I am getting a patient 
from XXX this is what he is supposed to be doing so that you 
know we communicate (05-V_P) 
 
Some at risk populations, it is disruptive because they have to 
do something they wouldn’t normally do to be seen.  So, it does 
change their daily routine (06-S_P) 
 
It’s just an email and phone call to the coordinator.  When you 
have a good coordinator, that’s easy to do. Patient doesn’t get 
lost they have one point person you know, they know exactly 
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what you need they send it to you.  They call the patients.  You 
know, the transition was smooth (11-P_P) 
 
In closing, participants were asked if there was anything else 
that hadn’t been discussed that they felt was important for me to 
know. Perhaps most notably, the issue of limited time and the 
importance of infrastructure surfaced again as evidenced by the 
following responses:  
No, I think the set up that we have here is very is ideal. It 
makes it easy for me to do it.  There’s really very little for me to 
do regarding the trial and that influences my participation more 
than anything else because I am busy taking care of patients. 
The last thing I want to do is have to do a lot of paperwork to 
keep people on the trials and so that would be the thing that 
made me not participate-if we somehow lost the infrastructure 
that we have I’d be less likely to participate because  I just 
couldn’t keep up with all the paperwork   (10-A_P) 
 
Don’t underestimate how busy the doctors are.  Another thing to 
consider for future prevention trials, that they have that 
dedicated slot, coming in to talk specifically about trial versus 
something being added on to what was already in place so if 
planning for future trials maybe keeping that type of thought 
process in place might help (12-S_P)  
 
Also relevant was commentary related to increasing participation from 
the community at large as noted by this participant: 
If you need bigger participation from the whole group it has to 
be a little but more organized.  It has to be presented to the 
group and it may have to go through the research coordinator. If 
you want bigger, you are dealing with many urologists and every 
one of them sees 100-120 patients a week.  If you want this 
volume you have to talk with the organization itself (11-P_P) 
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Additionally, they were asked if there any other factors that influenced 
their willingness or ability to participate in cancer prevention 
intervention trials that had not yet been discussed.   Some 
respondents reinforced comments made earlier such as: 
I think at the end of the day my drive to want to put patients on 
specific chemoprevention trials is believing that they are at 
increased risk of something developing and that ultimately from 
a biological standpoint (the) chemoprevention agent makes 
biological sense and is being given or administered at a time 
point where prevention is possible (01-S_P) 
I think the willingness to participate in general with the 
practitioners is an understanding of what it means, prevention. 
Because many don’t understand it, that there are different levels 
of prevention.  It could add to the quality of care, participating in 
those trials and (also) to understand the mechanisms of the drug 
because many don’t understand them (03-S_P) 
Others noted regulatory challenges and difference in priorities that had 
not been noted previously as seen with the next response:  
Well, there are organizational problems I guess you could say.  
Difficulty with the regulatory affairs certainly…difficulty dealing 
with people within the institution who don’t care about research 
and patient care. That’s a big one right there. And I think that’s 
getting more of an obstacle.  It’s just the volume of work.  It’s 
business versus patient care and research, totally trying to meet 
different ends. And then the whole regulatory thing, the HIPAA 
and all the regular stuff, it gets impossible (06-S_P) 
 
Also not specifically noted previously was the influence of the 
physician’s interpretation of biopsy results and how this may influence 
participation in a cancer prevention clinical trial as described by one 
participant: 
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What makes or breaks whether a physician will even mention a 
trial is their interpretation of how significant the biopsy findings 
are.  So if they think HGPIN -it’s benign it’s one thing. But (if) 
interesting finding- it’s going to be a whole different 
interpretation and sense of what needs to be done. And then I’m 
sure it’s also comes down to what the doctor’s interpretation of 
what the patient wants to hear.  If you are going to design this 
type of trial I think you really need to get feedback from the 
people that are going to be involved in it, at least on a PIN sort 
of prevention trial.  (And) the urologist because they’re the ones 
who do the biopsy, they’re the ones who interpret it. They’re the 
ones whose name is on the pathology report.  And then it comes 
to how they interpret or respond to that, if they’re one that will 
that it’s not cancer so instead of yearly we’ll see him at 6 
months or if they say whoa something’s starting up (12-S_P)  
 
Possible challenges at the institutional level between the dual role as a 
surgeon and researcher and financial considerations were also noted in 
the following response:  
Nobody is going to give a physician 40% research time, a 
surgeon, when I can go bill in a quarter what the grant is going 
to be for the whole 3-5 years.  The institutions like, you gotta be 
kidding me, my surgeon’s going to the OR. I think that prevents 
a lot of good research from happening and it prevents a lot of 
physicians who have an interest in research from being able to 
pursue that as their career goes on. And, you have physicians 
who have done a lot of preparation in terms of research 
preparation and to be in academia who eventually fall out of 
academia for that very reason.  The bottom line (is) I can’t get 
the grant because I’m too busy taking care of patients. And 
that’s what research is for, supposedly (10-A_P) 
 
Finally, some comments shed light into the private practice 
arena, suggesting a role for future urological prevention studies, and 
noting future potential challenges when involving those physicians in 
private practice in future cancer prevention intervention projects:   
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A urologist can’t back down from the bread & butter urology that 
men need. So I have 2 groups of patients. I have patients that 
have cancer that I operate on and follow them along and guide 
them through that whole process and that’s what I like to do and 
that’s why I do what I do.  But I’ve got this whole cohort of 
patients that I follow for prostate cancer screening and BPH and 
they come see me on a regular basis. They get to know me and 
how the practice is. I think definitely the group that I develop 
the relationship with over time is most appropriate place for a 
prostate cancer prevention trial.  And so the cancer prevention, I 
don’t think should be focused on tertiary/cancer surgeon but 
more on my primary role as a urologist. So that’s where cancer 
prevention (needs to be) and with primary care doctors as well. 
But getting them interested, that’s a whole different story I 
suppose (07-P_N) 
 
The important thing, the way to do that is you have to have a 
protocol that is logical. People like it and agree upon it and want 
to participate. One of the major reasons that people do not like 
to participate in the project done in centralized area is that they 
lose control of the patient (11-P_P) 
 
Section III-Qualitative, Ethnographic Findings from Participant 
Observation 
 
This collection of data focused primarily on the interactions 
between the physician and research team in order to better 
understand the internal working mechanisms of each facility and the 
process of research as it occurred at each local healthcare site.  
Observations were conducted in the backstage (Ellingson 2005) of the 
clinic environment, not in the presence of any patients or study 
participants.  For consistency in data collection, an observational 
checklist was used to compare observations across sites and included 
items such as the use of clinical trial alert systems, the availability of 
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dedicated research staff, and communication between staff related to 
potential eligibility to participate in a study that were not collected by 
other means.  During this time I was also fortunate to be able to 
engage in conversations with research coordinators, a research nurse, 
a regulatory specialist, a grant administrator and a research manager.  
I was also able to draw upon my familiarity and comfort level in the 
clinical arena and report on observations that were made beyond what 
was originally planned.  Due to privacy and other considerations, this 
methodology was not utilized at VA medical centers or any private 
practice/community offices.  At these sites this information was 
obtained when possible directly from the key informant during the 
semi-structured interview or via informal conversations with the 
parties noted above.  
Use of Clinical Trial Alert system (CTA). 
None of the specialty centers used a CTA system to alert 
practitioners about trials for which a patient could potentially be 
eligible.  During the observations I had the opportunity to speak with 
coordinators and research nurses.  When asked about the use of such 
a system, several expressed some concern that though a CTA may 
alert the physician regarding potential eligibility to participate in a trial 
(therefore increasing awareness), it would only be a starting point to 
enrolling a patient and would not eliminate the detailed screening for 
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eligibility that would follow and was usually completed by them, prior 
to physician involvement with the patients.  Echoing comments from 
the coordinators and research nurses, the physicians also expressed 
reservation about the potential for a system (CTA) to accurately 
identify the appropriate patients for participation, noting that some 
element of human involvement would still be needed to verify the 
system’s results.  Several physicians voiced an interest in this type of 
alert during the interview; however, also expressed skepticism as the 
following quote reflects:  
(It) May be my own lack of exposure but I’ve never seen one 
that would work well, you have to pull together a lot of data 
points. Not saying it’s not possible, it’s just not easy (02-V_N) 
 
Respondents from one center did note a “flag” that was 
supposed to be used to identify subjects currently participating in 
research projects.  Not all staff at this facility was aware of this feature 
suggesting that it was not universally or consistently utilized.   Another 
specialty center did not use a CTA; however, the participant noted that 
their recent transition to an electronic medical record (EMR) would 
make it easier to keep referring physicians abreast of what was 
happening with a patient that had been referred for clinical trial 
participation: 
With the new electronic medical records and computerized scans 
you know you can do a lot just looking at that which should 
make it easier to stay in contact (12-S_P) 
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All respondents from VA sites reported that a CTA was not 
utilized and two out of the three also reported that a “flag” specifically 
identifying research patients was not in use.  One VA site participant 
did report the use of such a system as the following response 
demonstrates:  
I have patients details on the electronic medical record (EMR) 
(and) the first thing that pops up is (notification that) this is a 
research patient (05-V_P) 
 
The physician at this site was not aware of how accurate or 
consistently this feature of the institution’s EMR was used.  However; 
the responses suggest variance even within one type of system.  The 
academic centers were not utilizing any form of CTA system or even 
an EMR at the time of data collection. 
Dedicated research staff. 
The importance of dedicated research staff cannot be 
understated as was evident from the interviews and observation 
conducted for this project.  Participants at all sites noted the critical 
and valued role of research staff as the following responses 
demonstrate:  
All that matters is who your research coordinator is. That’s 
basically 99% of it.  The other things may differ a little but the 
research coordinator is all that matters (02-V_N) 
 
I think the set up that we have here is very is ideal…(the 
coordinator) takes care of everything and there’s really very little 
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for me to do regarding the trial and that influences my 
participation more than anything else because I am busy taking 
care of patients. The last thing I want to do is have to do a lot of 
paperwork (10-A_P) 
 
When you have a good coordinator, it’s easy to do (11-P_P) 
 
Clinical trial coordinators were noted most often followed by regulatory 
support staff with participants often noting that without this support, 
participation in clinical trials would not be possible as the following 
response illustrates: 
That would be the thing that made me not participate-if we 
somehow lost the infrastructure that we have I’d be less likely to 
participate because I just couldn’t keep up with all the 
paperwork (10-A_P) 
 
There were various ways that this staff was structured and utilized 
depending on the site.  Some were integrated within the surgical 
department while others were supported via a clinical research or 
other research department within the institution.  Even within systems 
that would seemingly be similar (VA hospitals) there was no one way 
to participate in research.  The participant in private practice did not 
have his own dedicated staff; however, noted that depending on the 
trial they were available via various scenarios allowing him to make 
participation in research projects a part of the comprehensive care 
that he provides to his patients.   
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Communication between staff. 
During the time that participant observation was conducted 
there was minimal discussion between physician and research staff in 
regards to the possibility of participation or enrollment of specific 
patients in a clinical trial.  In one instance a clinical trial coordinator 
made the physician aware that a patient was potentially eligible to 
participate in a clinical trial and then reminded him of the inclusion 
criteria before the physician entered the patient room.   When 
research coordinators were observed in the clinic setting, it was 
noticed that they functioned very independently from the physician, 
relying more on communication from nursing and other staff (other 
coordinators, scheduling specialists, medical assistant, etc.) regarding 
patient status and other details necessary to identify patients that may 
be eligible to participate in a particular research study.  In one 
specialty center there was a very collegial atmosphere between the 
research coordinators who often made each other aware of the 
specifics about a patient, which were then used to help determine 
potential eligibility.   
At some sites it was difficult to discern if the minimal discussion with 
the physician could be attributed to the presence of an “outsider” with 
the usual flow of practice interrupted by my presence or if indeed this 
was the norm in that particular setting.  Utilizing the observation 
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checklist as a guide, a summary of the data collected during actual 
observations can be found in Table 22 below.   
Table 22. Participant observation (n=6) 
Criteria Site type (times observed)  
Use of CTA S (0) A (0)  
Dedicated research staff S (3) A (3)  
Consideration of patient for 
participation in research 
study by physician 
S (0) A (0)  
Consideration of patient for 
participation in research 
study by other staff 
S (4) A (0)  
Communication between 
staff related to eligibility to 
participate in a trial 
S (2) A (1)  
Definitive plans to present a 
clinical trial to a patient 
S (0) A(0)  
 
Beyond the checklist. 
During my time in the various clinics, observations were made 
that were not initially included on the observation checklist; however, 
further expanded my understanding of how research was conducted at 
each of the various sites.  This helped to identify the variances at each 
location and to glean insight as to what best practices for a future trial 
may be.  Of great interest to me was that though research 
infrastructure was in place in varying degrees at all of the sites where 
observation occurred, many of those involved in the work of research 
(nurses, coordinators, physicians) found the structure to be more 
prohibitive than helpful.  This was mainly due to the many levels of 
documentation that needed to be completed at varying steps in the 
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research process.  Though thorough documentation was recognized as 
necessary and important, many coordinators in particular felt that 
there were redundant steps that could be stream lined, resulting in a 
more efficient use of their time while still adhering to the necessary 
guidelines that are considered good clinical practice.   
Also of interest was that though the study had a very specific list 
of inclusion and exclusion criteria that was to be used in identifying 
and pre-screening appropriate subjects for participation, one 
coordinator reported, “We have our own set of pre-inclusion criteria”  
This was echoed by study teams at several of the sites who reported 
that things like overall health history and presence of other 
comorbidities, transportation, flexible job schedules (which would allow 
for adherence to required monthly study visits), family support, 
education level and perceived patient interest were often considered 
before the actual study inclusion/exclusion criteria were reviewed or 
the possibility of participating was presented to the patient.  This 
unofficial set of criteria often eliminated potential subjects that 
otherwise may have been interested and/or eligible to participate in 
the trial.  It is unclear from the data collected for this research how 
this ultimately impacted the screening and recruitment numbers 
reported by each site in the ancillary study; however, it did most likely 
result in the underreporting and elimination of potential participants.  
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 A final observation was that research visits occurred primarily in 
one of two modes at the different sites.  One model was that patients 
were identified by research coordinators or physicians and approached 
about participation in the trial in clinic on the same day that they were 
present in clinic for another reason.  If approached then about trial 
participation, the result was often a conflict of time for all parties 
involved.  If interested in participating, the visit was then extended 
and longer than the patient and staff had planned resulting in a 
competition for time and clinic space as well.  The second model was 
that patients were identified in advance, while away from the clinic and 
then contacted about participation.  If they expressed an interest and 
met initial criteria then a research specific visit was scheduled.  
Patients then came to the clinic for a future appointment where time 
and space were dedicated to them.  The second model seemed to work 
more effectively in that the patient as well as the research team was 
better able to prepare for the visit.  This lessened the competition for 
time and space at the initial visit.  Subsequent visits were all arranged 
in advance and there seemed to be less competition for resources 
because of this.    
An awareness of these additional factors may help to further 
identify the best sites for future cancer prevention trials and should be 
considered in the design of upcoming trials.  Additional insights about 
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the overall clinic environment, the patient population at the various 
research sites and how each may influence future trials are found in 
Chapter Five.   
Section IV-Quantitative Data from Surveys 
Participants. 
Participants were asked about involvement in clinical trials and 
all reported previous involvement in one or more  
(range: 3-100) clinical trials.  Types of involvement ranged from 
recommending that a patient participate in a clinical trial to actually 
participating in the design of a clinical trial.  The range of responses 
and more specific descriptions about the types of involvement are 
further described in Table 23.  The reasons for involvement in clinical 
trials were also captured and the variance in responses can be found 
below in Table 24.  The main reason noted for participating fell into 
four broad categories including altruism and benefit for patients (n=4), 
advancing medical science/scientific knowledge (n=4), 
education/keeping current (n=1) and personal interest in clinical trials 
(n=1).   More specifically in regards to participation in prevention 
trials, participants reported prior participation in a range of 1-12 
(mean=3.5) trials each.  The reasons noted for participating in 
prevention trials are found in Table 25 and the main reason for 
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participation in prevention clinical trials verbatim as reported by 
participants can be found in Table 26 below. 
Table 23. Types of involvement in clinical trials (n=9) ( 
  Types of involvement in clinical trials # 
responses 
% 
I have participated in a clinical trial 
(therapeutic or prevention) in other ways. If 
so, please explain 
3 33 
I have had patients inquire about clinical trials 
(therapeutic or prevention) 
5 56 
I have participated in the design and 
implementation of a clinical trial (therapeutic 
or prevention). 
5 56 
I have recommended patients participate in a 
clinical trial (therapeutic or prevention) 
administered by others. 
6 67 
I have had patients enroll at a clinical trial 
(therapeutic or prevention) at another location 
because it was not locally available. 
7 78 
I have recommended patients participate in a 
clinical trial that I administer. 
8 89 
 
Table 24. Reasons for involvement in clinical trials (n=10) 
Reasons for involvement  in clinical trials # responses % 
Advancing Medical Science 8 80 
Providing access to a novel treatment 9 90 
To expand available services 4 40 
Challenge 3 30 
Variety 1 10 
To earn extra income for my practice 1 10 
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Table 25. Reasons for participating in prevention trials (n=10) 
Reasons for participating in 
prevention trials 
# responses % 
Advancing Medical Science 9 90 
Providing the best possible care 5 50 
Providing access to a novel 
treatment 
5 50 
To expand available services 3 30 
To earn extra income for my practice 1 10 
 
Table 26. Main reason for participating in prevention clinical trials (n=9) 
Main reason for participating in prevention 
clinical trials 
# responses 
                 % 
Advancing Medical Science 4 44 
Interest in their effect 1 11 
Impact a premalignant condition before it 
develops into   malignancy 
1 
11 
Prevent cancer suffering 1 11 
Prevent cancer 1 11 
A personal belief in the benefits of prevention 1 11 
To offer patient chance to prevent disease 1 11 
Improve healthcare delivery for mankind 1 11 
 
Somewhat in contrast to work by Weinberg et al. (2004) that 
reported survey participants would be much more likely to enroll 
patients to treatment than screening, diagnostic or prevention trials, 
this group of respondents was interested in participating in prevention 
trials for the reasons noted above.  The factors influencing the 
participants and their decision to participate in any type of clinical trial 
are found in Table 27. 
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Table 27. Factors influencing participation in any clinical trial (n=10) 
 
Factors influencing participation in any 
clinical trial 
# responses 
                % 
Influence on clinical care process 6 60 
Time 6 60 
Financial Incentives 1 10 
Cost to you/your institution 3 30 
Paperwork requirements 4 40 
Staffing 4 40 
Concern for your patients well-being 7 70 
Introduction of another care provider or 
decision maker 
1 
         10 
Requirements of the research protocol 7 70 
Institutional support 4 40 
 
These factors reported by participants and noted in Tables 24-27 as 
influential in their participation in all types of clinical trials are similar 
to those previously reported in the literature such as the presence of 
incentives and disincentives (Cohen 2009; Yates 2003), staffing 
challenges (Meropol et al. 2007), documentation and paperwork 
requirements (Comis et al. 2000; Crosson et al. 2001; Orozco 2009; 
Weinberg et al. 2004) and the presence of research infrastructure or 
support (Al Refaie 2011; Somkin et al. 2005).   
Non-participants. 
Non-participants were also asked about their prior involvement 
in clinical trials and this ranged from addressing patient inquiries about 
clinical trials to participating in the design and implementation of trials.  
The responses related to involvement in all clinical trials can be found 
in Table 28. 
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Table 28. Types of involvement in clinical trials (n=4) 
Types of involvement in clinical trials  # 
responses 
% 
I have had patients inquire about clinical trials 
(therapeutic or prevention) 
3 75% 
I have recommended patients participate in a 
clinical trial that I administer. 
1 25% 
I have recommended patients participate in a 
clinical trial (therapeutic or prevention) 
administered by others. 
4 100% 
I have participated in the design and 
implementation of a clinical trial (therapeutic or 
prevention). 
1 25% 
I have had patients enroll at a clinical trial 
(therapeutic or prevention) at another location 
because it was not locally available. 
1 25% 
 
Of those responding to survey question seven, two respondents 
reported participation in one or more therapeutic or prevention clinical 
trial while two reported no prior participation.  Reasons for 
involvement in clinical trials as noted by respondents are found in 
Table 29 which follows. 
Table 29. Reasons for involvement in clinical trials (n=2) 
Reasons for involvement in clinical trials  # 
responses 
% 
Advancing Medical Science 1 50% 
To expand available services 1 50% 
Challenge 1 50% 
Variety 1 50% 
To earn extra income for my practice 1 50% 
 
Similar to participants in the PCPICT, advancing medical science, 
expanding available services and earning extra income were all noted.  
140 
 
Additionally, non-participants note challenge and variety as two 
additional reasons for prior involvement in clinical trials.  The main 
reasons noted for participation were to earn income for the practice 
(n=1) and advancing medical science (n=1). 
 Two non-participants reported that they have participated in 
prevention trials as an investigator or other study personnel noting the 
reasons shown in Table 30.    
Table 30. Reasons for participating in prevention clinical trials (n=2) 
Reasons for participating in prevention clinical trials # 
responses 
% 
To earn extra income for my practice 1 50% 
Providing the best possible care 1 50% 
Advancing Medical Science 1 50% 
 
The main reasons reported for previously participating in prevention 
clinical trials were earning extra income for the practice and providing 
the best possible care, which were different than the main reasons 
noted by participants who most commonly reported advancing medical 
science.   This differential would benefit from further exploration if 
more direct inquiry (interviews) with non-participants was possible.  
Additionally, factors influencing the decision to participate in any type 
of clinical trial can be found in Table 31.  
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Table 31. Factors influencing the decision to participate in clinical trials (n=2) 
Factors influencing the decision to participate in 
clinical trials 
# 
responses 
        % 
Time 1 50% 
Cost to you/your institution 1 50% 
Paperwork requirements 1 50% 
Staffing 1 50% 
Concern for your patients well-being 1 50% 
Institutional support 1 50% 
 
Staffing, documentation and paperwork requirements, and research 
infrastructure or support are factors similar to those reported by the 
participants in the PCPICT and prior literature as discussed above.  The 
concern for patient’s well-being is a factor influencing participation 
which has been previously identified by Weinberg et al. (2004).  
Concerns related to time and cost were also identified in the interviews 
as the following quotes reflect:  
I think that the biggest constraints are time (12-S_P) 
As time goes by there is less and less and less money.  
(Previously) resources were almost limitless and you could do 
any research you wanted because there was a lot of money. Now 
money is very tight (3-S_P) 
 
One respondent provided a reason for not participating in clinical trials, 
whether therapeutic or preventive in nature, writing in that “clinical 
trials not part of the practice model that I joined”.  Unfortunately due 
to the nature of reporting via survey, this response could not be 
expanded upon; however, commentary from one participant may 
provide some perspective:  
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Most (physicians) are in private practice for a reason. ..If I was 
in private practice, I would have to think of myself as not as 
someone who is not interested in academics. I’m not interested 
in research. Why would I do this? (research) I got a tee time at 
(1), you know?  I wouldn’t do it (10-A_P) 
 
The various medical practice models and ability as well as desire to 
participate in clinical trials should be an additional consideration when 
determining future recruitment sites for prevention trials.  The overall 
response rate to the surveys was not significant enough to consider 
additional analysis using SPSS.  The results from the interviews and 
surveys were analyzed independently and will be integrated in chapter 
five for the purposes of interpretation in order to address the research 
objectives. 
Summary 
 This was a formative, exploratory study conducted to provide an 
in-depth understanding of the individual and structural factors 
influencing a physician’s participation in a PCPICT, a topic with little 
documented research to date.  A mixed methods research design using 
qualitative, ethnographic (open ended semi-structured interviews and 
participant observation) and quantitative (survey) methods was 
employed to examine factors of influence within the context of an 
ongoing PCPICT.    
This chapter provided the results of the data that was obtained 
from the open ended semi-structured interviews, participant 
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observation, and survey methodology employed.  Analysis was 
conducted in order to identify individual and structural factors 
influencing a physician’s participation in a PCPICT with a consideration 
of factors that may vary across practice site/area and to identify ways 
to improve collaboration between researchers and physicians to 
improve the success of this and future projects.  The ethnographic 
detail within the context of an ongoing project that would not have 
been obtained via other means can be used to inform the design of 
future cancer prevention studies requiring multi-site participation in 
order to recruit participants reflective of our diverse population.  
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Chapter Five: 
 
Discussion and Conclusions 
  
Introduction 
This chapter discusses the responses of the 
physician/investigators who participated in the open ended semi-
structured interviews, findings from participant observation where 
possible, as well as the results of the quantitative surveys as related to 
the research objectives, questions and hypotheses.  The reader will be 
reintroduced to the model proposed initially as well as a modified 
version, reflecting the data collected with this study.  The contributions 
of this research to theory, applied anthropology, and biomedicine will 
be elucidated.  The implications of the research with recommendations 
for future cancer prevention clinical trials will be discussed and 
recommendations for future research directions will be presented.  The 
limitations of this study will be delineated including those related to 
my vantage point and familiarity in the research setting prior to 
completing this work.   
Research Question 1  
This question attempted to explore and document individual 
provider level factors such as explanatory views on prevention, notions 
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of risk and uncertainty, shared decision-making, duality of roles, and 
other individual factors influencing a physician/investigator’s 
participation in cancer prevention intervention clinical trials.  Physician 
involvement is thought to be essential for the provision of many 
preventative services with the physician serving a critical link in the 
chain of events leading to the delivery of preventative services (Jaen 
et al. 1994).   
Explanatory views on prevention. 
A personal interest and/or belief in preventive medicine and 
cancer prevention in particular were motivating factors for participants 
in this study and this was observed across all site types.  As one 
participant remarked:  
I think that as we embark in medicine today I think the 
emphasis is sort of moving away from treatment to prevention. 
We know that it’s more cost effective. We know from a society 
standpoint, if we can prevent something you’re much better. 
From a patient standpoint, obviously if you can prevent and not 
have to deal with actual malignancy, prevention is the ultimate 
goal. It’s what we strive for everyday.  So I think that prevention 
is the future of medicine (01-S_P) 
 
Preventive medicine was recognized for its potential cost savings and 
preference over treatment of disease and participants had been 
influenced by their training as well as professional and personal 
experiences.  This is exemplified in the following quote by one 
participant:  
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It’s pretty much what I’ve learned in my training. And it’s pretty 
much what life teaches you in a bit of time. You’ve seen people 
die and born in front of you and grow up into men and women in 
front of you and people who were adults when you were children 
you see them pass away by the time you are in this age that I 
am so it kind of gives you a broader perspective of life. Plus 
what I’ve learned in medicine as well.  So both personal and 
professional influence the broader perspective (05-V_P) 
Support of preventive strategies was also noted to positively 
influence the willingness to participate in the PCPICT though 
interestingly, some felt that their role in prevention was limited due to 
their role as surgeons:  
The cancer prevention, I don’t think should be focused on 
tertiary/cancer surgeon but more on my primary role as a 
urologist. So that’s where cancer prevention (needs to be) and 
with primary care doctors as well (07-P_N) 
This response mirrors work by Hall et al. (2010) who found that 
though oncologists were interested in referring patients to prevention 
trials, they felt that they did not have access to eligible (i.e., healthy) 
patients in order to do so.  Similarly, as noted in the review of 
literature, Crosson et al. (2001) reported how the preference of 
primary care physicians (PCPs) to refer their patients to an oncologist 
for discussion of cancer treatment may extend to discussions related 
to cancer prevention trials as well.   This perspective would benefit 
from further exploration prior to the design of future prostate cancer 
prevention intervention trials.  A consideration of the most appropriate 
referral source for future studies is critical in an era of healthcare 
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reform and limited funding for research, to assure fiscal responsibility 
and that accrual goals are met in a timely fashion.  
Notions of risk and uncertainty. 
As previously noted in Chapter Two, anthropologists Douglas and 
Wildavsky (1982) consider risk perception to be the beliefs, attitudes, 
judgments and feelings in addition to the socio-cultural disposition that 
people adapt towards both hazards and their benefits.  Risk perception 
grounded in culture and the cultural theory of risk is one way to 
interpret how and why individuals make judgments about danger, 
pollution, or threat (Tansey 1999).  Since risk may have varied 
meanings to different groups, all risk must be understood within the 
larger social, cultural and economic context that it occurs (Douglas and 
Wildavsky 1982).    This is an important consideration in a discussion 
about prostate cancer prevention and risk within the culture of 
biomedicine.  In this study, risk perception and assessment were 
observed at two distinct levels, that of the patient, as the following 
quote demonstrates:  
If the consumer thinks that prostate cancer is a non-entity then 
in reality why are we doing the study? (08-A_P) 
 
As well as that of the provider, as suggested in the following quote:   
I personally think one of the keys is the urologists, and how do 
they want to deal with the reporting of prostate biopsy showing 
PIN?  What makes or breaks whether a physician will even 
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mention a trial is their interpretation of how significant the 
biopsy findings are   (12-S_P) 
Similar to risk and “risk status” as reported by Hunt et al. (2006), the 
“risk of cancer development” had multiple meanings that were 
understood differently by the physicians participating in this study.  
Although the patient voice was absent from this research, its influence 
in relation to study participation was mentioned by the participating 
physicians and cannot be ignored.   In reality, the decision to 
participate or recommend that a patient participate in a cancer 
prevention trial is likely influenced by factors at both levels.  A 
consideration at the patient level may be used to determine which 
patients would be willing (based on their perceived risk of disease) as 
well as those that could benefit (based on the provider’s interpretation 
of risk) from participation.  A lack of consistency in the definition of 
risk within the medical community and ambiguity in the current 
management of prostate cancer and its precursors was noted as 
exemplified with the following statement: 
You know the other thing that’s detrimentally affecting 
particularly prostate cancer I think is the ambiguity in the 
medical community about the significance of prostate cancer and 
the significance of prostate cancer treatment (08-A_P) 
The overall subjectivity in determining risk is important to recognize, 
as it may influence trial participation as well.   
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Hales et al. (2001) noted that physicians may experience 
discomfort disclosing uncertainty in clinical management, as may be 
required as part of the participation in a clinical trial.  Since this 
research was with a therapeutic trial, exploration in regard to cancer 
prevention, intervention trials was warranted.  In this research, neither 
uncertainty in the plan of care nor the outcome associated with 
participating in the clinical trial was negatively influential.   Uncertainty 
was seen as the “nature of science” with participants across sites 
offering suggestions (such as honesty and communication with 
patients) as a means to deal with the possibility of uncertainty.  
Shared decision-making. 
Similar to the findings of Hunt et al. (2005), disparate starting 
points related to the perceived problem (or lack thereof) and how to 
prevent or control it may greatly influence what treatment options are 
considered in this context as well.  The lack of consensus and 
subjectivity in determining risk as noted above, in addition to variance 
in clinical priorities may influence the information and treatment 
options that are shared with each individual patient, as abnormal 
biopsy results are identified.  This likely influences the process of 
shared patient decision-making between the patient and physician, as 
it relates to participation in prevention trials.   
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As would be anticipated considering the focus with this project, 
shared decision making was contemplated at the level of the provider.  
Questions were situated to elicit feedback related to various scenarios 
where research efforts may be coordinated with actors beyond their 
local site, in an effort to increase participation opportunities for their 
patients.  Participants expressed a variety or responses and shared 
decision making was indeed a salient factor, but not in the ways 
anticipated by me during project design.  Considerations such as 
logistics were pointed out as shown in the quote below: 
The only problem I guess is just logistics (10-A_P) 
As well as the importance of coordinating the details of care as one 
respondent noted:  
All of us have a fear that when patients leave here, (are) sent 
out, they can be lost in the paperwork and the shuffle (01-S_P) 
 
Also the importance of considering the benefit to the patient was 
mentioned:   
If I have a patient who is eligible for a prevention trial 
somewhere else and if I don’t have something for that 
population I would send them.  Wherever there is a good study 
for the patient, we send them (09-S_N) 
 
And interestingly, the possibility of losing control of patients was 
mentioned as the following quote demonstrates:  
No, in the sense that you are sending your patients somewhere 
else and they may not come back. So, why should they? It’s 
almost like saying that if you’re not cutting edge enough to have 
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their research trial at your institution so why should I come back 
to you? (10-A_P) 
 
Heterogeneity in responses varied depending on the practice site as 
well as the tenure of experience.  The following suggests that those 
with an established medical practice may be less concerned about 
losing control of their patients than those still in the process of 
establishing their practice: 
You ask a guy like me, I’m not just beginning out in this 
business. I’m not as threatened by sending off as some might 
be.  So no, I wouldn’t have trouble with that.  If you talk to 
someone who’s trying to build a practice they might be less 
inclined to do that (12-S_P) 
 
These findings are similar to prior work by Cornuz et al. (2000) who 
suggested factors such as age, gender, specialization, and the 
physician’s own health habits influenced the likelihood of preventative 
care.  
Duality of roles/role conflict.   
Hunninghake et al. (1987) suggested that clinical trials may be 
seen as a competing service to clinical care and noted challenges with 
role delineation and personal integrity when serving as both clinician 
and investigator.  More recently, Ruffin IV and Baron (2000)  suggested 
that conflict may arise between the physician’s role as care giver and 
that of scientist.  The possibility that varied and separate roles may 
contribute to conflict related to the ultimate goals and populations 
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targeted in clinical research have also been noted by others (Frayne 
2001; Hales et al. 2001; Orozco 2009).   Ka'ano'i et al. (2004) 
identified conflict between the roles of clinician and research advocate 
as physician-related barriers specific to participation in cancer 
prevention clinical trials. Prior to this study, it was unclear how salient 
this was specifically in relation to a PCPICT.    
Participants at all types of sites noted that their ethical 
responsibilities did not change when a patient participates in a cancer 
prevention intervention trial.   One noted that this could be a unique 
difference between pharmaceutical (treatment) and prevention 
focused trials. In terms of role conflict, this had been experienced 
specifically in regards to participation in the ongoing trial by at least 
one participant working at an academic center when the course of 
action required by the protocol deviated from the usual care he would 
have provided, as he stated:  
When these LFTs (liver function tests) are elevated, how 
elevated? Is it elevated enough to take them off the study? Is 
the drug doing some harm? So yeah, every time there is 
something (like that) you have to consider (that) there’s conflict 
(10-A_P) 
 
 For others, at all site types, it was not an issue with some 
noting protective stops in place such as the IRB oversight and lack of 
financial interest or benefit as possible factors contributing to the lack 
of conflict.  This is reflected in the following quote:  
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No, if I don’t have any financial interest or financial benefit and 
(it) is a study I am convinced to do, I don’t think it changes 
anything. Also (if) the study passes the IRB, you know that (it is 
ethical) (11-P_P) 
 
Other factors of influence. 
Additional individual factors influencing the likelihood of 
participation in cancer prevention intervention trials were noted such 
as personal motivation and/or interest in research, scientific 
recognition and altruism. The following quotes provide examples of 
response from the participants:  
It’s not money; it’s academic and scientific credit (04-V_P) 
If the study appeals to my mind, that the study is going to be 
something good for the betterment for the future, in my little 
field (05-V_P) 
These were noted by participants across all site types.  In general, the 
participants were willing to consider multiple means of participation in 
trials such as patient referral to outside facilities, training their own 
staff and utilizing staff provided by the research sponsor in order to 
provide the best possible care options for their patients.  Ka'ano'i et al. 
(2004) identified changes in the doctor/patient relationship as 
physician-related barriers specific to participation in cancer prevention 
clinical trials.  This was not observed in this research and the impact of 
participation in the trial on the physician-patient relationship was 
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generally seen as favorable across all types of practice sites as the 
following responses demonstrate:  
I think that the fact that we do participate in these trials helps 
the patient physician relationship and it also lets the patient 
know on a different level that we are concerned about their 
overall health (08-A_P) 
It’s actually (a) very good rewarding relation.  Some get 
recycled; they enter new trials, similar disease spectrums. Oh 
it’s very rewarding. Wonderful relationship with this patient. It’s 
fun.  Absolutely (04-V_P) 
A glimmer of insight.  
Perhaps most informative for consideration in the design of 
future trials was insight by providers as to why physicians in private 
practice may be hesitant to participate in prevention trials:  
I don’t know how you would incentivize a guy in private practice 
to participate in trials like this. It would almost have to be 
completely financial somehow…Chemoprevention like this, I just 
don’t know how you would incentivize them because you have to 
have extra visits, you know for research and you have the IRB 
stuff to go through. I don’t know how you would incentivize 
them (10-A_P) 
 
The need to incentivize in some way, excessive regulatory 
requirements without the infrastructure such as adequate staffing to 
support the required work, a consideration of the benefit of 
participation as perceived by the urologist, and potential loss of control 
in decision-making were all important factors that were suggested to 
influence the likelihood of participation in a prostate cancer prevention 
intervention trial.  These proposed barriers and facilitators to research 
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participation should be explored in further detail to improve the 
success of future endeavors.  
Research Question 2 
This question aimed to explore and document the structural 
(organizational and infrastructural) considerations that influence 
participation in a PCPICT and to provide a comparison of factors across 
types of sites.   
Resources and other support. 
As noted in the prior chapter, there was heterogeneity in the 
responses both within types of centers and when making comparisons 
across them.   A disjuncture between the organizational expectation to 
participate in research and the resources provided was noted by an 
informant working at a specialty center, as he said:  
From the organizational level our mandate is to do research.  
There is a difference between what is expected and the 
resources provided (03-S_P) 
 
Similarly, a participant in the VA system noted insufficient resources 
“stifling progress” in clinical research:   
Currently, everybody does it by himself or herself, the 
investigators. It stifles progress. There are lots of patients who 
are interested in trials but (there are) insufficient resources to 
help investigators bring trials to patients and accommodate 
patients in trials (04-V_P) 
The presence of research infrastructure was a critical component noted 
by those in private practice as well.  These findings are similar to work 
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by others (Roberts 2002; Ruffin IV and Baron 2000; Somkin et al. 
2005) where organizational support and other health care system 
related factors were noted as predictors of enrollment as well as 
barriers to participation in treatment trials, with infrastructural support 
(including support staff) noted as critical. 
Similar to work by Ka’ano’i et al. (2004), staffing and time 
constraints were potential infrastructural factors noted as important 
considerations influencing participation by these key informants. 
Funding not only to support research efforts but to contribute to the 
institution’s bottom line was noted as relevant across all site types 
though not as significant within the VA system.  A clear preference to 
participate in funded research over non-funded research was observed 
across all site types.  This was a more important factor than the actual 
sponsor at most sites though all noted a preference to participate in 
investigator initiated, federal or state and cooperative group trials over 
pharmaceutical trials. As evidenced by the following remark from a 
participant:  
We always give precedence to studies that are NIH funded 
studies and investigator initiated studies and then if there is 
room then industry sponsored studies are supported (09-S_N)  
Interestingly several reported changing priorities as a result of the 
current economic environment as the following responses 
demonstrate: 
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Of course you know when the funding is getting tougher to get 
you may have more pharmaceutical studies (09-S_N)  
So, if we say we can’t get these big grants from the    
government … I think the shift is just to say, well try to get 
these other grants, the pharma grants and such that don’t have 
that requirement (10-A_P) 
Research Question 3 
Cancer clinical trials recruitment has historically occurred in 
academic settings (Nguyen et al. 2005), with community and 
nonacademic hospitals less likely to participate (Al Refaie 2011).   
Pinto et al. (2000) suggested a strategy for increasing enrollment in 
clinical trials is to improve communication and outreach with 
community physicians; however, it is also noted that increasing 
participation in screening and prevention activities would require more 
attention be given to logistical barriers and an increased awareness of 
cancer information and research services (Ka'ano'i et al. 2004).  Since 
much, but not all, of the prior research has focused on therapeutic 
trials, this question was addressed by considering how practice area 
(specialty centers, academic centers,  Veteran’s (VA) medical centers, 
community offices) may impact the feasibility of participating in a 
prostate cancer prevention intervention trial.  The results from the 
various modes of data collected in this study suggest that for a variety 
of reasons, some sites may be better suited than others to participate 
in the prevention trials of the future. 
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The right place. 
As previously noted, practice site influenced not only the 
facilitation of research (due to the absence or presence of 
infrastructure) but also the types of patients that were seen at each 
site.  This is problematic since research done primarily in university or 
teaching centers may result in unintended subject bias due to the 
population seeking care there (Carbone et al. 2005).  Additionally, 
since the opportunity to participate in trials may not be a reality for all, 
Azevedo and Payne (2006) have suggested that differential access to 
research opportunities due to structural or other barriers may 
disparately impact certain populations.  The unavoidable reality that 
patient pool was influenced by other factors such as the presence or 
lack of insurance and unofficial “pre-inclusion” criteria at some sites 
warrants further exploration.  This is especially important in the face of 
impending health insurance reform, since the standard of care in many 
medical treatment regimens are the direct result of clinical research.  
The reality of unequal access could have implications for many 
conditions and is not simply limited to the spectrum of cancer care.    
All participants reported limits in access to the resources 
necessary to participate in research, even those specifically designated 
as research centers.  This was reported by key informants during 
formal interviews as well as by other members of the research team 
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during participant observation.  Suaveness and creativity on the part 
of the physician/investigators made it possible for the current project 
to occur at their facility.  Some respondents reported better support 
than others and a physician at one private practice site had found a 
way to access resources beyond his own in order to expand the types 
of services that were available and offer participation in clinical trials to 
his patients, despite the lack of his own research infrastructure, as 
described in the following response: 
There’s a research coordinator at XXX Hospital.  We can use her 
and that’s another way we can take advantage of (the) XXX IRB 
and their research coordinators.  If I have to use my 
infrastructure, I don’t have anyone in the office so I have to go 
through XXX or I have to hire someone. Hiring someone for a 
small project is not a good idea.  You have to have the 
infrastructure, that’s why I think the community guys shy away 
from research, there’s too much paperwork to do. It’s a lot of 
paperwork to do (11-P_P) 
The right time. 
Across all sites the common theme noted by all was time, 
broadly speaking, and the influence it had on their ability to participate 
in research as seen with the following responses:  
The time to do it that’s the issue (02-V_NP) 
I think their limitation is similar to our limitation in terms of time    
(07-P_N)  
Don’t underestimate how busy the doctors are (12-S_P)  
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Time was seen as both a positive and negative influence on 
participation.  When trial requirements were in-line or able to be 
incorporated into the usual schema of care this was seen as positive 
factor making participation more feasible as the following respondent 
explains:  
It allows me to participate in research that has a translational 
bent and also be able to work it into my regular routine of seeing 
patients (10-A_P) 
However, when time related to fitting a discussion about research into 
a time slot that was previously established for a clinical encounter; the 
time allotted by administration as dedicated for research (vs. clinical 
care); the time required to document research participation or even 
the time for a patient to see a research coordinator because they were 
present and readily available in the clinic, it was seen more as a 
negative factor of influence.  Despite the negative time factors noted, 
this was not seen as a finite barrier making physicians unwilling to 
participate in this and future projects, yet is definitely a factor that 
should be considered in future trial design and resource allocation.  
The ways in which conflicts for time and space were handled varied in 
each of the research sites; however, a consideration of the two  
models noted during participant observation may help to lessen the 
competition for time and space often reported by these key 
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informants, observed in the clinic and noted in prior research, further 
reducing this challenge in the future. 
A Comparison of Results 
When considering the quantitative results for a comparison of 
responses from those who are currently involved in the clinical trial 
and those that are not, similar responses were noted by both groups.  
Reasons for participation in clinical trials included advancing medical 
science, expanding available services, providing challenge and variety 
and earning extra income noted by participants in both groups.  These 
results are similar to work by Crosson et al. (2001) who reported 
comparable reasons for participation in clinical trials.  As would be 
expected based on total accrual, there was unequal representation 
between groups (participant and non-participant) with a greater 
number of participant responses in most categories.   
The reasons noted for participating in prevention trials was also 
similar (advancing medical science, providing the best possible care, 
earning extra income for practice) among the groups.  The participants 
also mentioned other motives such as providing the best possible care 
and access to a novel treatment.  In terms of overall participation in 
any type of clinical trial, similarities between participants and non-
participants included the influence of time, cost to individual or 
institution, paperwork requirements, staffing, concern for patients 
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well-being, and institutional support.  Factors reported by participants 
but not non-participants also included the influence on the clinical care 
process, financial incentives, the introduction of another care provider 
or decision maker, and the requirements of the research protocol.  
Overall, the groups had more similarities than differences in this area 
and there was consistency when triangulating the findings generated 
by qualitative and quantitative means.  One reason for the similarity in 
findings could be that though respondents were not currently 
participating in the PCPICT, most had participated in research 
previously.  It is likely that a disjuncture between the individual 
willingness or interest in participating and limitations at the structural 
level (due to practice site, medical practice model or lack of 
infrastructure or resources) existed, ultimately influencing participation 
in the current PCPICT.    
The primary hypothesis for this study was that both individual 
and structural factors intersect and influence both the willingness and 
the ability of the physician/investigator to participate or refer patients 
for participation in a PCPICT as shown in Figure 2: 
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Figure 2: Proposed Model: Individual and structural factors influencing 
physician participation in cancer prevention, intervention clinical trials 
 
 Dark blue boxes represent individual factors believed to impact the 
physician’s participation in cancer prevention intervention clinical trials  
 Light blue boxes represent structural factors believed to impact the 
physician’s participation in cancer prevention intervention clinical trials 
 
Additionally, it was hypothesized that these factors would vary 
based on practice site/area and the interactions will both facilitate and 
deter participation in these types of trials.   The results of this study 
show that the hypothesis is supported and that both individual and 
structural factors intersect, influencing the willingness and ability of 
physician/investigators to participate or refer patients for participation 
in a PCPICT.  Individual factors such as explanatory views on 
prevention, notions of risk and uncertainty, shared decision-making 
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and duality of roles appear to have a greater influence on the 
willingness of physicians to participate while structural factors such as 
staffing, other resources and time are more influential in regards to 
the ability to participate.  Though individual and structural factors did 
vary across sites to some degree, there was more heterogeneity 
among various physician/investigators than across the different site 
types.  What was not examined in this project and would be a next 
logical step, is to further explore how willingness and ability was 
reflected in the actual accrual at the various sites participating in the 
PCPICT. 
Contributions to Theory 
An adaptation of the theory of competing demands that included 
a theoretically-grounded exploration of individual provider level factors 
(notions of risk and shared decision-making, explanatory views on 
prevention, and duality of roles) as well as structural level factors 
(practice area and organizational/infrastructural considerations) that 
as noted in previous chapters, were shown to be salient in other types 
of research, was proposed for this project.  Within this framework, I 
was able to draw upon both micro and macro level factors of influence 
to provide a more holistic understanding of the multitude of individual 
and structural variables influencing the physician’s participation in a 
PCPICT.  Jaen et al. ( 1994) proposed a three-part model to better 
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understand the delivery of preventative services in the primary care 
setting.  Components of the model included the physician, the patient, 
and the practice environment.  My research expanded this concept via 
mixed methods exploration to show that these factors are similarly 
influential in the delivery of services associated with participation in a 
PCPICT.   Willingness and desire to participate on the part of the 
physician was unfortunately not always enough to result in actual 
participation since the ability to participate was influenced by 
constraints within the practice environment such as competing 
demands for time, space and personnel.   
As noted previously, Joseph and Dohan (2009) suggested that 
enrollment in therapeutic cancer clinical trials is shaped by biomedical 
and social factors.  Similarly, this research has revealed that these 
factors are also influential as physicians consider participation and 
enrollment in a PCPICT.    Biomedical factors such as risk perception 
and scientific rationale; as well as social factors such as explanatory 
views on prevention, concerns for their patient’s well-being, and prior 
personal and professional experiences were reported as salient and 
influential by participants in this study.   As with the prior research, 
the intersection of these individual, social and biomedical (physician 
and patient) and structural (practice environment) factors influences 
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not only the willingness but the ability of physician/investigators 
creating barriers as well as facilitators to participation in a PCPICT.   
The factors of influence identified following a review of the 
literature and proposed in the original model were supported by the 
findings of this research.  With the results of this study, a much better 
understanding of the intersection of these various factors within this 
particular context is now possible.  As noted in the results section, 
individual factors such as explanatory views on prevention, notions of 
risk and uncertainty, shared decision-making and duality of roles 
appear to have a greater influence on the willingness of physicians to 
participate in a PCPICT.  Structural factors such as staffing, access to 
other resources and time are more influential in regards to the ability 
to participate.  This research did not examine how physician 
willingness and ability ultimately influenced actual recruitment to the 
PCPICT as compared to the project goals.  This would be a valuable 
consideration and could add overall insight to better understanding the 
greater challenge of recruitment to prevention clinical trials within 
each of the four contexts.  Further examination would also further 
delineate if some factors were more influential than others.  The 
following, revised model (Model 2) demonstrates the interactions of 
the various individual and structural factors influencing these 
physicians as they function as gatekeepers in access to the PCPICT.   
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Figure 3: Revised Model: Individual and structural factors influencing 
physician participation in a PCPICT 
 
These factors served as both barriers and facilitators to the 
physicians as they considered participation in a PCPICT.  The findings 
from this project show that factors previously shown to influence 
participation in therapeutic clinical trials are influential within the realm 
of prevention trials as well.  Though all key informants were interested 
and willing to participate in the PCPICT due to individual factors, not all 
were able to due to the structural constraints of their specific practice 
environment.  While this project focused on a very specific context-
prostate cancer prevention intervention clinical trials- a consideration 
of these factors and how they may influence the willingness and ability 
of physicians to participate in other types of prevention trials should be 
considered by investigators that seek to design this unique and 
challenging type of study.   Additional exploration of the intersection of 
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factors within each local environment would add additional insight and 
investigators designing such projects are encouraged to consider how 
the various factors may or may not be relevant depending on their 
planned recruitment site (specialty center, academic center, VA 
hospital, private practice). 
Contributions to Applied Anthropology  
This research provides an in‐depth and nuanced understanding 
of the individual and structural factors that influence a physician’s 
participation (or lack thereof) in a PCPICT.  It provides a novel 
qualitative component within the context of an ongoing research 
project, greatly contributing to the literature and expanding the theory 
of competing demands into the field of anthropology and prevention 
clinical trials.  The results can be applied to inform the design of future 
cancer prevention intervention trials which require multi‐site 
participation in order to recruit participants reflective of our diverse 
population, in a timely and cost-effective manner. This is an area that 
to the best of my knowledge has not been previously examined 
specifically from an anthropological perspective.  Anthropological 
contributions in the arenas of cancer control, clinical trials, ethics, and 
clinically applied anthropology were considered in the design of the 
project; however, a direct comparison of my findings is not possible 
due to the lack of analogous prior work.  My project expands the 
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presence of the anthropological voice, making a contribution to this 
broad topical area while using a holistic perspective to address 
challenges previously identified by other disciplines.  The results of this 
research provide novel insight and therefore answer Kleinman’s call 
(1985) for medical anthropologists to be able to consider the practical 
as well as theoretical aspects of health issues.  By asking questions 
instead of making judgments as suggested by Barnett (1985), it helps 
to better understand why practitioners behave and believe as they do 
regarding PCPICTs.   By considering physicians as actors in an 
ethnomedical belief system, an analysis of their beliefs and the social 
and cultural construction of biomedical disease concepts within a 
particular context was possible, as suggested by Chavez et al. (1995).   
Contributions to Biomedicine  
Kleinman (1985) noted that clinically applied anthropologists are 
able to consider the divergent views and visions of patients, 
professionals and the community, facilitating perspectivism and 
contributing to a broader understanding of all relevant issues.  This 
project was able to elucidate the views and perspectives of 
professionals as they relate to participation in a specific type of clinical 
trial.  Swanson and Ward (1995) identified the need for studies of 
physicians’ attitudes and behaviors regarding clinical trial participation, 
and prior to this work there was limited literature specifically exploring 
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the role of physicians as gatekeepers in access to PCPICTs.  This 
project contributed to a gap in the literature and allowed for an in-
depth examination of the individual experiences of the 
physician/investigators within the larger social and economic contexts 
in which health care is provided.   
Al Refaie (2011) reported that infrastructure, realignment of 
incentives and compensation, and improved patient and physician 
navigation systems have been suggested by surgeons as ways to 
improve their engagement in clinical trials.  These are also noted as 
important among the participants in this study.  Similarly, Meropol et 
al. (2007) noted that tailoring approaches to a specific practice area 
(academic vs. nonacademic) may help to optimize participation.  This 
research shows that overall the differing practice areas have 
challenges that are more similar than different.   
Application to future trials 
The analysis of these findings provides the opportunity to make 
suggestions that should be considered in the design of future prostate 
cancer prevention intervention clinical trials, and may be useful in the 
design of other types of prevention trials as well.  Additionally, this 
research identifies and addresses the invisible barriers (named such 
due to the lack of formal evaluation or documentation previously) such 
as structural and infrastructural barriers, the identification of which 
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was suggested as critically important due to the increasing number of 
new chemotherapeutic agents needing evaluation (Dilts and Sandler 
2006). 
The urology clinic is a fast paced and ever changing 
environment.  The clinical encounter is limited by both time and space 
resources, as observed during participant observation and reported by 
participants.  Dedicated infrastructural support to provide for both may 
allow for the successful facilitation of future prostate cancer prevention 
research projects.  A closer examination of the ways in which patients 
are identified and visits are scheduled may have a positive impact on 
future recruitment as well as result in a more efficient use of limited 
resources.   The patient population at each clinical site influences the 
ability to meet recruitment goals, creating yet another structural 
challenge if there is a disjuncture between the two and as Sharp and 
Pentz (2004) note, the enrollment of adequate numbers of patients, 
within a reasonable time period is particularly critical in 
chemoprevention trials.    An additional observation is that some of the 
types of sites where this project is taking place may not be ideal and 
should be reconsidered for future endeavors.  Practitioners working in 
specialty and academic centers typically have a relatively small volume 
of low risk (cancer free) patients which is the population best served 
by a prostate cancer prevention intervention trial.  Since the VA 
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hospitals function more as a primary care facility, there are a 
significantly greater proportion of potential patients available at these 
sites.  Perhaps the best referral source is from within the community, 
urologists who are working to provide the “bread and butter” urology 
care to their patients over a life time and have an established 
relationship well before cancer diagnosis.  Each of these sites has 
infrastructural challenges as noted previously and they must be 
considered within the greater health care structure as it continues to 
evolve.  Finding ways to bridge paths of partnership with the 
community is highly recommended for the success of future cancer 
prevention studies.   A summary of the main points from the key 
informants which should be considered by any investigator in the grant 
writing phase of a project follows:    
1.) Future studies must make biological sense and be for a 
condition where the scientific rationale is clear and no 
ambiguity regarding the significance of treatment exists 
 
2.) Protocol requirements must be closely in line with usual 
practice for the condition under study to minimize patient 
and physician burden 
 
3.) Dedicated research time and personnel is highly desirable 
 
4.) Partnerships with “friendly” community physicians must be 
forged to extend availability to a wider range of patients 
 
5.) A collaborative project, available at the site of usual care 
delivery when possible with the urologist remaining key 
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decision maker (in partnership with patient and research 
team) is highly desirable 
 
6.) Trial must utilize existing resources or provide for 
additional so that venture is at least cost neutral for the 
institutions involved 
 
As previously noted, though willing to participate, those working 
in specialty and academic centers simply do not have access to the 
“healthy” and cancer free population that is needed for such a study.  
Finding ways to build relationships with community physicians where 
they are not threatened by collective work is imperative since these 
settings have the potential to recruit a much larger and more 
representative sample (Somkin et al. 2005).   This will not only assure 
the best use of limited fiscal resources but also facilitate the 
recruitment of a wider and more diverse population, representative of 
those impacted by the burden of prostate cancer.  As well, additional 
research should further explore more specifically what financial 
incentives would be considered necessary for those in private or 
community practice to participate in such a study as well as what 
infrastructure is or may be available to support their participation in 
prostate cancer prevention clinical trials. 
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Limitations 
As with all research, this study is not without its limitations. 
What follows is a summary of obstacles as well as a brief discussion 
regarding non-participants.   
1) This study included interviews with twelve 
physician/investigators currently participating or asked to 
participate in a prostate cancer prevention clinical trial as the 
primary research participants.  Though the sample size was 
sufficient for this dissertation, it is not meant to generalize to all 
physician/investigators or even to all types of prevention 
intervention clinical trials, instead it was meant to describe the 
population within a particular context and provide implications 
and recommendations for future research.  
 
2) Though some insight into possible reasons for non-participation 
can be gleaned from the responses provided by those who did 
participate, their responses should not be considered 
generalizable or reflective of the opinions of all non-participants. 
Soliciting this voice is incredibly important for the success of 
future prostate cancer prevention research projects.  
  
3) Due to a poor response from community physicians, the sample 
size of “non-participants” from the private practice setting was 
limited.   Despite the request to participate from a well- 
respected gatekeeper within this community, only 4 non-
participant surveys and no interviews were completed.  Though 
response was limited, those that did participate in the interviews 
and/or complete the surveys did provide some important insight 
that should be examined in future projects.   
 
4) Non-random sampling was the primary means to recruit 
participants.  The potential for bias in participant response exists 
due to the fact that all interviewees had a previously established 
working relationship with me prior to the time of data collection.  
Due to the specific nature of this project, this sample was 
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considered best qualified to address the research questions.  
Additionally, this association was thought to positively influence 
the willingness of the key informants to talk with me, as 
evidenced by the three interviews with non-participants that I 
was unable to complete.  No physicians with whom a prior 
relationship did not exist were willing to be interviewed.   
 
5) All key informants in this project were male and I am female.  
While this was unavoidable, it is unclear how this may have 
influenced the willingness to participate or the responses 
provided. 
 
Certainly the most notably missing voice from this project was 
that of the physicians who did not agree to participate in the 
interviews or even complete the survey.  Unfortunately due to a 
change in dynamics in the large, local urology group, I was unable to 
administer the survey in person as originally planned.  The use of the 
modification of the Dillman Total Design Survey Method, using the 
letter/survey packet and a follow-up postcard provided little additional 
response (n=2).   In person distribution may have increased the total 
number of surveys completed but it is unclear how it responses may 
have added to the depth of data collected since as noted in chapter 
four, little variance was noted between participants and non-
participants, utilizing this methodology.    
Reflecting on Familiarity in the Research Setting 
Concerns about the familiarity of researchers in the research 
setting have been noted and include a lack of objectivity and possible 
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role confusion (Hanson 1994).  Arguments have also been made that 
acting in familiar role as well as that of researcher may compromise 
objectivity (DiCicco-Bloom and Crabtree 2006).  Additionally, the 
concern that motivates the research and potential to focus attention 
on a specific element or issue has been described as both a potential 
weakness and a strength when functioning as an ”insider” (Hanson 
1994:941) and Preston (1997) suggested that carrying out 
ethnography in a familiar culture has the advantages of access and 
familiarity of the setting.  There is clearly not a consensus on this 
issue.  
DiCicco-Bloom and Crabtree (2006) noted that establishing trust 
and finding out new perspectives is best done by reducing the 
hierarchy between informants and researchers therefore, it could be 
argued that this may be facilitated more easily in a research setting 
with some level of familiarity to the researcher.  Hanson (1994) noted 
several positive aspects of familiarity including subjective knowledge 
and awareness of the cultural norms and values of the health care 
professionals involved in the study and suggest these strengths may 
be particularly salient when using qualitative methods.  Researcher 
reflexivity is always essential to acknowledge power differentials and 
integrate reciprocity into the creation of new knowledge (DiCicco-
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Bloom and Crabtree 2006) and this was of particular importance when 
“studying up” as this project required.   
 When considering my own agency and the possible 
constraints of working in a familiar setting, reflexivity, or the 
awareness that the production as well as distribution of knowledge is a 
social action (Hahn and Kleinman 1983) was critical during the 
completion of this dissertation project.   While developing the study, 
familiarity in the research setting and with the challenges facing the 
project allowed me to truly apply anthropology to design a project that 
would provide a broader and more holistic perspective of the issues; 
providing data from the individual actors and within their local context 
that would not have been obtained without a mixed methods 
approach.  Perspectivism and the ability to mediate between varying 
viewpoints on the same phenomenon was a valuable skill in the 
anthropologist’s toolkit that proved absolutely useful while arranging 
interviews and site visits and completing my work in the field.  
Conducting the participant observation was the part of the research 
process where reflexivity was perhaps the most important.  I had to 
constantly interpret my findings based on observations, acknowledge 
power differentials and integrate reciprocity; however, the sum of my 
prior experiences as a clinician, research coordinator and project 
manager could not be completely avoided.  
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Once the actual data was collected, I was pleasantly surprised to 
experience an ease in separation between the professional experience 
prior to data collection, my role as scientist during data collection and 
the focus required to analyze and elicit the details necessary to answer 
the research questions.    A  keen awareness of my differing role and a 
more analytic focus during my time in the field while maintaining a 
collaborative approach as the research questions are addressed was of 
critical importance.  The data that was collected was sorted and 
analyzed from my perspective, based on the totality of my experiences 
as is inherent to this type of research.   Anthropological research is an 
interactive endeavor and this project resulted in exchanges between 
the key informants and researcher that were more rich and detailed 
than I could have hoped for.  I am not sure that this result would have 
been the same, were I not considered to some degree, an insider.  In 
this particular case, I believe that there were more strengths than 
weaknesses with familiarity with the research setting as I was able to 
build from existing relationships to focus on the specific details needed 
to address the study objectives and research questions. Buy-in to the 
project was not problematic and participants were more than willing to 
share their time and perspective as the key informants had the same 
vested interest in the parent trial’s success as I did.  
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Opportunities 
The findings from this project offer several prospects to expand 
into other arenas for further research and provide suggestions for 
training and education related to clinical trials.  These include, but are 
certainly not limited to contributions to other arenas of prevention 
research, development of improved patient-trial identification systems, 
and implications for physician education.  
Prevention research. 
 Though this research focused on the specific context of a 
prostate cancer prevention intervention clinical trial, the findings are 
likely applicable to challenges observed in other areas of prevention 
research.  Funding agencies, sponsors and investigators involved in 
the design and funding of such trials may benefit from a review of the 
six main findings reported previously, for applicability to their own 
local context.  
 Clinical trial alert systems. 
 With advances in technology and the increasing use of the 
electronic medical record (EMR), collaborations between researchers, 
information technology (IT) professionals and clinicians may increase 
the use of CTAs to improve the ease with which participants for all 
clinical trial types (therapeutic as well as prevention) are identified at 
various medical settings. Ultimately this could improve resource 
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utilization, minimize physician burden, boost enrollment and speed the 
rate at which new discoveries are tested for efficacy via clinical trials.   
 Implications for physician education. 
  Participants in this study had not received specific training or 
education related to clinical trials as part of their medical school 
curriculum.  With few exceptions, most had not had any such training 
during their residency or surgical training either.  Considering the 
importance of clinical trials to continuously improve the provision of 
medical care, providing an early introduction of the basic concepts, 
and laying the foundation of knowledge regarding clinical trials in 
medical school may be an effective means to improve understanding 
of physicians, ultimately improving future involvement in trials.  This 
exposure could occur via workshops provided within the medical school 
curriculum or perhaps at conferences and other educational venues.     
Dissemination and Future Directions 
 The dissemination of these findings is crucial to maximize the 
application as I intended at the outset of project design.  This can 
occur through various channels including the preparation of an 
executive summary of findings, publication in peer-reviewed journals 
and presentation at scholarly meetings.  An executive summary may 
be most useful to physicians already participating or interested in 
participating in prevention clinical trials as well as investigators 
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involved in trial design.  Publication in peer-reviewed journals could 
cater to two audiences, those more in the biomedical arena who may 
be interested in the application of the findings (such as trial sponsors, 
funding agencies and physician investigators) as well as to 
anthropological or other social science journals where the theoretical 
contributions may be more valued.  Participation in scholarly meetings 
in both arenas could also increase the dissemination of results, thereby 
reaching a much broader audience.  
 On a more personal level, I envision future projects at several 
different levels.  The “work” of research and how in reality it played 
out, varied greatly in the different spaces I visited.  The physician 
clearly serves as a gatekeeper, often providing direct access to the 
potential research participant; however, a host of support is occurring 
in the backstage.  This support varied greatly at each type of research 
site and additional research could explore in greater detail the valuable 
work of nurses, clinical trial coordinators and regulatory staff without 
which, the true work of research would not occur.   
An additional expansion from this project is to attempt to 
capture the experiences of those physicians who are non-participants 
in research, either due to their current medical practice model or other 
barriers which have not yet been identified.   I believe this work would 
be the most relevant in the private, primary care and specialty setting, 
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where potential prevention research patients are seen prior to the 
development of cancer and other such conditions. Relationships with 
“friendly” physicians in private practice was suggested by those at 
specialty centers as a way to increase participation in prevention trials 
so this could provide timely insight into the world of “non-participants” 
and specifically explore their willingness and ability to participate or 
refer patients for participation.  Access would remain the largest 
challenge since just as was observed in the parent PCPICT, this group 
was challenging to reach in my study as well.  
A final area of exploration would be to more closely examine the 
process of research within a particular setting to better understand the 
structural factors that influence a physician’s involvement in research.  
This is critical because support such as infrastructure and staffing 
ultimately impacts patient recruitment and the attainment of accrual 
goals to all types of clinical trials.  Findings could contribute to an 
improvement in organizational support impacting the recruitment to 
and completion of prevention trials in a more timely and cost-effective 
manner.   This may be most relevant in the VA setting, where some 
level of research infrastructure is already in place and a wide range of 
patients are seen for their primary medical care.   
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Conclusion  
Using an applied anthropological perspective I examined the 
individual and structural factors influencing physician/investigators in 
their role as gatekeeper in access to a PCPICT.  This research extends 
work by Probstfield and Frye (2011) to show that physicians also serve 
as gatekeepers for participation in a PCPICT, and provides valuable 
insights and information related to the reality that is experienced 
within each local context where study recruitment and participation 
take place.  The results fill a void, building from prior work where 
Ruffin IV and Baron (2000) recommended further research to not only 
better understand barriers unique to prevention trials but to identify 
successful strategies to overcome them and used ethnographic 
methods to specifically explore the individual and structural factors of 
influence impacting physician/investigators in their role as 
gatekeepers.  I was able to provide applied recommendations for 
researchers considering the design of future cancer prevention 
intervention projects as well as identify areas where additional 
research would be beneficial.   
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Appendix A. Recruitment Letter (current trial participants) 
Month TBD, 2012 
 
 
Dear Dr. _____________, 
 
I am contacting you because of your involvement in the prostate 
cancer prevention trial: Phase II, Randomized, Double-blind, Multi-
centered Study of Polyphenon E in Men with High-grade Prostatic 
Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar 
Proliferation (ASAP).   
 
I am a student at the University of South Florida, interested in 
exploring the factors that influence physician’s participation in a 
prostate cancer prevention intervention clinical trial and  
identifying ways to improve collaboration between researchers and 
physicians, thus improving the success of future projects.   
 
This letter is to invite you to participate in an additional research 
study: Physicians as Gatekeepers: Applying Anthropology for a New 
Perspective (eIRB#7442) which is being conducted in partial fulfillment 
of the requirements for the degree of Doctor of Philosophy and 
approved by the University of South Florida Institutional Review Board.  
The study consists of an interview and a brief paper or computer based 
survey.  Both are designed to gain a better understanding of the 
factors that have influenced your participation in this project.  The 
interview will be conducted at your convenience, off site and on your 
own time as may be required by your institutional guidelines. 
 
Your expertise is very important and the results will inform my 
dissertation research as well as the design of future cancer prevention 
studies.  In total, participation will take approximately ninety minutes 
of your time.  To schedule a time for this interview, please contact me 
at 813-745-6046 or 813-507-7912.  I look forward to speaking with 
you soon.  
 
 
Kind regards, 
Theresa Crocker, MS, RD 
Doctoral Candidate, Department of Anthropology  
University of South Florida 
tomaszts@mail.usf.edu 
196 
 
Appendix B. Recruitment Letter (invited or inquired) 
Month TBD, 2012 
 
Dear Dr. _____________, 
 
I am contacting you because of your invitation to or prior interest in 
participating in the prostate cancer prevention trial: Phase II, 
Randomized, Double-blind, Multi-centered Study of Polyphenon E in 
Men with High-grade Prostatic Intraepithelial Neoplasia (HGPIN) and 
Atypical Small Acinar Proliferation (ASAP).   
 
I am a student at the University of South Florida, interested in 
exploring the factors that influence physician’s participation this 
prostate cancer prevention intervention clinical trial and  
identifying ways to improve collaboration between researchers and 
physicians, thus improving the success of future projects.   
 
This letter is to invite you to participate in an additional research 
study: Physicians as Gatekeepers: Applying Anthropology for a New 
Perspective (eIRB#7442) which is being conducted in partial fulfillment 
of the requirements for the degree of Doctor of Philosophy and 
approved by the University of South Florida Institutional Review Board.  
The first part of this study consists of a brief paper or computer based 
survey which should take no more than thirty minutes to complete.  
The completion of this survey will serve as affirmation of your 
agreement to participate in this portion of the project.  The survey can 
be completed at your convenience so as not to interfere with your 
usual work duties.  Additionally, you will have the opportunity to 
participate in a more in depth, interview at a later time, which will take 
approximately sixty minutes of your time.  The interview will be 
conducted at your convenience, off site and on your own time as may 
be required by your institutional guidelines.  Both are designed to gain 
a better understanding of the factors that have influenced your 
participation in this project.  
 
Your expertise is very important.  To schedule a time for the interview, 
please contact me at 813-745-6046 or 813-507-7912.  I look forward 
to speaking with you soon.  
 
Kind regards, 
Theresa Crocker, MS, RD 
Doctoral Candidate, Department of Anthropology  
University of South Florida /tomaszts@mail.usf.edu 
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Appendix C. Interview Guide 
 
Participant ID (Interview number-site type-P/NP): _________    
Date: ________   
 
“Thank you for taking the time to meet with me today.  I know your 
schedule is busy and I really appreciate your willingness to share your 
expertise and experiences with me.  Please keep in mind that there 
are no correct answers to these questions. I am truly interested in 
your responses to inform our current project and those in the future.  
Every part of this discussion is considered confidential.  Your responses 
will be identified by using a unique code, not your name or any other 
identifying information. You can stop the interview at any time and 
there is no penalty if you stop taking part in this study. Do you have 
any questions?” 
 
1. a.  Can you tell me a little about the organization that you work for?   
    b.  Can you tell me about how the organizational infrastructure  
    facilitates participation in research/clinical trials?   
    c.  Can you tell me about how the organizational infrastructure  
    constrains participation in research/clinical trials?   
 
2. a. When considering how the organizational infrastructure may  
        Facilitate participation, can you talk about what differences may  
        exist, depending on the sponsor of the trial? [probe: Federal   
        government, State University, Community Hospital, Private  
        Industry such as a pharmaceutical company] 
     b. When considering how the organizational infrastructure may  
         constrain participation, can you talk about what differences may  
         exist, depending on the sponsor of  the trial? [probe: Federal  
         government, State University, Community Hospital, Private  
         Industry such as a pharmaceutical company] 
     c. How are some sponsors preferred over others? 
 
3. a. Describe how have you participated in research at other  
        institutions that you may have worked. 
    b. Can you tell me about things that made it similar to where you  
        currently work? [probe: are there things that made it  
        better/worse, easier/more challenging?] 
    c. Can you tell me about things that made it different from where  
        you currently work? [probe: are there things that made it  
        better/worse, easier/more challenging?] 
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4. Are the trials that are available to you appropriate for the 
population that you serve?  
     b. If so, how is this so?  
     c. If not, how is this so?  
 
5. Please tell me your thoughts about sending your patients to another 
facility to participate in a cancer prevention intervention trial.     
     a. Would this be acceptable to you [why or why not]?   
     b. Would a preferred alternative be study staff coming to your  
         office or workplace?   
     c. How you feel about receiving support to train your staff so your  
         patients could participate but stay at your office/workplace? 
 
6. Tell me about your experience enrolling a patient into a clinical trial. 
     a. In your experience, to what extent is it disruptive to do this at  
         their usual site of healthcare delivery?    
     b. How disruptive is it to refer them elsewhere?  
 
7. a. Is there any concern of financial loss if patients move care to  
    participate in a prevention, intervention trial?  
    b. How salient is this concern? 
    c. Are there ways this can be mediated so that more people can be  
    involved in cancer prevention trials?  
          
8.  From the perspective of your institution, what would help to 
increase the likelihood of participation in cancer prevention clinical 
trials in the future? [probe: compensation, protected time, staff 
training or dedicated study staff, less paperwork, simplified approval 
process, personal interest in the trial] 
 
So far we have talked about organizational or structural (bigger 
picture) influences, now I am interested more in individual or personal 
factors (those factors that are closer to home so to speak).   
 
9. What factors are most important to you, when considering whether 
or not to participate in a cancer prevention intervention clinical trial?   
[probe: personal interest, participation in the trial design, authorship, 
meeting the needs of the community that you serve, other] 
 
10.  At what phase in the research process do you prefer to become 
involved?    [probe: design/initiation/training, analysis, results, other]  
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11. From your perspective, what would help to increase the likelihood 
of participation in cancer prevention clinical trials in the future?  
[probe: compensation, protected time, staff training or dedicated 
study staff, less paperwork, simplified approval process, personal 
interest in the trial] 
 
12. a. Can you tell me about your general philosophy towards 
preventive medicine?  
      b. Is this similar to what you learned in your training or different? 
      c. Has this changed due to your professional experience?  
      d. Has this changed due to your personal experience?  
 
13. How does your philosophy towards preventive medicine influence 
your willingness to participate in a cancer prevention intervention trial? 
 
14. Tell me about how participation in a cancer prevention trial 
impacts the physician-patient relationship? [probe: neutral, positive or 
negative?] 
 
15.  Thinking back to times when you have decided to offer 
participation in a clinical trial,  
a. How has the possibility of uncertainty in the plan of care associated 
with participation in the trial played a role in your decision to offer the 
trial?  If so, can you tell me more about this?  
b. How has the possibility of uncertainty in the outcome associated 
with participation in the trial, played a role in your decision to offer the 
trial?  Can you tell me more about this? 
 
16.  How do your ethical responsibilities as a physician change when a 
patient participates in a cancer prevention intervention trial? 
 
17. Prior research suggests a possible conflict when a provider plays 
the dual role of advocate for the patient and for the research.   
a. Have you ever experienced this?   
b. Can you tell me about what changes when patient becomes 
research participant?  
c. Can you tell me about what changes when the study is done and the 
research participant becomes the patient again? 
 
In this time together we have discussed both organizational/structural 
and individual factors that may influence your willingness and ability to 
participate in a cancer prevention intervention trial. 
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18. Is there anything else that we haven’t discussed that you feel is 
important for me to know about?   
 
 
19. Are there any other factors that influence your willingness or 
ability to participate in cancer prevention intervention trials?  
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Appendix D. Content Matrix 
Explore and document individual provider level factors (such as 
notions of risk and shared decision-making, explanatory views on 
prevention, and duality of roles) that influence participation in a cancer 
prevention intervention clinical trial. 
 
5. Please tell me your thoughts about sending your patients to another 
facility to participate in a cancer prevention intervention trial.     
     a. Would this be acceptable to you [why or why not]?   
     b. Would a preferred alternative be study staff coming to your  
         office or workplace?   
     c. How you feel about receiving support to train your staff so your  
         patients could participate but stay at your office/workplace? 
 
9. What factors are most important to you, when considering whether 
or not to participate in a cancer prevention intervention clinical trial?   
[probe: personal interest, participation in the trial design, authorship, 
meeting the needs of the community that you serve, other] 
 
12. a. Can you tell me about your general philosophy towards  
      preventive medicine?  
      b. Is this similar to what you learned in your training or different? 
      c. Has this changed due to your professional experience?  
      d. Has this changed due to your personal experience?  
 
13. How does your philosophy towards preventive medicine influence 
your willingness to participate in a cancer prevention intervention trial? 
 
14. Tell me about how participation in a cancer prevention trial 
impacts the physician-patient relationship? [probe: neutral, positive or 
negative?] 
 
15.  Thinking back to times when you have decided to offer 
participation in a clinical trial,  
a. How has the possibility of uncertainty in the plan of care associated 
with participation in the trial played a role in your decision to offer the 
trial?  If so, can you tell me more about this?  
b. How has the possibility of uncertainty in the outcome associated 
with participation in the trial, played a role in your decision to offer the 
trial?  Can you tell me more about this? 
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16.  How do your ethical responsibilities as a physician change when a 
patient participates in a cancer prevention intervention trial? 
 
17. Prior research suggests a possible conflict when a provider plays 
the dual role of advocate for the patient and for the research.   
a. Have you ever experienced this?   
b. Can you tell me about what changes when patient becomes 
research participant?  
c. Can you tell me about what changes when the study is done and the 
research participant becomes the patient again? 
 
 
Explore and document structural (organizational and infrastructural) 
considerations that influence participation in a prostate cancer 
prevention intervention clinical trial (with a comparison of factors 
across types of sites). 
 
2. a. When considering how the organizational infrastructure may  
        facilitate participation, can you talk about what differences may  
        exist, depending on the sponsor of the trial? [probe: Federal  
        government, State University, Community Hospital, Private  
        Industry such as a pharmaceutical company] 
    b. When considering how the organizational infrastructure may  
        constrain participation, can you talk about what differences may  
        exist, depending on the sponsor of the trial? [probe: Federal  
        government, State University, Community Hospital, Private  
        Industry such as a pharmaceutical company] 
     c. How are some sponsors preferred over others? 
 
7. a. Is there any concern of financial loss if patients move care to  
        participate in a prevention, intervention trial?  
    b. How salient is this concern? 
    c. Are there ways this can be mediated so that more people can be  
         involved in cancer prevention trials?  
 
8.  From the perspective of your institution, what would help to 
increase the likelihood of   participation in cancer prevention clinical 
trials in the future? [probe: compensation, protected time, staff 
training or dedicated study staff, less paperwork, simplified approval 
process, personal interest in the trial] 
 
10. At what phase in the research process do you prefer to become 
involved? [probe: design/initiation/training, analysis, results, other]  
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11. From your perspective, what would help to increase the likelihood 
of participation in cancer prevention clinical trials in the future?  
[probe: compensation, protected time, staff training or dedicated 
study staff, less paperwork, simplified approval process, personal 
interest in the trial] 
 
Consider how practice area (specialty centers, VA medical centers, 
academic centers and  community offices) may impact the feasibility of 
participating in a prostate cancer prevention intervention trial. 
 
1. a.  Can you tell me a little about the organization that you work for?   
    b.  Can you tell me about how the organizational infrastructure  
         facilitates participation in research/clinical trials?   
    c.  Can you tell me about how the organizational infrastructure  
         constrains participation in research/clinical trials?   
 
3. a. Describe how have you participated in research at other  
        institutions that you may have  worked. 
    b. Can you tell me about things that made it similar to where you  
        currently work? [probe: are there things that made it  
        better/worse, easier/more challenging?] 
    c. Can you tell me about things that made it different from where  
        you currently work? [probe: are there things that made it  
        better/worse, easier/more challenging?] 
 
4. Are the trials that are available to you appropriate for the 
population that you serve?  
     b. If so, how is this so?  
     c. If not, how is this so? 
 
6. Tell me about your experience enrolling a patient into a clinical trial. 
     a. In your experience, to what extent is it disruptive to do this at  
         their usual site of healthcare delivery?    
     b. How disruptive is it to refer them elsewhere?  
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Appendix E. Participant Survey (current trial participants) 
 
PARTICIPANT QUESTIONNAIRE 
 
Thank you for agreeing to participate in this project.  This portion 
contains some general questions to provide a better idea of who we 
are working with and what your general research experience has been.   
 
Please do not write any personal information (e.g. your name) on this 
form. 
 
1. Please choose the site(s) that most closely represents your 
practice location:     
[     ]   Academic Center/Teaching center 
[     ]   Specialty Center, Please specify type ________________ 
[     ]   Private practice 
[     ]   Veterans Affairs Medical Center 
[     ]   Other (please specify) _______________ 
 
2. How many years have you been working at this location?    
[___|____] 
 
3. How many years have you been in practice?    [___|____] 
 
4. What is your area of medical specialty?  
____________________ 
 
5. In what country did your primary medical training occur?    
____________________ 
 
6. In your practice, what has been your involvement in any type of 
clinical trial? Check all that apply. 
[     ] I have had patients inquire about clinical trials (therapeutic 
or prevention). 
[     ] I have recommended patients participate in a clinical trial 
(therapeutic or prevention) that I administer. 
 [     ] I have recommended patients participate in a clinical trial  
         (therapeutic or prevention) administered by others. 
 [     ] I have participated in the design and implementation of a  
         clinical trial (therapeutic or prevention). 
 [     ] I have had patients enroll at a clinical trial (therapeutic or  
         prevention) at another location because it was not locally  
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         available. 
 [     ] I have participated in a clinical trial (therapeutic or  
         prevention) in other ways. _________________________ 
 [     ] I have never been involved in a clinical (therapeutic or  
         prevention) trial.  
 
7. How many clinical trials (therapeutic or prevention) have you 
participated in as an investigator or other study personnel?  
____________________ 
 
If none, please skip to question 14. 
If 1 or more, please continue to question 8.  
 
8. What are your reasons for involvement in clinical trials?  Check 
all that apply. 
[     ] Advancing Medical Science  
 [     ] Providing access to a novel treatment  
 [     ] To expand available services 
 [     ] Challenge 
 [     ] Variety 
 [     ] To earn extra income for my practice  
 [     ] Other _____________________ 
9. What is your main reason for participating in clinical trials?  
 ___________________________________________________
 ___________________________________________________
 ___________________________________________________ 
 
10. How many prevention trials have you participated in as 
an investigator or other study personnel?   
____________________ 
 
11. What are the reasons for involvement in prevention 
clinical trials?  Check all that apply. 
[     ] Advancing Medical Science  
[     ] Providing the best possible care 
 [     ] Providing access to a novel treatment  
 [     ] To expand available services 
 [     ] To earn extra income for my practice  
 [     ] Other _____________________ 
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12. What is your main reason for participating in prevention 
clinical trials?  
 ___________________________________________________
 ___________________________________________________ 
 ___________________________________________________
 ___________________________________________________ 
 
 
13. Which of the following factors influence your decision to 
participate in any type of clinical trial?  Check all that apply. 
    
[     ] Influence on clinical care process 
[     ] Time  
 [     ] Financial Incentives 
 [     ] Cost to you/your institution 
 [     ] Paperwork requirements 
 [     ] Training and education 
 [     ] Staffing 
 [     ] Concern for your patients well-being 
 [     ] Impact on primary role  
 [     ] Introduction of another care provider or decision maker 
 [     ] Requirements of the research protocol  
[     ] Institutional support   
 [     ] Other _____________________ 
 
After completion, please skip to question 16. 
 
14. What are your reasons for not participating in clinical trials 
(therapeutic or prevention)?   
       Check all that apply. 
[     ] Influence on clinical care process 
[     ] Time  
 [     ] Financial Incentives 
 [     ] Cost to you/your institution 
 [     ] Paperwork requirements 
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 [     ] Training and education 
 [     ] Staffing 
 [     ] Concern for your patients well-being 
 [     ] Impact on primary role  
 [     ] Introduction of another care provider or decision maker 
 [     ] Requirements of the research protocol  
[     ] Institutional support   
 [     ] Other _____________________ 
 
15. What is your main reason for not participating in clinical 
trials (therapeutic or prevention)?  
 ___________________________________________________
 ___________________________________________________ 
 ___________________________________________________
 ___________________________________________________ 
16. What is your gender? 
 [     ]    Male 
 [     ]    Female  
17. What is your age?  
 [     ] 20-29 
 [     ] 30-39 
 [     ] 40-49 
 [     ] 50-59 
 [     ] 60-69 
 [     ] 70 years or older 
  
Note: Please be sure to answer both question numbers 
18& 19 about your ethnicity and race. 
 
18. How would you describe your ethnicity? 
 [     ]    1. Hispanic or Latino 
 [     ]    2. Not Hispanic or Latino  
19. How would you describe your race?                            
Select all that apply.   
 [     ] 1. American Indian or Alaska Native 
 [     ] 2. Asian 
 [     ] 3. Black or African American 
 [     ] 4. Native Hawaiian or Other Pacific Islander 
 [     ] 5. White 
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 [     ] 6. Other (please specify) _______________ 
 [     ] 7. More than one race (mark all that apply) 
 
 
Thank you for answering these questions 
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Appendix F. Participant Survey (invited or inquired)  
 
PARTICIPANT QUESTIONNAIRE 
 
Thank you for agreeing to participate in this project.  This survey 
contains some general questions to provide a better idea of who we 
are working with and what your general research experience has been.   
 
Please do not write any personal information (e.g. your name) on this 
form. 
 
1. Please choose the site(s) that most closely represents your 
practice location:     
[     ]   Academic Center/Teaching center 
[     ]   Specialty Center, Please specify type ________________ 
[     ]   Private practice 
[     ]   Veterans Affairs Medical Center 
[     ]   Other (please specify) _______________ 
 
2. How many years have you been working at this location?    
[___|____] 
 
3. How many years have you been in practice?    [___|____] 
 
4. What is your area of medical specialty?  
____________________ 
 
5. In what country did your primary medical training occur?    
____________________ 
 
6. In your practice, what has been your involvement in any type of 
clinical trial? Check all that apply. 
[     ] I have had patients inquire about clinical trials (therapeutic 
or prevention). 
 [     ] I have recommended patients participate in a clinical trial  
         (therapeutic or prevention) that I administer. 
 [     ] I have recommended patients participate in a clinical trial  
         (therapeutic or prevention) administered by others. 
 [     ] I have participated in the design and implementation of a  
         clinical trial (therapeutic or prevention). 
 [     ] I have had patients enroll at a clinical trial (therapeutic or  
         prevention) at another location because it was not locally  
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         available. 
 [     ] I have participated in a clinical trial (therapeutic or  
         prevention) in other ways.                            
         _________________________ 
 [     ] I have never been involved in a clinical trial (therapeutic or  
        prevention).  
 
7. How many clinical trials (therapeutic or prevention) have you 
participated in as an investigator or other study personnel?  
____________________ 
 
If none, please skip to question 14. 
If 1 or more, please continue to question 8.  
 
8. What are your reasons for involvement in clinical trials?  Check 
all that apply. 
[     ] Advancing Medical Science  
 [     ] Providing access to a novel treatment  
 [     ] To expand available services 
 [     ] Challenge 
 [     ] Variety 
 [     ] To earn extra income for my practice  
 [     ] Other _____________________ 
9. What is your main reason for participating in clinical trials?  
 ___________________________________________________
 ___________________________________________________ 
 ___________________________________________________
 ___________________________________________________ 
 
10. How many prevention trials have you participated in as 
an investigator or other study personnel?   
____________________ 
 
11. What are the reasons for involvement in prevention 
clinical trials?  Check all that apply. 
[     ] Advancing Medical Science  
[     ] Providing the best possible care 
 [     ] Providing access to a novel treatment  
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 [     ] To expand available services 
 [     ] To earn extra income for my practice  
 [     ] Other _____________________ 
12. What is your main reason for participating in prevention 
clinical trials?  
 ___________________________________________________
 ___________________________________________________ 
 __________________________________________________
 ___________________________________________________ 
 
13. Which of the following factors influence your decision to 
participate in any type of clinical trial?   Check all that apply.  
[     ] Influence on clinical care process 
[     ] Time  
 [     ] Financial Incentives 
 [     ] Cost to you/your institution 
 [     ] Paperwork requirements 
 [     ] Training and education 
 [     ] Staffing 
 [     ] Concern for your patients well-being 
 [     ] Impact on primary role  
 [     ] Introduction of another care provider or decision maker 
 [     ] Requirements of the research protocol  
[     ] Institutional support   
 [     ] Other _____________________ 
 
After completion, please skip to question 16. 
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14. What are your reasons for not participating in clinical trials 
(therapeutic or prevention)?   
       Check all that apply. 
[     ] Influence on clinical care process 
[     ] Time  
 [     ] Financial Incentives 
 [     ] Cost to you/your institution 
 [     ] Paperwork requirements 
 [     ] Training and education 
 [     ] Staffing 
 [     ] Concern for your patients well-being 
 [     ] Impact on primary role  
 [     ] Introduction of another care provider or decision maker 
 [     ] Requirements of the research protocol  
[     ] Institutional support   
 [     ] Other _____________________ 
 
15. What is your main reason for not participating in clinical 
trials?  
 ___________________________________________________
 ___________________________________________________ 
 ___________________________________________________
 ___________________________________________________ 
 
16. What is your gender? 
 [     ]    Male 
 [     ]    Female  
17. What is your age?  
 [     ] 20-29 
 [     ] 30-39 
 [     ] 40-49 
 [     ] 50-59 
 [     ] 60-69 
 [     ] 70 years or older 
  
Note: Please be sure to answer both question numbers 
18& 19 about your ethnicity and race. 
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18. How would you describe your ethnicity? 
 [     ]    1. Hispanic or Latino 
 [     ]    2. Not Hispanic or Latino  
19. How would you describe your race?   
Select all that apply.   
 [     ] 1. American Indian or Alaska Native 
 [     ] 2. Asian 
 [     ] 3. Black or African American 
 [     ] 4. Native Hawaiian or Other Pacific Islander 
 [     ] 5. White 
 [     ] 6. Other (please specify) _______________ 
 [     ] 7. More than one race (mark all that apply) 
 
20. If you would be interested in providing additional 
information related to your experiences  
with clinical trials, please provide the following contact 
information: 
 
Name:  _____________________________ 
Contact number:  _____________________ 
Best time to contact:   _________________ 
Email address:  _______________________ 
 
You will be contacted by the researcher to schedule a mutually 
convenient time to meet.   
Please note this information will be used for contact purposes 
only and will not be linked in any way to your responses.  
 
Thank you for answering these questions 
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Appendix G. Observational Checklist 
Research Site: 
 
Date: 
 
Time: 
 
 
 Y/N 
Use of Clinical 
Trial Alert System 
 
Dedicated 
research Staff 
 
 
 
 Observed  Not Observed 
Consideration of 
patient for 
participation in 
research study by 
physician  
  
Consideration of 
patient for 
participation in 
research study by 
other staff 
  
Communication 
between staff 
related to 
eligibility to 
participate in a 
trial 
  
Definitive plans 
to present  a 
clinical trial to a 
patient 
  
 
Comments: 
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